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Abstract 
 
Prostate cancer kills over 10,000 men every year in the UK, mainly as a 
consequence of the spread of the disease to other sites in the body. It is important to 
understand what controls the spread of prostate cancer cells, as this may lead to 
treatments that either slow down or prevent metastasis, and perhaps result in the 
cure of some of the advanced prostate cancers.  
 
Semaphorins act as chemotactic cues for axon guidance and cell movement, via 
their transmembrane receptors, plexins.  It has been found that semaphorins and 
their receptors are overexpressed in some human prostate cancer cell lines. These 
cell lines have been screened for mutations in genes in the semaphorin signalling 
pathway. 13 somatic missense mutations in the cytoplasmic domain of the Plexin 
B1 gene have been identified in clinical samples of primary and metastatic prostate 
cancers. One of the mutations C5662T was predicted to result in a substitution of a 
Proline to a Serine.  
 
The aim of this research is to determine if the mutation C5662T in the Plexin B1 
gene alters cell behaviour and contributes to prostate cancer progression.  
 
This thesis describes the method of constructing an expression vector containing the 
mutation and transfecting the mutation into COS7 cells to produce stable and 
transient clones. 
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The effect of the mutation on cell collapse was examined.  It was possible to show 
that Plexin B1 is involved in cell collapse and that Rnd1 is required for this process 
and this effect is independent of its ligand Semaphorin 4D (Sema4D). Although no 
functional difference between the wild type Plexin B1 and the mutant (C5662T) 
was observed, the rate of cell collapse may be important and more work will be 
needed to define whether this is a mutation that alters prostate cancer cell 
behaviour. 
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1.1 Prostate cancer 
 
 
1.1.1 Epidemiology of prostate cancer 
 
 
Prostate cancer is the most frequently diagnosed male cancer. In 2007 there were 
10,239 deaths in the UK from prostate cancer (Office for National Statistics, 2009).  
In 2004, there were 34,986 new cases of prostate cancer diagnosed in the UK 
(Office for National Statistics, CSR).  The incidence of prostate cancer is increasing 
steadily in almost all countries (Hsing et al. 2000). Over the last three decades 
prostate cancer rates have increased significantly in Great Britain. In Great Britain 
the age-standardized incidence rate almost trebled from 32 per 100,000 in 1975 to 
95 per 100,000 in 2005. There was little change in death rates during the 1970‟s and 
death rates from prostate cancer only began to rise from 1980 onwards. The age 
standardized death rate peaked in 1995, and since then death rates from prostate 
cancer have declined (Figure 1.1) (Majeed et al. 2000).  
 
The lifetime risk of being diagnosed with prostate cancer is 1 in 14 (Cancer 
research UK, www.cancerresearchuk.org), the strongest risk factor is age. It is 
largely a disease of older men and is rare below the age of 50 (Cancer Research 
UK, www.cancerresearchuk.org). Half of all cases are registered in men aged over 
75. The median age of both diagnosis and mortality is 75 years (Chamberlain et al. 
1997). 
20 
 
 
 
 
 
Figure 1.1 Age standardized incidence and mortality rates of prostate cancer, 
males, Great Britain, 1975-2006 (Cancer Research UK). The number of prostate 
cancer cases diagnosed each year has been steadily rising. Much of this increase is 
due to the increased detection of prostate cancer by PSA testing and a growing 
awareness of the condition Overall in the United Kingdom, prostate cancer 
mortality was fairly stable during the 1970s but began to increase in the early 
1980s, however since 1995 the mortality has been declining. The reason for this is 
unclear but may be due to screening picking up the disease at an earlier stage.  
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The incidence of prostate cancer varies widely between ethnic populations and 
countries. The lowest rates are in Asia, especially Chinese people in Tianjin, China 
(1.9 per 100 000 per year), and the highest are in North America and Scandinavia, 
especially in African-American people in the USA (137 per 100 000 per year) 
(Parkin et al. 1997).  However, migration studies show that as men from low-risk 
countries move to high-risk countries the risk increases, suggesting that lifestyle 
plays an important role (Winter et al. 1999). 
 
A family history of prostate cancer is an important risk factor. It is estimated that 5-
10% of all prostate cancers are caused by inherited genes (Bratt, 2002). The relative 
risk of prostate cancer is increased 2-fold with one first degree relative diagnosed 
aged 70 or under and rises to 4-fold with two relatives, if one of them is diagnosed 
under the age of 65 (Cancer Research UK, www.cancerresearchuk.org). The 
clustering of prostate cancer in families can be because of exposure to 
environmental factors, genetic susceptibility or chance since prevalence of this 
cancer is so high. A high concordance rate also exists in monozygotic twins. The 
site of the affected gene or genes is currently the subject of much investigation.  
The lifestyle related factor that may play a part in the promotion of prostate cancer 
is diet. Studies suggest that prostate cancer is associated with a western diet that 
includes a high intake of fat and meat. However the results of these studies are 
conflicting except for a few dietary components that appear to be more promising 
such as lycopene (present in tomatoes), selenium and vitamin E (Gronberg 2003). 
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However, the Selenium and Vitamin E Cancer Prevention Trial (SELECT) recently 
showed that neither Selenium nor vitamin E prevented prostate cancer (Lippman et 
al. 2009).  
 
The role of benign prostatic hypertrophy in the development of prostate cancer 
remains unclear. It is generally believed that the benign, hypertrophic prostatic cells 
do not directly transform into malignant cells (Carter et al. 1990). One possible 
contributory factor to the pathogenesis of prostate cancer is elevated serum 
testosterone concentrations. This hypothesis is supported by observations that 
prostate cancers are responsive to testosterone suppression. Black men have higher 
serum testosterone levels than white men, and the incidence of detectable prostate 
cancer, in eunuchs, who have below-average or negligible levels of testosterone, is 
low (Ross et al. 1986; Hill et al. 1979). 
 
The prevalence of incidental tumours is characteristic of the prostate gland. 
Autopsies of men over the age of 50 years have revealed microscopic foci of well-
differentiated adenocarcinoma in serial sections of prostate glands. It has been 
estimated that 9 out of 10 men who eventually develop clinically recognized 
prostate cancer had cancer that remained undetected for decades (Gittes 1991). 
 
Despite progress in the diagnosis and local therapy of prostate cancer, many 
fundamental questions remain unanswered. What is the cause of this disease? How 
can we prevent it? Which cancers are clinically significant? Progress in the 
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management of prostate cancer requires ways to distinguish the harmless cancers 
from the potentially lethal, and developing effective ways to prevent or treat the 
potentially lethal cancers.  
 
1.1.2 Pathology of prostate cancer 
 
 
High-grade prostatic intraepithelial neoplasia (PIN) is a clinically significant 
finding on prostate biopsies and is a well documented precursor to adenocarcinoma. 
PIN consists of architecturally benign prostatic ducts lined with cytologically 
atypical cells (McNeal 1969; McNeal et al. 1986). Low grade PIN, previously 
referred to as mild dysplasia or PIN-1, is of no prognostic significance and patients 
are at no greater risk of developing an invasive carcinoma. When high-grade PIN is 
found on needle biopsy, there is a 30 to 50 percent risk of finding carcinoma on 
subsequent biopsies (Keetch et al. 1995).  
 
PIN itself does not give rise to elevated serum PSA levels (Ronnett et al. 1993; 
Alexander et al. 1996; Ramos et al. 1999). The presence of high grade prostatic 
intraepithelial neoplasia indicates increased risk of prostate cancer somewhere in 
the prostate, but not necessarily at the site where the neoplasia was found at biopsy 
(Shepherd et al. 1996; Langer et al. 1996; Kamoi et al. 2000). Although high grade 
PIN appears to be a well recognized precursor lesion to prostate cancer, it is not a 
required precursor for carcinomas to arise within the prostate (Epstein et al. 1996). 
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Histologically, almost all prostate cancers are adenocarcinomas, derived from 
prostatic acinar cells. Approximately 75% will arise in the peripheral zone, 15% in 
the central zone and 10% in the transitional zone. Carcinomas tend to be multifocal 
and even if it appears to be unilateral on rectal examination, these lesions occur on 
both sides in approximately 70 percent of surgical specimens that are examined 
pathologically (Mostofi et al. 1992).  
 
Similar to other cancers, prostate adenocarcinomas are graded by the pathologist 
according to their degree of differentiation and overall aggressiveness. The Gleason 
grading system is the most widely accepted. Patients are given a Gleason Score 
which is a number from 2-10. Dr. Gleason provided a diagram (Figure 1.2) to show 
the progressive deterioration of the cancer cell architecture, and the four dividing 
lines along this grading system which he discovered are able to identify patients 
with significantly different prognosis, derived from a study which included 2,900 
patients (Gleason et al. 1974, 1992). 
The Gleason grading system recognises the fact that prostate cancer is a multifocal 
disease with heterogeneous glandular patterns. It combines the two most dominant 
(primary and secondary) histological patterns of cancer within the sampled 
specimen. Each of the two most common patterns is assigned a grade from one to 
five, with one the most differentiated and least aggressive and five the least 
differentiated or most aggressive pattern. Gleason sum score is reported as the two 
scores added together. If the most common pattern of grading was a 3 pattern and 
the second most common pattern was a 4, the Gleason grade would be reported as 
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Gleason 3+4=7. The major prognostic shift is between 6 and 7 and Gleason score 7 
tumours behave much worse than tumours scoring 5 or 6. The value of the Gleason 
grading system is its ability to predict survival rates. It correlates with all important 
pathological variables seen in the radical prostatectomy sample, with prognosis 
after radical prostatectomy, and with outcome after radiotherapy (McNeal et al. 
1990; Epstein et al. 1996; Green et al. 1998).   
The histology of the remaining few percent of prostate cancers is heterogeneous, 
arising from epithelial, stromal, or ectopic cells. Endometrioid carcinoma involves 
the prostatic urethra and periurethral prostatic ducts. This variant is aggressive and 
often is associated with metastatic disease. Similarly mucinous adenocarcinomas 
have a poor prognosis. Squamous cell carcinoma of the prostate accounts for 0.5% 
of cases and in these, serum tumour markers such as PSA tend to remain normal 
(Okamoto et al. 1996). Small cell carcinoma is another type of prostate cancer 
derived from neuroendocrine cells. These cancers tend to develop in men treated 
with long term hormonal ablation therapy. Primary transitional cell carcinoma of 
the prostate has also been reported, although secondary spread from the bladder is 
much more common (Reese et al. 1992).  
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Figure 1.2 This illustration shows Dr. Gleason's own simplified drawing of the five  
 
Gleason grades of prostate cancer. The Gleason Score reflects how abnormal 
prostate cells look under the microscope. Abnormal-looking cells tend to grow and 
spread more quickly and have a worse outcome. A pathologist assigns a Gleason 
grade ranging from 1 through 5 based on how much the cancer cells under the 
microscope look like normal prostate cells. Those that look like normal cells are 
graded as 1, while those that look the least like normal cells are graded as 5.  
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1.1.3 Natural history of prostate cancer 
 
Low-grade tumours can grow very slowly and remain localized to the gland for 
relatively long periods, during which they remain clinically undetectable. Tumours 
that become clinically significant arise mainly in the peripheral zone of the prostate 
gland and less frequently in the central zone or transition zone (Mostofi et al. 1992). 
 
Prostate cancers may spread locally or distantly, typically they grow peripherally 
through the capsule along perineural sheaths that perforate the capsule at the upper 
outer corner and at the apex. Such tumours often invade the seminal vesicles and 
the neck of the urinary bladder. Extension through the prostatic capsule and into the 
rectum is rare, owing to separation of the bladder and rectum by Denonvilliers 
fascia (Gillenwater et al. 2002).   
 
Distant metastatic spread is both lymphatic and haematogenous. Lymphatic spread 
occurs in a stepwise manner, first affecting the obturator lymph nodes, then 
advancing contiguously into the external iliac and hypogastric nodes, and finally 
involving the common iliac and periaortic nodes (Touijer et al. 2007). 
Haematogenous spread is also characteristically orderly. Bone is one of the most 
common site of metastasis and about 20% of newly diagnosed prostate cancer 
patients present with metastasis (Esper et al. 1999). Bone metastasis will occur in 
up to 85% of patients who die of prostate cancer (Narayan et al. 1995) and studies 
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show that 50%-70% of all prostate cancer patients will develop skeletal metastases 
during the course of their disease (Buckwalter et al. 1997; Hage et al. 2000). The 
axial skeleton is particularly vulnerable, this is followed by spread to the proximal 
appendicular skeleton. Bone metastases are typically osteoblastic. Only in advanced 
disease do pulmonary and hepatic metastases appear. Metastases to the brain and 
other visceral sites are uncommon. Paraneoplastic syndromes have been associated 
with disseminated prostate cancer and include disseminated intravascular 
coagulopathy and neuromuscular abnormalities.  
 
1.2 Cancer cell invasion and metastasis 
 
 
Metastasis which is defined as the formation of progressively growing secondary 
tumour foci at sites discontinuous from the primary lesion, is the most clinically 
significant behavioural trait of malignant cancer (Welch et al. 1999). It is this 
dissemination of tumour cells which commonly defeats surgery, chemotherapy and 
radiotherapy that is responsible for a large proportion of cancer deaths.  
 
The metastatic process is a complex cascade of many steps. The cancer cells must 
detach from the primary tumour, invade the surrounding stroma and enter the 
vasculature or lymphatic system. These cells must survive in the blood circulation 
before entering the capillary beds of distant organs. The disseminated cells must 
attach to the target endothelium, extravasate and invade the target tissue. The new 
tumour focus must then establish a blood supply before developing into a secondary 
29 
 
cancer (Souhami et al. 2002). Finally, the metastatic foci of tumour cells must 
evade eradication by immune responses.  Since all of these steps are required for 
metastases, inhibition of any of these should prevent metastases from developing.  
 
Metastasis formation is clearly a complex process and studies have shown it to be 
inefficient. A large number of tumour cells are shed into the vascular system of a 
primary tumour (Butler et al. 1975). It has been demonstrated that only a small 
number of metastatic tumour cells when injected intravenously will form tumour 
foci.  
 
Cells, with few exceptions, stay in their tissue of origin. They remain in place by 
sticking to one another through cell-cell adhesion and by sticking to a meshwork of 
protein – the "extracellular matrix" – that fills the space between them. Cancer cells 
must evade the multiple controls in the body that keep normal cells in place.  
 
It has long been recognised that tumours of different tissue origins have a 
predisposition to metastasise to specific target organs. Prostate cancer preferentially 
spreads to bone. The observation that metastases are organ-specific was first 
noticed by Dr. Stephen Paget.  In 1889, he proposed that cancer cells shed from an 
initial tumour were dispersed randomly throughout the body by the circulatory 
system. He called these circulating cancer cells "seeds" and proposed that only 
some seeds fall onto fertile soil - organs where they can grow (Paget 1889). 
Evidence of the seed and soil theory was provided by the observation that B16 
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melanoma cells injected into mice metastasised to selective organs (Fidler et al. 
1976).  
 
James Ewing challenged Paget's theory by arguing that cancer cells don't spread 
randomly throughout the circulation in search of fertile soil.  He suggested that 
circulating cancer cells become trapped in the first small blood vessels, or 
capillaries, they encounter and then grow in the surrounding organ (Ewing 1940). 
 Using autopsy studies of cancer patients and measurements of blood flow to 
organs, Leonard Weiss  showed that, on its own, neither Ewing's theory nor Paget's 
completely explained the pattern of cancer metastasis (Weiss et al. 1986, 1988). 
 
A large amount of evidence now indicates that molecular factors that are present in 
each organ can influence the ability of each type of metastatic cancer cell to grow in 
that organ (Fidler 1995). Prostate cancer cells that arrive in bone may be stimulated 
to grow because of molecular interactions that occur between cancer cells and cells 
in the bone.  
 
The study of chemokine receptors is providing important clues concerning why 
some cancers metastasise to particular organs. Studies have shown that tumour cells 
express patterns of chemokine receptors that match chemokines that are expressed 
in organs to which these cancers commonly metastasise (Muller et al. 2001).  So it 
has been suggested that chemokines cause cancer cells to „home‟ to specific 
secondary sites (Liotta 2001). 
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There is also research on the characteristics of adhesion molecules in an effort to 
understand the metastatic process. A variety of cell surface receptors that mediate 
cell-cell adhesion and interactions with the extracellular matrix have been 
characterised, including cadherins, integrins and CD44. Cell adhesion molecules on 
the cell's surface are unique to certain tissues or organs and identify where cells 
should reside. The initial escape of a tumour cell from its primary location requires 
the loss of the cell-cell attachment which maintains tissue cohesion. In epithelial 
tumours this is mediated by cadherins (Souhami et al. 2002).  In cancer cells, cell 
adhesion molecules are altered or lost, allowing the cells to leave their appropriate 
location and re-establish themselves in a new environment. Cancer cells also lose 
the requirement of normal cells to anchor to the tissue matrix for survival.  
 
As a primary tumour grows it needs to develop a blood supply that can support its 
metabolic needs – a process called angiogenesis (Holleb et al. 1972). Cancer cells 
promote angiogenesis by disrupting the normal balance between the naturally 
occurring molecules that stimulate this process and those that inhibit it (Holleb et al. 
1972). A required early step in cancer growth is the "angiogenic switch," when this 
balance is lost and new blood vessel growth is promoted (Bergers et al. 2003). 
 Angiogenic peptides are released by neoplastic cells, such as vascular endothelial 
growth factor (VEGF).  Researchers are developing agents that can impede the 
effects of angiogenesis-stimulating growth factors in the body; and developing new 
techniques to increase the production of naturally-occurring anti-angiogenic factors 
to prevent tumour spread. It has been shown that antibodies specific to the VEGF 
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peptide will inhibit the growth of different human tumour cell lines in recipient 
athymic mice (Kim et al. 1993). 
 
The design of more effective therapies to treat metastatic cancer requires a better 
understanding of the molecular events and cellular processes that are involved in 
the process of metastasis.  
 
1.3 Semaphorins and Plexins 
 
1.3.1 Classification of Semaphorins and Plexins 
 
 
Semaphorins are a large family of secreted and membrane-bound proteins 
(Semaphorin nomenclature committee, 1999). Semaphorin is derived from the word 
“semaphore” meaning to convey information by a signalling system. Over the past 
ten years since the identification of the first semaphorin, many different names and 
classification systems have been used. In 1999 the nomenclature for these proteins 
was standardized (Semaphorin nomenclature committee, 1999).  More than 20 
members are now known and they fall into eight subfamilies. These subfamilies are 
defined in Figure 1.3. 
 
A distinctive protein module of 500 amino acids, called the sema domain, 
characterises all semaphorins (Kolodkin et al. 1993). This domain is known to 
mediate receptor-binding specificity of semaphorins (Feiner et al. 1997). The sema 
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domain is also present in other cell surface proteins, namely the plexins, which are 
the functional receptors for semaphorins, as well as the scatter factor receptors 
which control similar biological functions (Winberg et al. 1998; Artigiani et al. 
1999). 
 
In humans, there are at least nine different plexin genes, which are grouped into 
four subfamilies according to sequence similarities – A, B, C and D (Tamagnone et 
al. 1999) (Figure 1.4). 
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Figure 1.3 The Semaphorin Family (Semaphorin nomenclature committee, 1999).                     
(1) Sema domain, transmembrane (TM) domain, and short cytoplasmic domain  
(found in invertebrates). 
(2) Sema domain, immunoglobulin domain (Ig), secreted (found in invertebrates). 
(3) Sema domain, Ig domain, short basic domain, secreted (found in vertebrates). 
(4) Sema domain, Ig domain, TM domain, and short cytoplasmic domain (found in  
vertebrates). 
(5) Sema domain, seven thrombospondin repeats (type 1 and type 1–like), TM  
domain, and a short cytoplasmic domain (found in vertebrates). 
(6) Sema domain, TM domain, and a cytoplasmic domain (found in vertebrates). 
(7) Sema domain, Ig domain, and a glycosylphosphatidylinositol (GPI) membrane  
anchor (found in  vertebrates). 
(V) Viral semaphorins, including to date a truncated secreted sema domain  
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(SEMAVA), and a sema domain followed by an Ig domain shown in parentheses  
 
(SEMAVB).   
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N-terminal                                          
 
                                              
 
Figure 1.4 Vertebrate plexins. Members of the Plexin A group bind Semaphorins of 
class 3, Plexin B1 binds Semaphorin 4D (Sema 4D), Plexin B2 binds Semaphorin 
4C, Plexin C1 binds Semaphorin 7A and Plexin D1 binds Semaphorin 3E. 
(Trusolino et al. 2002). 
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There are at least two families of semaphorin receptor, plexins and neuropilins 
which interact to form receptor complexes (Figure 1.5) (Tamagnone et al. 2000; 
Kolodkin et al. 1997). Secreted semaphorins bind to receptor complexes that 
include neuropilins and plexins whereas membrane bound semaphorins bind 
directly to plexins. Plexins alone seem unable to interact with secreted semaphorins 
and neuropilins are required for binding these ligands (Feiner et al. 1997). Plexin 
B1 is a high affinity receptor for Sema4D. 
 
 
1.3.2 Structure of plexins 
 
Plexins are large transmembrane proteins that have a large extracellular region, a 
transmembrane area and a cytoplasmic region (Figure 1.5).  
 
The extracellular domain of all plexins has features in common with scatter factor 
receptors and semaphorins (Winberg et al. 1998) and it contains the sema domain, 
the MRS domain, IPT/GP domain and the convertase cleavage site.  
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E/C   
                                        
I/C 
 
 
 
 
Figure 1.5 Structure of Plexin B1. The extracellular domain of Plexin B1 can be 
divided into the sema domain, the MRS domain, IPT/GP domains and a cleavage 
site, indicating a heterodimeric structure. The cytoplasmic portion of Plexin B1 
comprises a 600 amino acid module which consists of the SP domain and the CRIB 
domain. The CRIB domain is thought to be the binding site of Rac and Rnd 
(Trusolino et al. 2002). 
 
 
 
Sema domain 
MRS  
G-P/IPT motif 
Convertase 
cleavage site 
SP domain 
CRIB domain 
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Sema domain – encompasses about 500 amino acids with 15 conserved cysteine 
residues spaced by stretches of conserved amino acids and a conserved potential 
glycosylation site (Winberg et al. 1998; Kolodkin et al. 1993). The sema domain 
has been identified in hepatocyte growth factor (HGF), semaphorins and viral 
proteins (virus encoded semaphorin receptors, VESPR) (Winberg et al. 1998; 
Kolodkin et al. 1993). The sema domains of plexins share 25%-30% amino acid 
identity between pairs of plexins (Winberg et al. 1998).  The role of the sema 
domain is not entirely understood, however crosslinking of Met occurs only in the 
presence of the sema domain, suggesting it is necessary in receptor dimerisation 
(Kong-Beltran et al. 2004).  
 
It has been speculated that the sema domain is crucial for biological activity and 
receptor specificity (Giger et al. 1998; Nakamura et al. 1998). The structure of the 
sema domain has recently been determined and is primarily composed of a seven 
bladed beta-propeller. Each blade comprises a four strand antiparallel beta sheet 
(Antipenko et al. 2003). 
 
The sema topology reveals an unexpected homology with integrins (Love et al. 
2003). There are strong parallels between integrin and semaphorin function. 
Integrins are cell adhesion molecules and there is evidence to suggest that their 
intracellular signalling pathways converge with those of semaphorins (Pasterkamp 
et al. 2003). 
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MRS (Met Related Sequence) – contains a cysteine- rich motif, and is named after 
the scatter factor receptor Met (Maestrini et al. 1996). It has also recently been 
found to be present in integrins (Bork et al. 1999). Plexins have three repeated MRS 
motifs, with the exception of Plexin C1 which has two. The MRS motifs are also 
known as PSI domains (Plexins, Semaphorins and Integrins) (Bork et al. 1999). 
 
G-P/IPT motif – This was first described by Bork et al. 1999, the immunoglobulin-
like fold shared by plexins and transcription factors. It was found to contain a 
repeat sequence, rich in glycine and proline residues (Bork et al. 1999). The role of 
this domain is unknown.  
 
Convertase cleavage site – located in the proximity of the transmembrane domain 
(Tamagnone et al. 1999). Plexin B1/B2 undergoes proteolytic processing in this 
region by proprotein convertases, thereby converting single-chain precursors into 
non-disulfide-linked, heterodimeric receptors. This processing of plexins occurs in a 
post-Golgi compartment, possibly at the cell surface. This conversion of Plexin B1 
into a heterodimeric receptor appears to enhance the binding and the functional 
response to its ligand Semaphorin 4D (Artigiani et al. 2003). 
 
The cytoplasmic domain is large, consisting of about 600 amino acids and it is 
conserved among family members and in evolution (Maestrini et al. 1996). It 
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consists of two SP domains and the CRIB domain. It contains stretches that are 
distantly related to GTPase activating proteins (Artigiani et al. 2003). 
 
SP domain – This domain has no homology to other proteins and although it 
includes a number of tyrosine phosphorylation sites it lacks the typical motifs of 
catalytic tyrosine kinases (Tamagnone et al. 1999). The two SP (sex-plexin) 
domains are thought to play an important role in signal transduction. They are 
highly conserved within the plexin family and in evolution with over 50% similarity 
between invertebrates and humans (Tamagnone et al. 1999). 
 
CRIB domain (Cdc42/Rac interactive binding) – The Cdc42/Rac interactive 
binding (CRIB) motif was identified between residues 1848 and 1890 of the 
intracellular region of Plexin B1 between the two SP domains (Vikis et al. 2000).  
This motif is thought to be essential for the binding of activated Rac. Mutation of 
three amino acid residues L1849G, V1850G and P1851A, in Plexin B1 abolishes 
the interaction of Plexin B1 with Rac (Vikis et al. 2000).  The minimal Rac binding 
domain has been identified as the 215 residues between 1696 and 1910 (Vikis et al. 
2000). 
 
Rac is involved in growth cone guidance. Activation of Rac, a small GTPase, 
results in the formation of lamellipodia (Hall 1998). The CRIB domain is also the 
site at which Rnd (Oinuma et al. 2003) and R-Ras (Oinuma et al. 2004) bind.  
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More recently it has been suggested that the CRIB domain is not involved in the 
binding of Rac and Rnd. Instead the small GTPases bind to a region adjacent to the 
CRIB domain and this interaction may play a role in Plexin B1 activation (Tong et 
al. 2007).  
  
 
1.3.3 Protein interactions of class B Plexins 
 
Plexins and the small GTPases – Rho, Rac and Cdc42 
 
 
The mammalian Rho GTPase family consists of a number of distinct proteins, the 
three best characterized members of the family are Rho, Rac and Cdc42. These 
proteins act as molecular switches to control cellular processes by cycling between 
active, GTP-bound and inactive, GDP-bound states (Mackay et al. 1998). The Rho 
family of small GTPases are critical for the regulation of actin structures (Hall et al. 
1998). In Swiss 3T3 cells, activation of Rho results in stress fiber formation (Ridley 
et al. 1992). Activation of Rac results in lamellipodia formation and Cdc42 results 
in filopodia formation. These small GTPases activate WASP/Wave1, which in turn 
activates Arp2/3 and this causes actin polymerization (Ridley et al. 2003).  
 
A direct interaction between Plexin B1 and activated Rac has been demonstrated, 
and it was found to occur at the Cdc42/Rac interactive binding (CRIB) motif in the 
cytosolic domain of Plexin B1, suggesting that Rac plays a role in mediating 
semaphorin signals, resulting in reorganisation of actin cytoskeletal structure (Vikis 
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et al. 2000). The same authors have shown that Plexin B1 and p21-activated Kinase 
(PAK) can compete for the interaction with active Rac and that Plexin B1 can 
inhibit Rac-induced PAK activation (Vikis et al. 2002) (Figure 1.6). The binding of 
Rac to Plexin B1 enhances the ability of Plexin B1 to interact with the ligand 
Sema4D by stimulating the localization of Plexin B1 to the cell surface (Vikis et al 
2002).  
 
Plexin B1 clustering induces assembly of actin and myosin filaments and cell 
contraction in fibroblasts, suggesting that Rho is also involved in Plexin B1 
signalling (Driessens et al. 2001). Using a yeast two-hybrid system, the C-terminus 
of Plexin B1 activates Rho via PDZ-Rho-GEF (Driessens et al. 2001). Ligand 
binding of semaphorin to plexins causes activation of PDZ-Rho GEF via its PDZ 
domain, thereby stimulating the exchange of GDP for GTP on Rho, through its Dbl 
homology domain (DH) and Pleckstrin-homology domain (PH). A parallel input on 
PDZ-Rho GEF is established by ligand binding to G protein-coupled receptors 
activating G13, which interacts with PDZ-Rho GEF through its RGS domain, thus 
catalysing the exchange of GDP for GTP on Rho (Driessens et al. 2002) (Figure 
1.7). 
 
Following this finding it was found that the PDZ domain of LARG is also directly 
involved in the interaction with the carboxy-terminal sequence of Plexin B1 
(Aurandt et al. 2002). LARG (leukaemia-associated Rho GEF) is a Rho specific 
guanine nucleotide exchange factor that was initially identified in patients with 
primary acute myeloid leukaemia (Kourlas et al. 2000).  
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The mechanisms of signal transduction by plexins remains largely unknown, 
however a hallmark of semaphorin receptors is their interaction with multiple 
GTPases. It is this interaction that is likely to regulate cytoskeletal arrangements.  
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Figure 1.6 Plexin B1/Rac interaction inhibits PAK activation and enhances 
Sema4D ligand binding (Vikis et al. 2002). 
Treatment of Plexin B1 expressing neurons with Sema4D results in the recruitment 
and sequestration of active Rac. This inhibits the ability of Rac to activate PAK and 
thus results in the disassembly of cytoskeletal structures (Vikis et al. 2002). This 
suggests that a function of Plexin B1 is to inhibit PAK activation and this results in 
changes in the cytoskeletal structure, which in turn causes growth cone collapse.  
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Figure 1.7 Mechanism by which plexins activate Rho via PDZ-Rho GEF (Driessens 
et al. 2002). (GPCR – G protein coupled receptor, RGS – regulators of G protein 
signalling).  
Ligand binding of Sema 4D to Plexin B1 activates PDZ-Rho-GEF at the PDZ 
domain and this stimulates the exchange of Rho GDP for Rho GTP. Ligand binding 
to G-protein coupled receptors also activates PDZ-Rho GEF by binding of Gα13 to 
the RGS domain of PDZ-Rho GEF and this stimulates the exchange of Rho GDP for 
Rho GTP. This suggests there are two mechanisms whereby plexins and G-protein 
coupled receptors can stimulate Rho-dependent pathways.  
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Plexin B1 interacts with Rnd1 
 
Rnd1 is a member of the Rho family GTPases. Its expression in fibroblasts inhibits 
the formation of actin stress fibres and integrin based focal adhesions. By inducing 
the loss of cell-substrate adhesion it causes cell rounding (Nobes et al. 1998).  
 
Rnd1 directly interacts with the cytoplasmic domain of Plexin B1 (Oinuma et al. 
2003).  In COS7 cells, coexpression of Rnd 1 and Plexin B1 induces cell 
contraction in response to Semaphorin 4D. The PDZ RhoGEF pathway appears to 
be directly involved in this morphological effect (Oinuma et al. 2003). Oinuma 
found that Rnd1 promoted the interaction between Plexin B1 and PDZ RhoGEF and 
thereby potentiated the Plexin B1 mediated Rho activation. The Rnd1 binding 
region in Plexin B1 appears to overlap with the region responsible for the 
interaction with Rac, since mutation of three amino acid residues in Plexin B1 
(L1849G, V1850G and P1851A) abolishes the interaction of Plexin B1 with Rac  
and suppresses the interaction with Rnd 1 (Oinuma et al. 2003).  
 
Rnd1 may act as a key regulator of the signal transduction of Plexin B1, leading to 
Rho activation during axon guidance and cell movement.  
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Plexins and R-Ras 
R-Ras belongs to the Ras superfamily of small GTP-binding proteins. It has been 
implicated in promoting cell adhesion and neurite outgrowth via integrins (Oinuma 
et al. 2004). Plexin B1 mediates Sema4D-induced repulsive axon guidance 
signalling by acting as a GTPase activating protein (GAP) for R-Ras.  Plexin B1 
stimulates the intrinsic GTPase activity of R-Ras and this action requires the 
interaction of Plexin B1 with Rnd1 (Oinuma et al. 2004).  The downstream 
signalling of Plexin B1 mediated R-Ras GAP activity has been studied in further 
detail. Plexin B1 inactivates phosphatidylinositol-3-OH Kinase [PI(3)K] and 
dephosphorylates Akt and glycogen synthase kinase-3beta (GSK-3 beta) through R-
Ras GAP activity and this induces growth cone collapse (Ito et al. 2006). 
R-Ras activity is critical for ECM-mediated β1 integrin activation and cell 
migration. Inactivation of R-Ras by Sema4D/ Plexin-B1–mediated R-Ras GAP 
activity controls cell migration by modulating the activity of β1 integrins (Oinuma 
et al. 2006). 
Plexin B1 also functions as an M-Ras GTPase activating protein during dendritic 
development (Saito et al. 2009). Plexin B1 is a dual function GAP for R-Ras and 
M-Ras, remodelling axon and dendrite morphology, respectively (Saito et al. 2009). 
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Plexin B1  interacts with Plexin A1 
The receptor for Sema 3A is neuropilin-1 (Kolodkin et al. 1997), but neuropilin 
does not contain cytoplasmic domains that initiate intracellular signalling cascades. 
Plexins that form complexes with neuropilin-1 are thought to be the receptors that 
transduce Sema 3A signals into cellular responses (Takahashi et al. 1999). Other 
classes of semaphorins do not utilize neuropilins and directly transduce their signal 
through plexins. Plexin B1 specifically interacts with Plexin-A1 at their cytoplasmic 
domains (Usui et al. 2002). The biological significance of this interaction is as yet 
unknown. However the proposed pathway for this interaction is Sema 3A binds to 
neuropilin-1 and then activates Plexin A1. Plexin A1 interacts with Plexin B1 
probably by facilitating the function of Rho and Rac through Plexin B1 and this 
leads to the reorganization of the actin cytoskeleton (Usui et al. 2003) (Figure 1.8). 
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Figure 1.8 Pathway of Sema 3A signalling (Usui et al. 2002). 
The receptor for Sema 3A is neuropilin 1 and on binding this activates Plexin A1.  
Plexin B1 interacts with Plexin A1 at their cytoplasmic domains and this interaction 
facilitates Rho and Rac which leads to the reorganization of the actin cytoskeleton. 
Since Plexin B1 directly interacts with Rac, this suggests that Plexin B1 is a 
mediator that links Plexin A1 to Rac.   
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Plexins couple with Met 
 
Semaphorins, plexins and scatter factor receptors share structural similarities and 
they are thought to derive from a common ancestor gene (Winberg et al. 1998). 
Plexins were identified through their homology to the extracellular domain of 
scatter factor receptors, all of which contain a conserved sequence of 500 amino 
acids (sema domain) and a cysteine rich motif of 80 amino acids (met related 
sequence, MRS) (Maestrini et al. 1996). Scatter factor receptors exist as 
heterodimers with intrinsic tyrosine kinase activity (Trusolino et al 2002). Met is 
the receptor for scatter factor 1 (also known as hepatocyte growth factor) which is 
encoded by the MET proto-oncogene (Giordano et al. 1989). Activation of the Met 
receptor induces „invasive growth‟ (Trusolino et al 2002).  
 
Plexin B1 forms a complex with Met.  Met can be activated in a dual mode: either 
directly, through an interaction with its own ligand (SF 1) or indirectly, through 
recruitment to the Plexin B1-Sema4D complex (Giordano et al. 2002). Binding of 
Sema4D to Plexin B1 stimulates the tyrosine kinase activity of Met, which results 
in tyrosine phosphorylation of both receptors (Giardano et al. 2002). These 
observations suggest a possible involvement of semaphorins and plexins in cancer 
and metastasis.  
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Plexin B1 interacts with ErbB2 
ErbB2 (HER2/neu) is a receptor tyrosine kinase and is the only ErbB for which no 
ligand has been found (Franklin et al. 2004). Plexin B1 can associate with the 
receptor tyrosine kinases ErbB-2 and Met (Swiercz et al. 2007). The binding of 
Sema4D to Plexin B1 stimulates the intrinsic tyrosine kinase activity of ErbB-2, 
resulting in the phosphorylation of both Plexin B1 and ErbB-2. A dominant 
negative form of ErbB-2 blocks Sema4D-induced RhoA activation as well as 
axonal growth cone collapse in primary hippocampal neurons (Swiercz et al. 2004). 
Sema4D-induced activation and inactivation of RhoA require ErbB-2 and Met 
respectively (Swiercz et al. 2008). 
 
Semaphorins and Integrins 
 
Integrins are a family of cell adhesion receptors that bind to extracellular matrix, 
cell-surface ligands and soluble ligands. Several integrins are involved in promoting 
tumour angiogenesis and tumour metastasis (Jin et al. 2004). They are known to 
associate with a large number of distinct proteins (Hynes 2002).  
 
Integrins have recently been shown to mediate semaphorin responses. It was found 
that mutation of the Sema7A integrin binding motif blocks Sema7A mediated axon 
growth. At the same time it was found that class 3 semaphorins control vascular 
morphogenesis by inhibiting integrin function (Serini et al. 2003). 
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Integrins and Plexin B1 share homology in their PSI cysteine rich domains (Bork et 
al. 1999). Plexin B1 activation by Sema 4D induces disassembly of integrin based 
focal adhesive structures and this is followed by actin depolymerization and cell 
collapse (Barberis et al. 2004). 
 
Plexin B1 promotes endothelial cell motility through RhoA and Rho Kinase by 
regulating integrin dependent signalling networks (Basile et al. 2007). 
 
Although a direct interaction has not been shown for class B plexins and integrins, 
an interaction has been shown to occur via R-Ras. R-Ras becomes inactivated on 
Plexin B1 activation through its GTPase activity (Oinuma et al. 2006). 
 
Several transmembrane and cytosolic proteins have been shown to bind to Plexin 
B1 and the precise mechanism by which these lead to modifications of the 
cytoskeleton remain poorly understood. However, as research continues on these 
interesting proteins new light is shed on the signalling network of plexins and 
semaphorins.  
 
1.3.4 Semaphorin Functions 
Semaphorins were originally identified as axonal guidance cues. Increasing 
evidence has shown that semaphorins play additional roles in processes unrelated to 
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axonal development, including organogenesis, angiogenesis, immunity and 
neoplastic transformation.  
 
Axon guidance 
The semaphorin family mediates axonal guidance in the nervous system. Guidance 
molecules can exhibit either attractive or repulsive effects, and different axons can 
respond differently to the same cue. Sema1A controls axonal elongation of 
peripheral neurons in grasshoppers (Kolodkin et al. 1992). Semaphorin 2A acts as a 
repulsive cue for axons when expressed ectopically in Drosophila (Matthes et al. 
1995). Sema 3A has a potent inhibitory effect on axonal outgrowth from embryonic 
dorsal root ganglion (Luo et al. 1993). The extension versus retraction of different 
edges of the growth cone appears to be controlled by local changes in the dynamics 
of the actin cytoskeleton. But how do guidance cues regulate the actin cytoskeleton? 
There is evidence that Rho family GTPases regulate the actin cytoskeleton during 
axonal outgrowth and guidance (Dickson et al. 2001). Activation of Rac and Cdc42 
induces lamellipodia and filopodia respectively, whereas Rho activation causes the 
formation of actin:myosin filaments and process retraction (Hall et al. 1998). One 
model postulates that attractive guidance cues activate Rac and Cdc42 in the growth 
cone, while repulsive guidance cues activate Rho.  It has previously been discussed 
how plexins interact with the small GTPases (Vikis et al. 2000). 
Although semaphorins and their receptors have emerged as important cellular cues 
in regulating the developing nervous system, the role of the plexin-B proteins is not 
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well understood. By developing Plexin B1 and Plexin B2 knock-out mice this role 
was further elucidated. Portions of the plexin B genes were deleted, which encoded 
the
 
transmembrane domain of the respective plexin-B proteins or
 
upstream 
sequences, to generate an early translational
 
stop via a frameshift mutation. The 
development of the nervous system was normal in mice lacking Plexin B1, whereas 
mice lacking Plexin B2 demonstrated defects in closure of the neural tube and the 
embryonic brain was disorganized (Deng et al. 2007). 
Organogenesis 
 
Mutations in the mouse semaphorin 3 gene cause certain embryonic bones and 
cartilaginous structures to develop abnormally, with vertebral fusions and partial rib 
duplications. The mice die shortly after birth owing to hypertrophy of the right 
ventricle of the heart and dilation of the right atrium (Behar et al. 1996). 
 
Plexin B1 and Sema4D are expressed in epithelial and mesenchymal cells during 
the development of the ureteric collecting duct. Mice that lack Plexin B1 show 
anomalies in kidney development in vivo. These effects seem to be mediated via the 
Rho-A-ROCK pathway (Korostylev et al. 2008).  
 
Immune cell respone 
Evidence suggests that a subset of semaphorins called „immune semaphorins‟ 
function in the immune system (Kumanogoh et al. 2001).  Sema4D was originally 
found to induce B cells to aggregate (Hall et al. 1996). Since then semaphorins have 
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been found to influence monocyte migration, T-cell activation, B-cell survival as 
well as T/B and T/dendritic cell cooperation (Elhabazi et al. 2003). 
Angiogenesis 
Semaphorin 4D has been identified as a potent proangiogenic molecule and this 
activity requires the coupling and activity of c-Met (Conrotto et al. 2005). The same 
group showed that the ability of cancer cells to grow is impaired in an environment 
lacking Sema4D. This observation is thought to be due to defective vascularisation 
within the tumour.  
 
Semaphorins – signals for invasion 
 
Semaphorin overexpression is associated with the invasion and metastasis of 
tumours. Sema3E is overexpressed in metastatic cell lines in comparison with the 
non-metastatic parental population (Christensen et al. 1998). Sema3C is 
overexpressed in cancer cells resistant to radiation and cytostatic drugs in recurrent 
squamous carcinomas and in metastatic lung adenocarcinomas (Martin-satue et al. 
1999; Yamada et al. 1997). Neuropilin 1 (receptor for Sema3A) expression in a 
prostate carcinoma cell line enhanced tumour growth and angiogenesis in vivo 
(Miao et al. 2000). Sema3F plays a role in adhesion in human lung cancer cell lines 
(Brambilla et al. 2000). Semaphorins Sema3F and its homologue Sema3B have 
been shown to be tumour suppressor genes, the expression of which are frequently 
lost in lung cancers (Tomizawa et al. 2001).  Using a Drosophila screening system, 
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Sema5C was required for the proliferation of lethal(2)giant larvae [I(2)gl] tumours 
(Woodhouse et al. 2003). 
 
More recently, Sema 3A, Sema 3D, Sema 3E and Sema 3G have been shown to 
display anti-tumourigenic and anti-angiogenic properties. This seems to be 
associated with the expression of Semaphorin 3 receptors by the tumour cells (Kigel 
et al. 2008).  
 
In contrast to this, Christensen et al. 2005 suggest that Sema3E promotes tumour 
progression and metastasis. Sema3E is expressed in human cancer cell lines and 
solid tumours from breast cancer patients. In vivo, expression of Sema3E in 
mammary adenocarcinoma cells induces the ability to form experimental lung 
metastasis. In vitro, the Sema3E protein exhibits both migration and growth 
promoting activity on endothelial cells and pheochromocytoma cells (Christensen et 
al. 2005).   
 
1.4 Semaphorin 4D and invasive growth 
 
Although semaphorins were originally described in the nervous system for their 
roles in axon guidance, they are by no means limited to this role. They are 
expressed in various non-neuronal organs and tissues. However their ability to 
mediate cell contraction (Takahashi et al. 1999), adhesion and migration (Miao et 
al. 1999; Brambilla et al. 2000) as well as growth and differentiation establishes 
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parallel pathways with the invasive growth program. In addition, the conserved 
sema domain that is found in semaphorins and plexins is also present in Met, a well 
known inducer of invasive growth (Comoglio et al. 2002).  
 
Semaphorin overexpression has been associated with the invasion and metastatic 
progression of tumours (Yamada et al. 1997; Christensen et al. 1998). However the 
available data implicating these proteins in tumour progression remains sparse 
compared with those for Met. Among the semaphorin receptors, Plexin B1 has the 
highest similarity (28%) to scatter factor receptors and is also present outside the 
nervous system in tissues and organs where Met is expressed (Tamagnone et al. 
1999).  
 
Two different ligand-receptor pairs join forces to promote invasive growth by 
cancer cells (Giordano et al. 2002). The first pair is Semaphorin 4D and Plexin B1. 
The second pair consists of a scatter factor, hepatocyte growth factor (HGF), and its 
receptor Met, a tyrosine kinase from the MET/RON/SEA oncogene family. 
Although HGF and Met are important during normal embryonic development, they 
have also been associated with malignancy when mutated. Plexin B1 and Met form 
a complex, and when Sema4D binds to its receptor, Plexin B1, this stimulates the 
tyrosine kinase activity of Met, resulting in tyrosine phosphorylation of both 
receptors (Giordano et al. 2002).  
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Giordano et al found that Sema4D could trigger a complex program for invasive 
growth, including cell-cell dissociation, anchorage-independent growth and 
branching morphogenesis. Semaphorin had no effect on cells where Met was not 
expressed indicating that this tyrosine kinase receptor is essential for semaphorin-
stimulated invasive growth (Giordano et al. 2002).    
This observation suggests a possible involvement of semaphorins in cancer and 
metastasis. 
There is some controversy over the role of Met interaction with Plexin B1. Plexin 
B1 can associate with the receptor tyrosine kinases Met and ErbB-2. However, in 
breast carcinoma cells, Sema4D can have pro- and anti-migratory effects depending 
on the presence of ErbB-2 and Met. The exchange of the two receptor tyrosine 
kinases is sufficient to convert the cellular response to Sema4D from pro- to anti-
migratory (Swiercz et al. 2008). The activation of Met by Sema4D/Plexin B1 
inhibits migration, whereas activation of ErbB2 via Sema4D/Plexin B1 enhances 
migration.  
Plexin B1 also acts as a tumour suppressor in melanoma cells. In primary 
melanoma cells, Plexin B1 blocked tumourigenesis as measured by growth of 
colonies in soft agar, spheroids in extracellular matrix and xenograft tumours 
(Argast et al. 2009). 
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1.5 Plexin B1 and prostate cancer 
 
The association between prostate cancer and Plexin B1 has been investigated 
(Wong et al. 2007). The cytoplasmic domain and part of the extracellular domain 
(exons 1-5) of Plexins A1, A3 and B1 were sequenced using cDNA from the human 
prostate cancer cell lines PC3, DU145 and LNCaP. A single nucleotide change 
(A5359G) was found in Plexin B1 in LNCaP, which potentially changes threonine 
1697 to an alanine. LNCaP is of Caucasian origin and the sequence change was 
absent from DNA from 60 control individuals, of Caucasian background. The rest 
of the Plexin B1 cDNA was sequenced in PC3, DU145 and LNCaP and no further 
mutations found. 
 
To look for further mutations, the study was extended using SSCP (Single Strand 
Conformational Polymorphism) analysis of exons 22-29 of the cytoplasmic domain 
of the Plexin B1 gene in DNA microdissected from 89 primary prostate tumours 
treated by radical prostatectomy, 17 lymph node metastases and 9 prostate cancer 
bone metastases. Aberrant bands were excised from the gel and sequenced. 12 
further missense mutations were found. Mutations were present in 89% (8/9) of 
prostate cancer metastases, in 41% (7/17) of lymph node metastases, and in 46%  
(41/89) of primary tumours. Forty percent of prostate cancers contained the same 
mutation. Mutations were also found in 6/30 breast cancer lymph node metastases 
(Wong et al. 2007). 
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The proportion of cells containing mutant Plexin B1 was higher in metastases than 
in primary tumour tissue.  The mutations and their frequencies are shown in Table 
1.1. 
Together, the data suggest that cells carrying mutated Plexin B1 are selected for 
during prostate cancer progression.  
 
One of the mutations was C5662T, that is predicted to result in a substitution of a 
proline to a serine at position 1798. This mutation was found in 1/9 prostate cancer 
metastases.  The amino acid, at position 1798 is highly conserved in evolution. A 
proline is present in the protein in mouse, Drosophila and C elegans and other 
classes of the Plexin family- A1, A2, B2, B3 (Table 1.2). 
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Nucleotide    
Amino 
acid 
Bone metastases 
(total of 9)  
 
LN metastases 
(total of 17)  
 
1° (total 
of 89) 
Total 
1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 
C5059T P1597S           x x x   1 4 
C5060T P1597L  x x  x     x     x 4 9 
G5074A  G1602R               x  1 
T5401A F1711I                1 1 
C5468T  T1733I      x           1 
A5474G N1735S      x           1 
A5596G T1776A                1 1 
A5653G  T1795A x x x x x  x x     x x  38 47 
C5662T P1798S        x         1 
A5674G  T1802A   x              1 
T5714C L1815P  x   x  x         2 5 
C5980T R1904W         x        1 
Total      8 of 9 (89%) 7 of 17 (41%) 
41 of 
89 
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Table 1.1 Mutations found in Plexin B1 (Wong et al. 2007).  
On screening the cytoplasmic domain of Plexin B1 from human prostate cancer cell 
lines a single nucleotide change was found in Plexin B1 in LnCaP (A5359G). 12 
further mutations were found in clinical samples of prostate cancer. Some of the 
mutations were found in many tumours, A5653G was found in 9 of 26 metastases 
and 38 of 89 primary prostate cancers. The C5662T mutation was found in 1 of 9 
prostate cancer bone metastases.  
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     1796 1797 1798 (position of mutation) 
Hs PLXNB1  Q R P 
Mm plex6  Q R P 
Dm plexB  M K P 
Ce plx-2   Q R P 
Hs PLXNB3  Q R P 
Hs PLXNB2  C W P 
Hs PLXNA2  Q R P 
Hs PLXNA1  Q R P 
       S (AA change) 
 
Table 1.2 Sequence conservation of Plexin B1 at amino acid position 1798.  
The C5662T, that is predicted to result in a substitution of a proline to a serine at 
position 1798 is highly conserved in evolution. A proline is present in the protein in 
mouse, Drosophila, C elegans, Plexin A1, A2, B2, B3 suggesting functional 
significance.  
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1.6 Aims and Objectives 
 
 
The finding that mutations in Plexin B1 occur in a high proportion of prostate 
cancers, approximately half the primary cancers and nearly all the metastatic 
cancers, suggests that this pathway is involved in the progression of prostate cancer.  
 
The aim of this research is to determine whether the mutation C5662T in the Plexin 
B1 gene alters cell behaviour and contributes to prostate cancer progression.  
 
The objectives: 
Objective 1: Construct an expression vector containing the mutation.  
By using primers containing the point mutation, the altered sequence will be 
introduced into the wild type gene. The altered construct will be used to transform 
E.Coli. Colonies will be selected, grown up and the identity of the mutation will be 
confirmed by direct sequencing. 
 
Objective 2: Transfect the mutation into NIH3T3 cells and COS cells to produce 
stable and transient clones. 
In order to determine the effect of the mutation, it must first be transfected into 
suitable cells. Using lipofectamine transfection, the construct will be transfected 
into NIH3T3 cells and COS cells. Transfected cells will be selected in G418 and 
individual colonies will be expanded and frozen stocks produced. The presence of 
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the mutation will be confirmed and the level of protein expression measured by 
western blotting and immunofluorescence. 
 
Objective 3: Determine the effect of the mutation on cell collapse and downstream 
signalling. In vitro assays will be used to assess the effect of the mutation on the 
behaviour of cells. At present it is not known which components of the semaphorin 
signalling pathway will be affected by the mutation. For example the mutation may 
affect the interaction with MET or downstream effectors such as Rho, Rac and 
cdc42.  
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Chapter 2: 
 
Methods and Materials 
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2.1 Materials and Methods 
 
 
2.1.1 DNA constructs 
The following constructs were provided by Alan Hall (A.Hall, Memorial Sloan-
Kettering Cancer Centre, New York, NY) and Mariette Driessens (The Netherlands 
Cancer Institute, Amsterdam; Driessens et al. 2001) 
1. Full length Plexin B1 cDNA in the expression vector pcDNA3 (Figure 2.1)  
2. Truncated Plexin B1 conjugated to CD2 in pcDNA3 (Driessens et al. 2001). The 
cytoplasmic domain (amino acids 1520–2135) of Plexin B1 (truncated Plexin B1) 
was fused to the transmembrane and extracellular domain of CD2 (a T lymphocyte 
antigen).  
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Figure 2.1 Plexin B1 in pcDNA3 (Invitrogen). The expression vector pcDNA3 has 
5446 nucleotides. It is designed for stable and transient expression in mammalian 
hosts. It has multiple cloning sites, Plexin B1 was cloned into the NOT1 site.   
(CMV promoter: bases 209-863, T7 promoter: bases 864-882, Polylinker: bases 
889-994, Sp6 promoter: bases 999-1016, BGH poly A: bases 1018-1249, SV40 
promoter: bases 1790-2115, SV40 origin of replication: bases 1984-2069, 
Neomycin ORF: bases 2151-2945, SV40 poly A: bases 3000-3372, ColE1 origin: 
bases 3632-4305, Ampicillin ORF: bases 4450-5310). 
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2.1.2 Cell culture 
 
Cell lines are immortal cell cultures that will proliferate indefinitely given 
appropriate fresh medium and space. A number of characterized cell lines are 
available.  
 
LNCaP cells are human prostate adenocarcinoma cells derived from the left  
supraclavicular lymph node metastasis of a 50 year old caucasian male in 1977 
(Horoszewicz et al. 1983). They were grown in RPMI medium 1640 (Gibco, 
Paisley, UK) with 8% foetal bovine serum (FBS; Labtech international). 
 
PC3 cells were established from a bone marrow metastasis isolated post-mortem 
from a 62-year-old Caucasian man with poorly differentiated prostatic 
adenocarcinoma after androgen suppression therapy (Kaighn et al. 1979). They 
were grown in RPMI medium 1640 with 8% foetal bovine serum.  
 
DU145 cells were derived from a patient with brain metastasis from prostate cancer 
(Stone et al. 1978). They were grown in RPMI medium 1640 with 8% foetal bovine 
serum. 
 
1542-CPT3X cells were derived from primary prostate tumour (Housseau et al. 
1999). 1542-NPTX epithelial cells were derived from normal prostate tissue of the 
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same radical prostatectomy specimen as 1542-CPT3X cells (Housseau et al. 1999). 
Pre2.8 were derived from Benign Prostatic Hyperplasia (BPH) epithelial cells and 
S2.13 derived from BPH stromal cells. They were grown in RPMI medium 1640 
with 8% foetal bovine serum. 
 
NIH3T3 cells are fibroblasts and were obtained from Swiss mouse embryo tissue in 
1962 (Jainchill et al. 1969). They were grown in Dulbecco‟s Modified Eagle 
Medium (D-MEM; Gibco BRL, UK), with 8% newborn calf serum (Gibco, New 
Zealand). 
 
COS1 and COS7 cells were derived from kidney cells of the African green monkey 
(Jensen et al. 1964). They were grown in D-MEM with 8% FBS. COS cells are 
amenable to transfection.  
 
All Cell lines were grown at 37ºC in 5% CO2 and passaged when 80% confluent.  
 
2.1.3 Site-directed in-vitro mutagenesis 
 
In vitro site-directed mutagenesis is used for studying protein structure-function 
relationships and gene expression and it allows the modification of a gene sequence. 
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The QuikChange XL Site-Directed Mutagenesis Kit (Stratagene) was used to 
introduce the C5662T mutation into the full length Plexin B1 construct and CD2 
(truncated) Plexin B1 construct (Figure  2.2).  
 
Mutagenic oligonucleotide primers were designed according to the mutation 
C5662T. 
Plexin B1sequence:  
5‟GAGTGCCTCTCACCCAGCGGCCAGACCCTCGCACCCTTGATG3‟ 
The following oligonucleotide primers were used: 
5‟GAGTGCCTCTCACCCAGCGGTCAGACCCTCGCACCCTTGATG3‟ sense 
5‟CATCAAGGGTGCGAGGGTCTGACCGCTGGGTGAGAGGCACTC3‟Antise-
nse 
To optimise the process of mutagenesis primers were designed with the following 
considerations as set out in the Stratagene instruction manual. Both primers 
contained the desired mutation and anneal to the same sequence on opposite strands 
of the plasmid. Primers were between 25-45 bases in length and the melting 
temperature of the primers was calculated to be 78ºC or greater (melting 
temperature = 81.5 + 0.41(%GC) – 675/N - % mismatch). The desired mutation was 
placed in the middle of the primer and there was a minimum GC content of 40% 
(QuikChange XL Site-Directed Mutagenesis Kit, Stratagene).  
 
Site directed in-vitro mutagenesis uses a supercoiled double stranded DNA vector 
and two synthetic oligonucleotide primers containing the desired mutation. During 
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temperature cycling the plasmid denatures and the primers anneal.  Using PfuTurbo 
DNA polymerase, incorporation of the oligonucleotide primers generates a mutated 
plasmid. The product is treated with Dpn1 to digest the parental DNA template, 
leaving the DNA containing a mutation. This DNA is transformed into XL10-Gold 
ultracompetent cells.  
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Figure 2.2 Site directed in-vitro mutagenesis 
 
 
 
 
Step 1: Plasmid preparartion  
 
Gene in parental DNA plasmid (thick black line) 
with target site for mutation 
 
 
Step 2: Temperature Cycling 
 
The plasmid is denatured and the oligonucleotide 
primers containing the desired mutation anneal. 
Using the non-strand-displacing action of pfu 
DNA polymerase, the mutatgenic primers extend 
and incorporate. The pfuTurbo DNA polymerase 
replicates both plasmid strands, generating a 
mutated plasmid 
 
 
 
 
Step 3: Digestion 
The nonmutated parental DNA is treated with 
Dpn. This is used to digest the nonmutated 
parental DNA, leaving the mutated DNA plasmid 
(thin black line) 
 
 
Step4: Transformation 
The mutated DNA is then transformed into XL-10- 
Gold ultracompetent cells 
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The control reaction was prepared using 5µl 10X reaction buffer, 1µl (10ng) 
dsDNA construct, 12.5µl (125ng) Primer 1, 12.5µl (125ng) Primer 2, 1µl dNTP 
mix, 3µl Quick solution, 15µl ddH2O and 1µl Pfu Turbo DNA polymerase. The 
PCR cycling parameters used were: 
 
95°C 1minute  1 cycle    
95°C 50seconds        
60°C 50seconds  18 cycles 
68°C  24minutes 
68°C 7minutes  1 cycle 
 
Following temperature cycling the reaction tubes were placed on ice for 2 minutes. 
The amplification products were then digested with 1µl of Dpn 1 (10U/µl) 
restriction enzyme and incubated at 37°C for 1 hour to digest the parental 
(nonmutated) DNA. XL10-Gold ultracompetent E.Coli cells (Invitrogen) were 
transformed with the constructs. The XL-10 E.Coli cells were thawed on ice. 15µl 
of the PCR product was added to 100µl of the E.Coli cells. The cells were 
incubated on ice for 20 minutes and heat-pulsed at 42ºC. The cells were then 
incubated on ice for 2 minutes. 0.5mls NZY
+  
broth (5g NZ amine, 2.5g yeast, 2.5g 
NaCl, 500mls H2O adjusted to pH 7.5) was added (preheated to 42°C) and 
incubated at 37°C for 1 hour with shaking at 250g. 250µl of each reaction mix was 
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then placed on LB ampicillin agar plates (20g LB agar, 500mls H2O), 250µl 
ampicillin) and incubated at 37°C for 16 hours.  
10 colonies were then selected and grown in Luria-Bertani medium (12.5gLB broth, 
500mls deionised H2O, 100µg/ml Ampicillin) and incubated at 37°C.  The bacterial 
cells were then harvested by centrifugation at 6000g for 15 minutes and DNA was 
extracted.  
 
 
2.1.4 DNA Extraction 
 
The Qiagen plasmid purification kit protocol (Qiagen) was used to extract DNA. 
The bacterial pellet was resuspended in 10mls of Buffer P1 (50 mM Tris·Cl, pH 
8.0, 10 mM EDTA 100 µg/ml RNase A). Then 10mls of Buffer P2 (200 mM 
NaOH, 1% SDS) was added and mixed by inverting 4-6 times. The reaction mixture 
was incubated at room temperature for five minutes. 10mls of chilled Buffer P3 (3.0 
M potassium acetate, pH 5.5) was added and mixed immediately by inverting 4-6 
times. The mixture was incubated on ice for 20 minutes. The mixture was then 
centrifuged at 20000g for 30minutes at 4°C. The supernatant containing plasmid 
DNA was then removed promptly. The supernatant was then re-centrifuged at 
20000g for 15minutes at 4ºC.  The supernatant was applied to a QIAGEN-tip 500. 
This was equilibrated by applying 10ml of Buffer QBT [750 mM NaCl; 50 mM 
MOPS, pH 7.0; 15% isopropanol (v/v); 0.15% Triton® X-100 (v/v)]. The 
QIAGEN-tip was washed twice with 30mls of Buffer QC (1.0 M NaCl, 50 mM 
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MOPS, pH 7.0, 15% isopropanol (v/v). DNA was eluted with 15ml of Buffer QF 
(1.25 M NaCl, 50 mM Tris-Cl, pH 8.5, 15% isopropanol (v/v). The eluted DNA 
was precipitated by adding 10.5ml of isopropanol. The mixture was centrifuged 
immediately at 15000 x g for 30 minutes at 4°C. The resulting DNA pellet was 
washed with 5ml of 70% ethanol and spun at 15000 x g for 10 minutes. The ethanol 
was decanted and the DNA pellet allowed to air-dry. The pellet was then dissolved 
in 0.5ml of TE (Tris-EDTA pH8). To determine the yield, the DNA concentration 
was measured by spectrophotometry and an agarose gel was used to confirm the 
presence of DNA. 
 
Analysis of DNA (Agarose gel analysis) 
 
To determine the presence of DNA, agarose gel electrophoresis was used (0.8% gel 
– 8mg agarose, 1ml 0.5% Tri-borate-EDTA, 0.5µg/ml ethidium bromide). The gel 
solution was placed into a tray with combs until set.  The gel was placed in the 
electrophoresis tank (Electro-4gel tank, Thermo Electron Corporation) containing 
TBE (54g Tris base, 27.5g boric acid and 20ml 0.5M EDTA, pH 8.0 in 5 litres 
ddH2O). 2µl of DNA/loading buffer (0.25% bromophenol blue, 0.25% xylene 
cyanol FF, 30% glycerol in H2O) were added to each well and 1µl of a 1Kb DNA 
marker (Invitrogen) was used. 150V was applied to the tank containing the gel and 
ethidium bromide-DNA complexes were visualised under UV light (254-366nm) 
using an ultraviolet transilluminator (Gene Genius, Bio Imaging System).  
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Spectrophotometric measurement of nucleic acid concentration 
 
A spectrophotometer is a photometer (a device for measuring light intensity) that 
can measure intensity as a function of the wavelength of light. 
Using 3µl of DNA mixed with 500µl of water, each sample was placed in the 
spectrophotometer and the concentration of DNA was calculated. Measurements 
were taken using a quartz cuvette (Qiagen).  
Spectrophotometric conversions for calculating the concentration of nucleic acids 
from their absorbance at 260nm (A260) are given below: 
  dsDNA  50µg/ml 
  RNA   40µg/ml 
Conc. of DNA sample = 50 x A260  x dilution factor 
Conc. of RNA sample  = 40 x A260  x dilution factor 
The purity of DNA was calculated by A260 / A280  
   
 
2.1.5 PCR (Polymerase Chain Reaction) 
 
PCR is a technique used to amplify the number of copies of a specific region of 
DNA in order to produce enough DNA to be tested. There are three basic steps in a 
PCR, which are repeated for 30 or 40 cycles. During denaturation the double strand 
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melts open to single stranded DNA, and all enzymatic reactions stop. The primer 
then binds to the DNA template, annealing. The final step, DNA replication, starts 
the process of “multiplying” the amount of DNA.  
 
PCR was used to amplify a segment of DNA containing the C5662T mutation. The 
following primers were used: 
Plexin B1 sense   5‟-GCCAGTGGACAGTGTGAC-3‟ 
Plexin B1 antisense  5‟-CTGCCTCACCAAGCATGTGC-3‟ 
 
PCR reagents: 
10X buffer     2.5µl 
Primer 1 sense (10pmol/µl)   2.5µl 
Primer 2 antisense (10pmol/µl)   2.5µl 
MgCl2 (25mM)     1.5µl 
dNTPs (10mM)     0.5µl 
Taq (5U/µl)     0.25µl 
DNA      100ng 
ddH2O      to make up to 25µl 
 
PCR conditions (Perkin Elmer PCR machine) : 
94°C  5minutes  1 cycle 
94°C  1minute   
60°C  1minute  30 cycles 
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74°C  1minute 
74°C  7minutes  1 cycle 
 
2.1.6 Digestion with Restriction Enzyme 
 
To confirm the presence of the mutation, the PCR product was digested with a 
restriction enzyme, Hae III (New England Biolabs).  
Hae III recognises and cuts at GG/CC. (5‟…GG^CC…3‟ and 3‟…CC^GG…5‟). 
Using the webcutter program (Webcutter 2004: internet communication) Hae III 
recognises 6 sites in the wild type plexin B1 PCR product. In the mutant (C5662T) 
Hae III recognises 5 sites.  
 
The reagents for Hae III digestion were:  
PCR product  14µl 
10X Buffer  2µl 
Hae III   1µl 
H2O    3µl 
Following incubation at 37°C for 4 hrs the product was run on a 3% agarose gel.  
 
2.1.7 Cycle sequencing 
 
The purpose of sequencing is to determine the order of the nucleotides and involves 
three major steps (like PCR), which are repeated for 30 or 40 cycles. During 
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denaturation the double strand melts open to single stranded DNA and all 
enzymatic reactions stop. The primer binds to the DNA template (annealing). In 
sequencing only one primer is used, so there is only one strand copied (unlike PCR: 
two primers are used, so two strands are copied). The polymerase then allows 
extension of the fragment.  
PCR products were loaded on a 1.8% agarose gel and run until the bands separated. 
The bands were cut from the gel under UV light and using the Qiagen gel extraction 
kit the DNA was purified and extracted.  
The gel slice was weighed and 6 volumes of buffer QG was added to 1 volume of 
gel. The gel slice was incubated at 50ºC for 10 minutes and to help dissolve the gel, 
the mixture was vortexed every 2 minutes. One gel volume of isopropanol was 
added to the sample to increase the yield of DNA fragments and centrifuged. To 
elute the DNA 50µl of buffer EB (10mM Tris-Cl, pH8.5) was added and 
centrifuged at 13000g for 1 minute.  
2µl of purified product was loaded onto an agarose gel to check that extraction had 
been successful and to estimate the DNA concentration. 
The ABI Prism dRhodamine terminator cycle sequencing ready reaction kit with 
AmpliTaq DNA polymerase (Applied Biosystems) was used for cycle sequencing. 
 
The following reaction mix was set up on ice: 
Primer     4 picomoles 
Purified PCR product  10µl 
Sequencing reaction mix 5µl (added last) 
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Sterile H2O   make up to 20µl 
 
The sequencing reaction mix was added last and was kept on ice at all times.  
The mixture was spun briefly and placed in the PCR machine.  
 
 
PCR reaction: 
96°C   30seconds  1cycle      
  
96°C   30seconds   
50°C   15seconds  25cycles 
60°C  4minutes 
 
The DNA was precipitated by adding 50µl 95% ethanol and 2µl 3M NaAc. The 
tubes were mixed by vortexing and left on ice for 10 minutes. The mixture was 
centrifuged at a 13000g for 25 minutes and the supernatant was removed. 100µl of 
70% ethanol was added and spun for a further 10 minutes. The pellet was then 
allowed to air-dry in the dark. 
The pellet was sent off for further analysis. The PCR reaction is loaded into a laser 
sequencer. The sequencer can read the different dyes as they pass the laser at the 
bottom of the gel. The computer then compiles the data into the image of a gel and 
the colours are then read as bases. Each base has its own colour, so the sequencer 
can detect the order of the bases in the sequenced gene.  
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2.1.8 Cloning of CD2-vector pcDNA3 
 
CD2 alone in vector pcDNA3 was produced by digestion of Plexin B1-CD2 with 
the restriction enzyme Not1 (New England BioLabs, Inc).  The bands were 
separated on a 0.8% agarose gel and the larger band was cut out and purified using 
QIAquick gel extraction kit protocol (Qiagen).  The purified linear product was 
ligated using T4 DNA ligase (New England BioLabs, Inc).  The reaction was as 
follows: 
 
DNA   4l 
Buffer 10x  1.5l 
T4 DNA ligase  1l 
ddH2O     8.5l 
 
The reaction mixture was incubated at 15C for 30 minutes. 
 
2.1.9 Transfection 
 
Lipofectamine 2000 is a cationic liposome that facilitates transfection of nucleic 
acids into eukaryotic cells giving a high level of expression and transfection 
efficiency for a broad range of cell types. Cationic liposomal transfection reagents 
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are the most common method of transfection, mainly due to their ease of use and 
high degree of success. They are based upon packaging the DNA into liposomes, 
which fuse with the plasma membrane and release the DNA into the cell. 
Lipofectamine 2000 (Invitrogen) was used to transfect NIH3T3, COS1 and COS7  
cells with mutant Plexin B1, wild type Plexin B1, vector only and mock (no DNA). 
Both stable and transient transfections were performed.   
The main advantage of using Lipofectamine 2000 is its ability to transfect a range 
of  different cell types coupled with a high efficiency of transfection. 
 
Transfection protocol: 
 
On Day 1 cells were plated into 6 well plates with 2mls medium, so that they would 
be 90% confluent at the time of transfection. To sterilise the DNA, 4µg of DNA 
was added to 4µl of NaAC and 80µl of ethanol. This was placed on ice for 10 
minutes and then spun at 13000g  for 20 minutes. The supernatant was removed and 
100µl of 70% ethanol added. This material was spun for a further 5 minutes and the 
supernatant removed. The pellet was allowed to air dry for 5 minutes and was 
resuspended with 250µl of Optimem 1.  
 
The following day 10µl Lipofectamine 2000 was added to 240µl Optimem 1 with 
glutamax-1 (Gibco, UK) and left for 5minutes at room temperature (for each 
transfection sample). 4µg DNA (diluted in 250µl Optimem 1) was added to the 
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Lipofectamine 2000 mix (above) and left for 30 minutes at room temperature. The 
500µl mix was added to the cells and incubated for 24 hours at 37°C. 
 
On day 3, for stable cell lines, cells were transferred to two T80 flasks. 
 
The following day, 1mg/ml (300µl) Geneticin (Gibco, UK) was added to each T80 
flask and media was changed until the mock transfected cells died (upto 5 days). 
 
Clones were then selected by ring cloning and each clone was grown separately. 
Ring cloning was performed by removing the top of the flask using a heated blade. 
The medium was removed and the cells were washed with PBS. A perspex ring 
coated with silicon grease was pressed onto the flask to surround a clone. Cells 
from each clone were transferred, using trypsin (50µl), into a new flask containing 
media.  
 
Each clone was grown and the relative expression of Plexin B1 was determined. To 
ensure the sequence had not been altered during the transfection process, and the 
mutation was still present, cycle sequencing and digestion with HaeIII were 
performed (see previous methods).   
 
To obtain the highest transfection efficiency and low non specific effects the 
transfection conditions were optimised. This was done by varying the DNA and 
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Lipofectamine 2000 concentrations, and cell density. The DNA (µg):Lipofectamine 
2000 (µl) ratios were varied from 1:0.5 to 1:5 (see results section).  
 
 
2.1.10 Relative expression of Plexin B1 RNA in stable clones 
 
RNA was extracted using the RNeasy mini protocol kit (Qiagen). All reagents were 
provided by Qiagen in the RNeasy mini protocol kit. Cells were initially grown in a 
monolayer and were trypsinized and collected as a cell pellet. The cell pellet was 
loosened by flicking and 600µl of Buffer RLT (RNeasy Lysis Buffer) was added (to 
5x10
6
 cells). The sample was homogenised. The lysate was loaded on a 
QIAshredder spin column and centrifuged for 2 minutes at maximum speed. 600µl 
of 70% ethanol was added to the homogenised lysate and mixed by pipetting. 700µl 
of the sample was applied to an RNeasy mini column and centrifuged for 15 
seconds at 10000g. The flow through was discarded. 350µl Buffer RW1 
(composition unknown) was added to the RNeasy mini column and centrifuged for 
15 seconds at 10000g to wash. The flow through was discarded. In a separate tube 
10µl of DNase 1 stock solution was added to 70µl Buffer RDD (composition 
unknown). This combination was mixed gently by inverting and left for 15 minutes. 
350µl Buffer RW1 was placed into the RNeasy mini column and centrifuged for 15 
seconds at 10000g. The flow through was discarded. Buffer RPE (composition 
unknown) was added and centrifuged for 15 seconds at 10000g. To elute, 50µl 
RNase free water was added and centrifuged at 10000g for 1 minute.  
86 
 
 
The RNA concentration was estimated using spectrophotometry and the formula: 
RNA concentration = spectrophotometric reading x A260 x dilution factor 
 
First strand cDNA synthesis was carried out on the samples. The following 
components were added to a microcentrifuge tube: 
Oligo(dT) 12-18 (500µg/ml)  1µl 
Total RNA    5µg 
H2O     to make up to 12µl 
 
The mixture was incubated at 70ºC for 10 minutes then quickly chilled on ice. The 
following components were added to the incubated mixture.  
 
5X First strand buffer   4µl 
0.1M DTT    2µl 
10mM dNTP mix   1µl (dNTP = 10mM dATP,dGTP, dCTP, 
dTTP) 
 
These components were further incubated at 42ºC for 2 minutes. 1µl of Superscript 
II (reverse transcriptase) was added and incubated for 50 minutes at 42ºC. The 
procedure was repeated without Superscript II, as a control. This mixture was then 
heated to 70ºC for 15 minutes to inactivate the reactions and the cDNA was stored 
at -20ºC or was used for PCR.  
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30ng of cDNA was used for the PCR reaction.   
 
PCR reagents: 
10X buffer     2.5µl 
Primer 1 sense (10pmol/µl)   2.5µl 
Primer 2 antisense (10pmol/µl)   2.5µl 
MgCl2 (25mM)     1.5µl 
dNTPs (10mM)     0.5µl 
Taq (5U/µl)     0.25µl 
DNA      30ng 
ddH2O      to make up to 25µl 
 
PCR conditions: 
94°C  5minutes  1 cycle 
94°C  1minute   
60°C  1minute  30 cycles 
74°C  1minute 
74°C  7minutes  1 cycle 
 
6µl of the product was run on a 0.8% agarose gel to determine the relative 
expression of Plexin B1 mRNA in the stable clones.  
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2.1.11 Protein Extraction 
 
Plexin B1 was extracted from transfected cells using different protein extraction 
buffers containing a number of protease inhibitors. These included RIPA buffer, EB 
buffer (used by Atigiani et al. 2003) and OBG. These buffers were chosen since 
they enable efficient cell lysis and protein solubilization while avoiding protein 
degradation. The buffer that yielded the most protein during the extraction process 
was used thereafter. Sodium butyrate was also used to increase the amount of 
membrane protein extracted (see below). Once the medium was removed, the T80 
flask was washed with PBS. In each T80 flask 400µl of the buffer was added, the 
cells left on ice for 30 minutes and using a cell scraper the cells were removed and 
placed in an eppendorf. The cells were then spun (10000g for 10minutes at 4ºC) and 
the supernatant placed in a new eppendorf and stored at -70ºC. 
 
Buffers used: 
RIPA Buffer     
50mM Tris-HCl pH 8 (buffering agent prevents protein denaturation)  
150mM NaCl (salt prevents non-specific protein aggregation) 
5mM EDTA (chelator of magnesium and calcium ions)    
1% (v/v) NP40 (detergent to extract protein)  
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0.5% (w/v) sodium deoxycholate (detergent to extract protein)  
0.1% (w/v) SDS        
10% (v/v) glycerol (cryoprotectant)  
EB buffer 
20mM Tris-HCl pH 7.4 (buffering agent prevents protein denaturation) 
150mM NaCl  (salt prevents non-specific protein aggregation)   
5mM EDTA (chelator of magnesium and calcium ions)  
1% Triton X-100 (detergent to extract membrane proteins)  
10% glycerol (cryoprotectant) 
 
OBG (n-Octyl-Beta-D-Glucopyranoside) 
OBG (AG Scientific Inc) is a biological detergent used for solubilizing membrane 
bound proteins in their native state. 
 
Anti-proteases were added to each buffer in the quantities shown: 
PMSF(Phenylmethyl sulfonyl fluoride) 20µg/ml (inhibits serine proteases) 
Aprotinin 10µg/ml (inhibits serine proteases) 
Leupeptin 10µg/ml (inhibits serine and cysteine proteases) 
Pepstatin A 5µg/ml (inhibits aspartic proteases) 
 
Sodium Butyrate 
Sodium butyrate can act to increase the efficiency of transfection and expression of 
both transient and stable transfections. It is a potent inhibitor of histone acetylation, 
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therefore its addition leads to histone hyperacetylation and a chromatin structure on 
the incoming plasmid DNA that is predisposed to transcription. Cells transfected 
with Plexin B1 were grown in 7mM sodium butyrate and then protein was extracted 
as described previously. 
 
Estimation of protein concentration 
 
The Modified Lowry Protein Assay was used for protein quantitation (Pierce 
Biotechnology, Illinois). The Lowry protein assay is a biochemical assay for 
determining the total level of protein in a solution. The total protein concentration is 
exhibited by a colour change of the sample solution in proportion to protein 
concentration, which can then be measured using colorimetric techniques. Protein 
standard solutions were made up using bovine serum albumin. 1 ml of Modified 
Lowry reagent was added to the test protein samples and standard solutions. After 
10 minutes Folin-Ciocalteu reagent (a reagent that uses phosphomolybdotungstate 
for the colorimetric detection of proteins) was added to each sample. After 30 
minutes the absorbance at 750nm was measured for each sample, using water as the 
reference. 
A range of protein standard solutions were made up using bovine serum albumin 
from concentrations of 50µg/ml to 400µg/ml and a standard bovine serum albumin 
(BSA) curve was plotted. Using the standard curve, the protein concentration was 
determined for each unknown sample. 
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2.1.12 Western Blotting 
 
Western blot is a technique used to detect proteins in a sample. Using gel 
electrophoresis, it separates proteins according to the length of polypeptides. The 
proteins are then probed using antibodies specific to the target protein.  
 
SDS-PAGE gels were made using the mini protean II gel kit (Bio-Rad laboratories, 
California). SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel 
electrophoresis, is a technique used to separate proteins according to their 
electrophoretic mobility.  
 
Resolving gel 
Gel   6% 8% 10% 13% 
H2O (ml)   5.3 4.6 3.9 3.0    
30% acrylamide (ml)   2.0 2.7 3.4 4.3 
1.5M Tris pH 8.8 (ml)   2.5 2.5 2.5 2.5  
10% SDS (ml)   0.1 0.1 0.1 0.1 
10% ammonium persulfate (ml) 0.1 0.1 0.1 0.1 
TEMED (µl)   8.0 8.0 8.0 8.0 
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7mls of the resolving gel mixture was poured into the assembled gel plates and left 
to polymerise for 15 minutes. The water was then poured off. 
Varying amounts of acrylamide were used to separate different sized proteins. The 
greater volume of acrylamide in the higher percentage gel enabled the separation of 
smaller proteins.   
 
Stacking gel 
H2O (ml)   3.0 
30% acrylamide (ml)   0.67 
1.0M Tris pH 6.8 (ml)   0.25 
10% SDS (µl)   40 
10% ammonium persulfate (µl)  40 
TEMED (µl)   6 
 
2mls of the stacking gel mixture was poured into the gel plate and a comb was 
inserted and the gel was allowed to set for 15 minutes. 
Protein samples were prepared (20-40µg protein) in 20µl of RIPA buffer with 10µl 
of SDS-PAGE loading buffer (4ml distilled water, 1ml 0.5M Tris pH 6.8, 0.8ml 
glycerol, 1.6ml 10% SDS, 0.4ml 2-mercaptoethanol, 0.2ml 2% bromophenol blue) 
and heated to 96°C for 6 minutes (using a Perkin Elmer PCR machine). Gels were 
assembled in the electrophoresis tank and the reservoirs filled with SDS-PAGE 
running buffer (7.5g Tris base, 36g Glycine, 2.5g SDS, 500ml deionized water). 
Samples were loaded and run at 140v until the bromophenol blue line was near the 
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Scouring pad 
Whatmann 3MM 
paper 
 
Gel 
 
 PVDF 
 
Whatmann 3MM 
paper 
Scouring pad 
bottom of the gel. A rainbow protein size marker (10µl) was also run alongside the 
samples.  
 
Electroblotting onto PVDF membrane 
 
 
The gels and membranes were assembled as shown above and were soaked in 1X 
transfer buffer (10% methanol, Tris base 150g, Glycine 720g, 10 litres deionized 
water). PVDF membranes (Polyvinylindene Difluoride, Sigma-Aldrich) were pre-
wet in 100% methanol for 15 seconds then soaked in transfer buffer before use. The 
sandwich shown was placed in a cassette in a western tank containing 1X transfer 
buffer and run at 40V overnight at 4°C.  
 
Probing the membrane with antibodies 
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The membranes were taken off the gels and rinsed with distilled water. They were 
placed in a bath of Ponceau S for two minutes, and the presence of bands confirmed 
protein transfer. Ponceau S is a sodium salt of a diazo dye that may be used to 
prepare a stain for rapid reversible detection of protein bands on PVDF membranes. 
The Ponceau S was rinsed off with PBS. The membranes were blocked in 5% 
Marvel (dried milk) in PBS + 0.1% Tween at room temperature for 1 hour. They 
were then incubated in primary antibody for 1 hour at room temperature. 
Membranes were washed with 0.1% PBS-Tween three times and then secondary 
antibody was added for 1 hour at room temperature (Table 2.1). The membrane was 
washed again with PBS-Tween three times and the Tween was removed by washing 
with PBS alone. Enhanced chemiluminescence was used to visualize the protein. 
2mls of ECL reagent A (substrate solution containing tris buffer) was added to 2mls 
of ECL reagent B (acridan substrate solution in dioxane and ethanol) (Pierce & 
Warriner) and the membrane added and incubated for 5 minutes. The membranes 
were wrapped in cling film and exposed to hyperfilm ECL (Amersham) in a dark 
room. The films were developed.  
 
Table 2.1 Antibodies used in western blot 
 
 1º Ab    2º Ab 
Antibody IC2    Goat anti rabbit with HRP 
Species Rabbit polyclonal  Goat 
Against Intracellular domain Rabbit 
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 of plexin B1 
Company Artigiani et al, 2003 Santa Cruz Biotec Inc. 
 
2.1.13 Immunofluorescence 
 
Immunofluorescence is a technique allowing the visualization of a specific protein 
in cells or tissue sections by binding a specific antibody chemically conjugated with 
a fluorescent dye such as fluorescein isothiocyanate (FITC). 
 
Borosilicate glass coverslips of 13mm diameter were sterilised and coated with 
fibronectin (Sigma). 10µg/ml of fibronectin was added to each well. The coverslips 
were incubated with fibronectin for 2 hours at room temperature and cells were 
seeded to 70-80% confluence. The cells were left overnight at 37ºC.  Cells were 
transiently transfected with 0.8µg of DNA per well using Lipofectamine 2000 as 
described previously. 
On day 3, the medium was aspirated and the cells transfected with CD2-Plexin B1 
were activated using a mouse monoclonal antibody against CD2 (OX34, Abcam). 
Cells were incubated at 37ºC for 30 minutes. The cells were washed three times 
with PBS. The OX34 antibodies were crosslinked using an anti-mouse IgG for 15 
minutes at 37ºC. The cells were washed in PBS and fixed with 4% 
paraformaldehyde (PAF) for 10 minutes. The cells were washed in PBS and to 
solubilise the cell membrane 0.2% Triton X 100 was added for 10 minutes at room 
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temperature. After washing the cells with PBS (3x5mins) on a shaker, 2% horse 
serum was used to block the cells for 20 minutes at room temperature. 
The primary antibody (Table 2.2) was then added and allowed to incubate for 1 
hour at room temperature on a shaker. The cells were washed three times for 5 
minutes with PBS and then incubated with secondary antibody for 1 hour at room 
temperature on the shaker in the dark. After washing the cells, the coverslips were 
mounted on slides using 2µl Vectashield with DAPI and stored at 4ºC. The cells 
were viewed using a fluorescent microscope (Nikon, C-SHG1 with epifluorescent 
attachment).  
 
 
 
Table 2.2 Primary and secondary antibodies used for immunohistochemistry 
 
 
 
Antibody 
 
Dilution 
 
Species Against Company 
OX34 1/400 Mouse 
monoclonal 
CD2 Abcam 
anti-VSV 1/200 Rabbit 
polyclonal 
VSV Abcam 
Goat 
anti-mouse 
FITC 
1/200 Goat Mouse Southern 
Biotechnology 
Phalloidin 
TRITC 
1/500 Amanita 
phalloides 
F-Actin Sigma 
Goat anti-rabbit 
TRITC 
1/100 Goat Rabbit Sigma 
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2.1.14 Preparation of Semaphorin 4D-Fc 
 
Recombinant Sema4D were prepared by protein-A sepharose affinity 
chromatography from the conditioned medium of transiently transfected COS7 cells 
(Turner et al. 2006). The Sema4D was fused to the Fc fragment of human IgG, to 
enable the proteins to be efficiently purified using protein-A (Turner et al. 2006).  
Three T80 flasks of COS7 cells were grown to 70% confluence and transiently 
transfected with 20µg of Sema4D-Fc (provided by Laura turner). Cells were 
cultured in medium containing 10% ultra low IgG FBS (Invitrogen) to prevent 
isolation of IgG‟s during the preparation. This provided 50mls of conditioned 
medium containing chimeric protein which was harvested 72 hrs post transfection 
and stored at –20C until required.  
Conditioned medium was centrifuged at 3000g for 10 min to remove cell debris and 
the supernatant was transferred to 50 ml Falcon tubes containing 2 ml of Buffer A 
(500mls of water, 0.15M NaCl2, 0.02M NaH2PO4, 0.1% sodium azide, adjusted to 
pH 8.0) and 250mg of Protein-A immobilised on Sepharose CL-4B (Sigma, P3391; 
binding capacity approximately 20 mg human IgG/ml lyophilised powder) and 
rotated overnight at 4C. A further 48mls was rotated in a 1ml Protein-A agarose 
suspension (Invitrogen, 15918-014).  Both suspensions were poured through a 
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disposable column (Amersham Biosciences, 2745700) at 4C to allow the 
sepharose/agarose to accumulate and then the column was washed with 15ml cold 
PBS. Bound semaphorins were eluted using 2.5 ml of 100mM glycine, pH 2.7. The 
elutes were collected in 15 ml Falcon tubes containing 250l of 1 M Tris, pH 9.0 
and placed on ice.  The protein concentration and purity were assessed by western 
blotting in comparison to known concentrations of Sema 3A-Fc (R&D systems). 
The concentration of recombinant semaphorin was estimated by comparison of the 
band intensities of known volumes of semaphorin with known quantities of BSA 
standards (Turner et al. 2006).  
 
2.1.15 Collapse assay 
 
Borosilicate glass coverslips, 13mm diameter, were placed in each well of a 24 well 
plate (Nunc). 1.5 x 10
5 
COS7 cells were counted using a haemocytometer. The 
COS7 cells were then seeded in each well. The cells were incubated overnight at 
37ºC. When the COS7 cells were 80% confluent they were transiently transfected 
with 0.8µg of the appropriate construct to be studied, per well using Lipofectamine 
2000. 10µl Lipofectamine 2000 was added to 240µl Optimem 1 with glutamax-1 
(Gibco, UK) and left for 5minutes at room temperature (for each transfection 
sample). 0.8µg DNA (diluted in 250µl Optimem 1) was added to the lipofectamine 
2000 mix (above) and left for 30 minutes at room temperature. The 500µl mix was 
added to the cells and incubated for 24 hours at 37°C. 
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48 hours post transfection, 50 µl of medium and 2µg/ml of Sema4D-Fc were placed 
on parafilm and the coverslips were laid upside down on top of this mixture and 
incubated for 5 minutes at 37ºC. The coverslips were placed in a 24 well plate and 
washed once with PBS. 4% paraformaldehyde  (2g in 50mls PBS heated to 60ºC for 
one hour adjusted to pH 7.4) was added for 20 minutes to fix the cells. The wells 
were washed with PBS and 0.2% Triton X 100 was added for 10 minutes at room 
temperature to permeabilise the membrane. The wells were washed with PBS (3 x 5 
minutes). 2% horse serum in PBS (blocking buffer)  was added for 20 minutes at 
room temperature on a shaker. The cells were incubated for 1 hour at room 
temperature with the primary antibody (Table 2.3) diluted in 2% horse serum and 
then washed with PBS (3 x 5 minutes). The secondary antibody diluted in 2% horse 
serum was added for 1 hour in the dark at room temperature with goat anti-mouse 
FITC and phalloidin conjugated TRITC. The wells were then washed with PBS (3 x 
5 minutes) and a drop of Vectashield with DAPI (Vector Labs, H-200) was placed 
onto the slides. The coverslips were removed from each well and allowed to dry for 
2 minutes and then placed over the top of the Vectashield. The coverslips were 
sealed onto the slides using clear nail varnish. The stained cells were then examined 
using a fluorescent microscope and pictures were taken (Nikon Diaphot 200 with 
epifluorescent attachment, C-SHG1). The images were taken using each of the three 
fluorescent filters and using Photoshop (Adobe) each image was assigned a colour 
(Red-TRITC, green-FITC, blue-DAPI). The images were merged and then opened 
using image J to calculate their area.  
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The number of collapsed COS7 cells, defined as rounded cells having a diameter 
<350µm² were counted (Oinuma et al. 2003).  The area of each cell was calculated 
by using Image J, version 1.38 (Image J\ plugins\Particle counting\Cell_Area.txt). 
Collapsed cells were counted as a percentage of the total number of transfected cells 
and the results are the mean of three independent experiments, with 50 cells sized 
per experiment.  
Confocal images were generated using a confocal microscope (Zeiss LSM 510W 
upright confocal microscope).  
 
 
 
Table 2.3 Antibodies used in the Collapse Assay 
 
 
Antibody 
 
Dilution 
 
Species Against Company 
 
1º Plexin B1 
 
 
1/200 
 
Rabbit 
Polyclonal 
IgG 
 
Plexin B1 
 
Santa Cruz 
2º Goat anti-
rabbit TRITC 
1/100 Goat Rabbit IgG Southern 
Biotech 
2º Anti-mouse 
FITC 
1/200 Goat Mouse IgG Southern 
Biotech 
PhalloidinTRITC 
 
1/5000 Amanita 
phalloides 
F-actin Sigma 
Phalloidin FITC 1/5000 
 
Amanita 
phalloides 
F-actin Fluka 
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Chapter 3 
 
 
Generation of Mutant Plexin B1  
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3.1 Introduction 
 
 
Semaphorins are a large family of secreted or membrane-bound proteins (Nakamura 
et al. 2000), whose function is mediated by plexins. Plexin B1 has been identified as 
the receptor for Semaphorin 4D (Tamagnone et al. 1999). Semaphorins are known 
to regulate axonal pathfinding in the developing nervous system (Tessier-Lavigne 
& Goodman, 1996). However evidence suggests that semaphorins are involved in 
the regulation of cell-cell interactions (Tamagnone et al. 1999) and there is 
increasing data suggesting that semaphorins and their receptors may play a 
regulatory role in tumorigenesis.  
 
The membrane anchored class 4 semaphorin has become a focus of intensive 
research. Wong et al. have found that semaphorins and their receptors are widely 
expressed in prostate cancer with overexpression of Plexin B1 in the cell line 
LNCaP. Thirteen somatic missense mutations have been found in the cytoplasmic 
domain of the Plexin B1 gene (Wong et al. 2007).  
 
In order to determine the functional significance of Plexin B1 mutations, a mutation 
was introduced into the wild type gene. Two constructs were provided by Alan Hall 
and Mariette Driessens, full length Plexin B1 in pcDNA3 and truncated Plexin B1 
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conjugated to CD2 in pcDNA3, respectively. These constructs had been used 
previously by Driessens et al. 2001 and Turner et al. 2006. PcDNA3 is an 
expression vector, a circular piece of DNA that can be transformed into a host for 
the purpose of producing the protein coded for by the DNA. The mutation C5662T 
is predicted to result in a substitution of a proline to a serine at position 1798.  The 
altered construct was used to transform E.coli. Colonies were selected, grown up 
and the identity of the mutation confirmed using restriction enzymes and direct 
sequencing. To determine the effect of the mutation it was transfected into 
mammalian cells. Transfection is a method by which experimental DNA may be put 
into a cultured cell. The expression of these constructs was confirmed using reverse 
transcription PCR, western blotting and immunofluorescence.  
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3.2 Results 
 
3.2.1 Generation of the mutation in Plexin B1 cDNA (full length-FL 
and truncated-CD2) 
 
The C5662T mutation in the Plexin B1 gene, which is predicted to result in a 
substitution of a proline to a serine at position 1798, was generated in full length 
and truncated Plexin B1 constructs. The QuikChange XL Site-Directed 
Mutagenesis Kit (Stratagene) was used to introduce the mutation into the two 
constructs.  
 
Once the mutation had been introduced using site directed mutagenesis the vector 
DNA incorporating the desired mutation was transformed into XL10 – Gold 
ultracompetent cells.  Transformed E-coli were grown on agar plates with 
ampicillin and colonies were picked for each construct. DNA was extracted for each 
construct and 1µl of DNA was run on an 0.8% agarose gel (Figure 3.1). 
All five colonies of the CD2 construct and three colonies (A-C) of the full length 
(FL) construct showed the expected pattern of linear, nicked and supercoiled DNA. 
Colonies may have different quantities of these subtypes of  DNA and will therefore 
show different patterns on the agarose gel. Plasmid DNA isolated using miniprep 
and maxiprep kits is a mixture of linear, nicked and supercoiled DNA and they can 
all exist in a single plasmid preparation. No product was seen in colony D full 
length Plexin B1 suggesting that it had not been transformed with Plexin B1.  
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                         A  B  C  D  E                       A  B  C  D   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Mutated full length Plexin B1 and truncated CD2 Plexin B1 DNA run on 
an 0.8% gel. Mutated Plexin B1 was transformed into E. coli cells and grown on 
agar plates. Following DNA extraction using the Qiagen plasmid purification 
method five colonies of the CD2 construct and three of the full length Plexin B1 
construct are shown, in their supercoiled, nicked and linear forms.  
 
 
 
  DNA      FL-Plexin B1 
  Marker    A-D colony 
  1Kb  
 
DNA        CD2-Plexin B1            
Marker       A-E colony 
1 Kb 
 
 
  
___  linear 
___   nicked 
___   supercoiled 
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Spectrophotometry was used to calculate the DNA concentration in the samples 
using the formula described (Table 3.1).  
 
Using the appropriate primers (Plexin B1 sense and antisense) for the mutation, 
PCR was used to amplify the segment of DNA containing the C5662T mutation and 
the product was run on a 1.8% gel using 6µl of PCR product (Figure 3.2). This 
confirmed the presence of DNA in the mutant full length Plexin B1 (colonies A-C) 
and in the CD2 Plexin B1 construct (colonies A-E).  
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Sample  Ab 260nm   DNA concentration (µg/ml) 
CD2 A 0.0038    31.7 
CD2 B 0.0147    122.5 
CD2 C 0.0025    20.8 
CD2 D 0.0093    77.5 
CD2 E 0.0048    40.0 
FL A 0.0577    480.8   
FL B 0.0095    79.2 
FL C 0.0039    32.5 
 
Table 3.1 DNA concentration of individual colonies. The concentration of the 
extracted DNA of the mutated full length Plexin B1 and truncated CD2 Plexin B1 
was calculated according to the formula: Conc. of DNA sample = 
spectrophotometric conversion x Ab260  x dilution factor. 3µl of DNA was combined 
with 500µl of water – giving a dilution factor of 167. The spectrophotometric 
conversion for DNA was 50 (1 A260 unit of double-stranded DNA=50 µg/ml).  
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                                     DNA               CD2-                       FL 
                                     Marker        Plexin B1               Plexin B1               
                                     1Kb    A    B   C     D    E            A  B   C       
                                
 
Figure 3.2 PCR product of truncated CD2 Plexin B1 and full length Plexin B1. The 
PCR product was run on a 1.8% gel using a 1Kb DNA marker. 6µl of PCR product 
with 2µl of loading buffer were loaded in each well. The presence of DNA in the 
five CD2 plexin B1 and three full length Plexin B1 mutant clones was confirmed.    
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3.2.2 Confirmation of the mutation 
 
To check that the mutation had been introduced into the Plexin B1 constructs and 
no new mutations had been introduced, two methods were used: 
 
1. Digestion with Restriction Enzyme – Hae III 
A restriction enzyme recognizes and cuts DNA at a particular sequence of 
nucleotides. For example, the bacterium Hemophilus aegypticus produces an 
enzyme named HaeIII that cuts DNA wherever it encounters the sequence 
5‟…GG^CC…3‟ and 3‟…CC^GG…5‟. 
 
Using the webcutter program (Webcutter 2004: internet communication) Hae III 
recognises 6 sites in the wild type (full length Plexin B1-without mutation) Plexin 
B1 PCR product. In the mutant (C5662T) Hae III recognises 5 sites.  
 
The digested products were run on a 3% agarose gel (Figure 3.3). The total number 
of base pairs in the uncut product is 410. The wild type Plexin B1 as expected has 
seven bands and the mutant has six bands. The lower bands had not separated 
entirely on the 3% agarose gel. Digestion with Hae III had shown that the full 
length clone A was not the same as full length clone B. The mutation was known to 
be present in the 144 length band and therefore the C5662T mutation appeared to be 
present in all of the CD2 Plexin B1 clones and the full length Plexin B1 clone A. 
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              DNA                CD2 cut               CD2 uncut 
 Marker             with Hae III            (no Hae III)   
 1Kb 
           A      B       C      D      E       A      B 
   
                                     
 
 
                                    DNA      FL cut       FL uncut     WT                
                                    Marker     
                                    1Kb    A      B      A     B      
                                       
 
Figure 3.3 Digestion of CD2 Plexin B1 and full length Plexin B1 using the 
restriction enzyme Hae III. PCR products, including wild type (WT) full length 
Plexin B1, mutant CD2 Plexin B1 and mutant full length Plexin B1 digested with 
 
410 bp 
 
 
 
144 bp 
108 bp 
86 bp 
 
 
30 bp 
26 bp 
16 bp 
 
 
410 bp 
 
 
144 bp 
108,101 bp 
86 bp 
 
43 bp 
30,26,16 bp 
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Hae III as well as uncut (No Hae III) CD2 Plexin B1 and full length Plexin B1 were 
run on a 3% agarose gel.  Digestion of the constructs with Hae III had confirmed 
the presence of the mutation in clones A-E of the truncated CD2 Plexin B1 and 
Clone A of the full length Plexin B1. The total number of base pairs in the uncut 
PCR product is 410. The mutation was present in the 144 base pair band. The 
smaller bands had not separated as expected and this was probably a reflection of 
their size and having not been run for long enough. Despite using a higher 
percentage gel and running the product for a longer time in the electrophoresis 
tank, the lower bands could not be separated (WT = wild type cut, bp = base pairs).  
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2. Cycle sequencing 
 
 
To independently confirm the presence of the mutation and that no new mutations 
had been introduced, cycle sequencing was used. Using the appropriate primers for 
the mutation a PCR was performed and the product run on a 1.8% gel. (Figure 3.4).  
 
This reaction confirmed the presence of DNA in the PCR product, which was also 
the correct size at 410 base pairs. Again it appeared that the FL B clone was a 
slightly larger product than FL A clone.  
 
Using the PCR products formed from the appropriate primers for the C5662T 
mutation, cycle sequencing was carried out (Figure 3.5).   The samples could not be 
analysed in the laboratory where this research was carried out and had to be sent to 
a centre which had a sequence analyser.  
 
The mutation was confirmed in the CD2 construct in clones A to E and the full 
length construct in clone A. A Cytosine had been changed to a Thymine at the 
correct position.  
 
From the cycle sequencing it became evident that the full length Plexin B1 clone B 
was not identical to clone A. It appeared that part of the sequence had been 
duplicated during mutagenesis and therefore it was no longer used (Figure 3.6).  
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                      DNA              CD2-Plexin B1             FL-Plexin B1 
                      Marker     A      B      C      D      E         A      B 
                                  
 
 
 
Figure 3.4 PCR products of DNA extracted from clones A-E CD2 Plexin B1 and 
clone A and B  full length Plexin B1. PCR products were loaded on to a 1.8% 
agarose gel. As expected the length of the PCR product was 410 base pairs and all 
of the clones were of the same size except the full length Plexin B1 clone B. With 
this consistent discrepancy in clone B of the full length Plexin B1 it was no longer 
used in future experiments (bp = base pairs).  
 
 
 
 
 
 
410 bp 
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              Mutation 
 
 
 
 
 
 
Figure 3.5 Cycle sequencing of the mutant Plexin B1 (C5662T). An automated DNA 
sequencing machine was used to analyze the DNA fragments produced. This 
directly confirmed that the mutation had been introduced into the constructs. The 
base Cytosine had been altered to a Thymine in all five of the CD2 Plexin B1 clones 
and clone A of the full length Plexin B1.  
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    Mutation 
    
 
 
 
 
 
 
 
Figure 3.6 Cycle sequencing of mutant full length Plexin B1 clone B. The results of 
the mutant full length Plexin B1 showed two separate sequences both containing the 
mutation. The reason for this was not clear but it was thought that part of the 
sequence had been duplicated possibly during mutagenesis, which would explain 
the larger size of the PCR product on gel electrophoresis.  
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The entire cytoplasmic domain of the wild type Plexin B1 and the mutant clones 
were then sequenced using five sets of primers to cover 2200 base pairs. The 
presence of the mutation was confirmed in the mutant clones and that no new 
mutations had been introduced and there were no changes in the wild type clones 
(results not shown). 
 
The primers used for sequencing the entire cytoplasmic domain of Plexin B1 and 
their sequence is shown below. See Appendix for positions of the primers on the 
gene sequence.  
 
B1-52 S   TGGGTCACGTGCAGTATGAC 
B1-52 AS AGTGACCTGGTTGCCCAGT 
B1-2S  CTCACCGTGGCACTGCATG 
B1-2AS  GATGTTGAGTGGCGGTCTGGG 
B1-3S  AGGAGTGCCTCTCACCCAGCG 
B1-3AS  GACCTGCTGGATGAGCAGGC 
B1-4S  TGCCGCTCGCTGTGAAGTAC 
B1-4AS  GCAGATTGCAGCTGCTGTGG 
Sp6 S  CCCTGCATGAACTCTACAAG 
Sp6 AS  TAGTGTCACCTAAATG 
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3.2.3 Generation of stable clones of full length Plexin B1 
 
The vector, mutant and wild type full length Plexin B1 constructs were transfected 
into NIH3T3 cells. Stable clones were selected using geneticin and ring cloned. The 
clones were then grown up individually and stored at -80ºC or in liquid nitrogen.  
 
The relative expression of Plexin B1 RNA in each stable clone was then determined 
by RT-PCR+/- superscript II (Figure 3.7). 
 
Most of the wild type (WT) clones and all of the mutant (M) clones strongly 
express Plexin B1. The vector (V) controls were negative, proving that there was no 
endogenous Plexin B1 being expressed. The control samples without superscript 
were all negative, showing that there was no cloned  Plexin B1 cDNA present in the 
RNA samples.  
 
Digestion with Hae III and sequencing were used to prove the presence of the 
mutation in each stable clone. Following the digestion with Hae III all the mutant 
clones showed the correct sized bands, as did the wild type (except WT4). 
Sequencing confirmed the presence of the mutation in the mutant clones and that no 
new mutations had been introduced in the wild type clones (Figure 3.8). 
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DNA     WT1    WT2    WT3      WT4  WT5  WT6   V1     V2        DNA   V3      V4        M1     M2    M3       M4    M5   M6  
Marker    +/-       +/-       +/-          +/-     +/-      +/-     +/-      +/-      Marker  +/-      +/-       +/-       +/-      +/-       +/-     +/-      +/-    
 
 
Figure 3.7 Relative expression of Plexin B1 RNA in stable clones by RT-PCR. The 
constructs had been transfected into NIH3T3 cells and grown up individually and 
stored at -80ºC. RNA was extracted and first strand cDNA synthesis was carried 
out on the samples. Following PCR, 6µl  product was run on an 0.8% agarose gel. 
A 1Kb DNA marker was used. Two of the wild type Plexin B1 clones (WT4 and 
WT5) and all of the mutant Plexin B1 clones express Plexin B1 at a range of levels. 
The control samples without reverse transcriptase (Superscript II) confirmed that 
there was no contaminated Plexin B1 DNA in the RNA samples. The vector controls 
demonstrated that no endogenous Plexin B1 RNA was present (WT – Wild type 
Plexin B1, V – vector, M – mutant, +/- with and without superscript II).    
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DNA      M1     M2    M3     M4   M5   M6   Uncut                       DNA      WT1   WT2   WT3  WT4  WT5  WT6        Uncut  
Marker                               Marker                                                                      
 
                                     
 
 
Figure 3.8 Checking the clones with Hae III digestion and cycle sequencing. 
Samples were run on a 3% agarose gel. All six of the mutant clones showed the 
correct sized bands following digestion with Hae III as did five of the wild type 
clones. The total number of base pairs in the uncut PCR product was known to be 
410 and this was confirmed on the DNA marker. Cycle sequencing had also 
confirmed the presence of the mutation and no new mutations had been introduced. 
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3.2.4 Protein expression of Plexin B1 
 
Western blotting and immunofluorescence was used to show the protein expression 
of full length Plexin B1 in stable clones. 
 
In 2003 Artigiani found that Plexin B1 undergoes proteolytic processing converting 
it into a heterodimeric receptor, this occurs in a post golgi compartment and likely 
at the cell surface. This processing may increase the binding and functional 
response of Plexin B1 to its ligand Semaphorin 4D. The group showed that Plexin 
B1 was cleaved into an α subunit of approximately 200KDa and a β subunit of 
approximately 100KDa (Figure 3.9) (Artigiani et al. 2003). The cleavage of Plexin 
B1 is mediated by proprotein convertases.  
 
No commercial antibody against Plexin B1 was available at the time of doing this 
work. However Artigiani et al. had raised a rabbit polyclonal antibody (IC2) against 
the β subunit of Plexin B1. Therefore IC2 antibody against the intracellular region 
of Plexin B1 was used to detect the β subunit and the unprocessed Plexin B1 of 
300KDa. 
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Figure 3.9 Full length Plexin B1 showing the α and β subunits (Artigiani et al. 
2003). In this schematic representation of Plexin B1, the arrow shows the predicted 
processing site resulting in an extracellular moiety (molecular mass 200KDa) and a 
transmembrane/ cytoplasmic moiety (100KDa). Cells that had been transfected with 
Plexin B1 were found to express both the full length (300KDa) and two cleaved 
subunits (200 and 100KDa) at the cell surface. The β subunit was detected using the 
IC2 antibody (Artigiani et al. 2003).  This suggested that Plexin B1 undergoes 
proteolytic processing converting it into an heterodimeric receptor. This process 
increases the binding and the functional response of Plexin B1 to its ligand Sema4D 
(Artigiani et al. 2003).   
 
122 
 
Using protein from HT29 cells (human colon adenocarcinoma cell line) known to 
express Plexin B1 (Artigiani et al. 2003) as a positive control a western blot showed 
that a 100kDa product was present in LNCaP, PC3 and HT29 (Figure 3.10). The 
concentrations of primary and secondary antibody used were a personal 
communication by V Blanc.  However there were many non-specific bands seen on 
the western blot. This problem is usually due to a non specific antibody, a poor 
primary antibody quality/ old antibody, inadequate blocking or the protein is 
detected but degraded.  
 
Attempts were made to visualize the membrane protein Plexin B1 in stable 
transfected cells. Various techniques were used to solve the problem of too many 
bands. Different protein extraction buffers were tried, replacing the antibody with a 
fresh stock, blocking with BSA prior to adding antibody and using sodium butyrate 
to increase the intensity of Plexin B1 100KDa band. To increase antibody 
specificity and reduce the background, different antibody concentrations were used 
and a variety of blocking agents were tried.  However, the problem of non specific 
bands continued. The use of sodium butyrate with the extraction buffer, RIPA, 
produced the brightest bands (Figure 3.11).  
 
It was not possible to conclude from the western blot experiments that Plexin B1 
was being expressed in the stable transfections as numerous bands from the vector 
control group were also seen on the western blots. This was thought to be because 
the IC2 antibody was non specific and/or the stable transfections were switching off 
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the expression of the protein. At the time of doing these experiments, there was no 
other antibody available and no further experiments were performed to verify these 
bands.  
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Figure 3.10 Western blot showing protein expression of endogenous plexin B1 
(26g protein loaded using RIPA buffer and run on an 8% SDS-PAGE gel). Using 
a specific anti-Plexin B1 antibody raised against the cytoplasmic domain of the 
protein (IC2) a protein is detected on western blot with a molecular mass of 
100KDa, corresponding to the truncated form of the Plexin B1 receptor. HT29 cells 
which are known to express endogenous Plexin B1 were used as a control. 
However, many non specific bands were seen on the western blot, suggesting there 
was non-specific binding of primary or secondary antibodies.  
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a)  Vector +/- NaB                  LNCaP +/- NaB 
   RIPA   OBG   EB                EB  RIPA  OBG 
       
  b)     Mutant +/- NaB                     HT29 + NaB 
        EB    RIPA    OBG               EB  OBG  RIPA  
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 c)      NIH3T3 + NaB                 WT +/- NaB 
         RIPA  OBG   EB          RIPA  OBG  EB 
 
 
Figure 3.11 a,b,c.  Protein expression of Plexin B1 using three protein extraction 
buffers Different extraction buffers RIPA, EB and OBG with and without sodium 
butyrate (NaB) were used. Using stable transfected NIH3T3 cells with wild type 
(WT) Plexin B1, mutant Plexin B1, vector only (HT29 and LNCaP cells as controls) 
western blots were carried out. 40µg of protein was loaded onto 8% SDS-page gels. 
Non specific bands were seen on each western blot and there was insufficient 
evidence to say that the stable transfected cells expressed either construct.  
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Western blotting was found to be unreliable most likely due to a non-specific 
antibody and so the research was now focused on a newly acquired antibody. The 
antibody to CD2 could be used to detect the truncated CD2 Plexin B1.  
 
Semaphorin 4D, the transmembrane ligand for Plexin B1, is thought to activate 
plexin receptors through clustering (Driessens et al. 2001). The chimeric molecule 
CD2-Plexin B1, in which the cytoplasmic domain of Plexin B1 was fused to CD2 (a 
T lymphocyte antigen) was used. Driessens et al. 2001 had shown that when the 
DNA of CD2-Plexin B1 was microinjected into 3T3 cells and antibodies to CD2 
added this led to the formation of stress fibers and cell contraction thus mimicking 
ligand binding.  
 
DNA of Vector-CD2, Wild type (WT)-CD2 Plexin B1 and Mutant-CD2 Plexin B1 
was extracted and transfected into COS1 cells and 3T3 cells (as described 
previously). Immunofluorescence was used to assess protein expression of these 
constructs using the anti-CD2 antibody (CD2 antibody, product name OX34, mouse 
monoclonal, Abcam). 
 
The results show membranous and nuclear staining indicating that both wild type 
and mutant transiently transfected cells express Plexin B1 and that the protein is 
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transported to the cell surface (Figure 3.12 – 3.21). The results suggest that the 
mutation does not have an effect on the protein expression of truncated Plexin B1.  
For each transfection three photographs were taken using filters to look at nuclear 
staining (blue), actin staining (red) and staining for Plexin B1 (green). A combined 
image was then taken (larger image). The cells were viewed using a fluorescent 
microscope (Nikon, C-SHG1 with epifluorescence attachment). OX34 primary 
antibody stained CD2, F-actin staining was with phalloidin TRITC and nuclear 
staining was with DAPI.  
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Figure 3.12 COS1 cells transiently transfected with WT-CD2 Plexin B1. Nuclear 
staining – DAPI; CD2 staining – OX34 primary antibody diluted 1/400, Abcam; 
goat anti-mouse FITC secondary antibody diluted 1/200, Southern Biotechnology; 
F-actin staining – phalloidin TRITC diluted 1/500, Sigma. The protein expression of 
truncated Plexin B1 conjugated with CD2 was detected using immunofluorescence 
with the anti-CD2 antibody. Membranous and nuclear staining was seen indicating 
that the protein is transported to the cell surface. Nuclear staining may be due to 
over expression of the protein. A low transfection efficiency was observed. Three 
photographs were taken using filters to look at nuclear staining (blue), actin 
staining (red) and staining for Plexin B1 (green). A merged image was then taken 
(larger image).  
 
 
 
 
 
 
 
 
   
 
 
 
 
                 CD2 Plexin B1                              Actin                                     Nuclear 
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Figure 3.13 COS1 cells transiently transfected with WT-CD2 Plexin B1 (no 1º 
antibody). Nuclear staining – DAPI; goat anti-mouse FITC secondary antibody 
diluted 1/200, Southern Biotechnology; F-actin staining – phalloidin TRITC diluted 
1/500, Sigma. As a control, when no primary antibody is added (anti CD2 
antibody), protein expression of CD2 Plexin B1 is not detected. Three photographs 
were taken using filters to look at nuclear staining (blue), actin staining (red) and 
staining for Plexin B1 (green). A merged image was then taken (larger image).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
               CD2 Plexin B1                              Actin                                          Nuclear 
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Figure 3.14 COS1 cells transiently transfected with Mutant-CD2 Plexin B1. 
Nuclear staining – DAPI; CD2 staining – OX34 primary antibody diluted 1/400, 
Abcam; goat anti-mouse FITC secondary antibody diluted 1/200, Southern 
Biotechnology; F-actin staining – phalloidin TRITC diluted 1/500, Sigma. The 
protein expression of truncated Mutant Plexin B1 conjugated with CD2 was 
detected using immunofluorescence with the anti-CD2 antibody. Membranous 
staining was seen indicating that the protein is transported to the cell surface. A 
low transfection efficiency was observed. Three photographs were taken using 
filters to look at nuclear staining (blue), actin staining (red) and staining for Plexin 
B1 (green). A merged image was then taken (larger image).  
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Figure 3.15 COS1 cells transiently transfected with Vector-CD2. Nuclear staining – 
DAPI; CD2 staining – OX34 primary antibody diluted 1/400, Abcam; goat anti-
mouse FITC secondary antibody diluted 1/200, Southern Biotechnology; F-actin 
staining – phalloidin TRITC diluted 1/500, Sigma. The protein expression of vector-
CD2 was detected using immunofluorescence with the anti-CD2 antibody. 
Membranous and nuclear staining was seen indicating that the protein is 
transported to the cell surface. Nuclear staining may be due to over expression of 
the protein. A low transfection efficiency was observed. Three photographs were 
taken using filters to look at nuclear staining (blue), actin staining (red) and 
staining for Plexin B1 (green). A merged image was then taken (larger image).  
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Figure 3.16 COS1 cells Mock transfected. Nuclear staining – DAPI; CD2 staining 
– OX34 primary antibody diluted 1/400, Abcam; goat anti-mouse FITC secondary 
antibody diluted 1/200, Southern Biotechnology; F-actin staining – phalloidin 
TRITC diluted 1/500, Sigma. Protein expression of CD2 Plexin B1 is not detected 
when COS1 cells are mock transfected (no DNA). This indicates that COS1 cells do 
not express endogenous CD2-Plexin B1. Three photographs were taken using filters 
to look at nuclear staining (blue), actin staining (red) and staining for Plexin B1 
(green). A merged image was then taken (larger image). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       CD2 Plexin B1                              Actin                                       Nuclear 
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Figure 3.17 3T3 cells transiently transfected with WT-CD2 Plexin B1. Nuclear 
staining – DAPI; CD2 staining – OX34 primary antibody diluted 1/400, Abcam; 
goat anti-mouse FITC secondary antibody diluted 1/200, Southern Biotechnology; 
F-actin staining – phalloidin TRITC diluted 1/500, Sigma. 3T3 cells were 
transiently transfected with wild type-CD2 Plexin B1. The protein expression of 
truncated Plexin B1 conjugated with CD2 was detected using immunofluorescence 
with the anti-CD2 antibody. Membranous and nuclear staining was seen indicating 
that the protein is transported to the cell surface. Nuclear staining may be due to 
over expression of the protein. A low transfection efficiency was observed. Three 
photographs were taken using filters to look at nuclear staining (blue), actin 
staining (red) and staining for Plexin B1 (green). A merged image was then taken 
(larger image).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             CD2 Plexin B1                                 Actin                                    Nuclear 
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Figure 3.18 3T3 cells transiently transfected with WT-CD2 Plexin B1 (no 1º Ab). 
Nuclear staining – DAPI; goat anti-mouse FITC secondary antibody diluted 1/200, 
Southern Biotechnology; F-actin staining – phalloidin TRITC diluted 1/500, Sigma. 
As a control, when no primary antibody is added (anti CD2 antibody), protein 
expression of CD2-Plexin B1 is not detected. Three photographs were taken using 
filters to look at nuclear staining (blue), actin staining (red) and staining for Plexin 
B1 (green). A merged image was then taken (larger image). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
              CD2 Plexin B1                              Actin                                        Nuclear 
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Figure 3.19 3T3 cells transiently transfected with Mutant-CD2 Plexin B1. Nuclear 
staining – DAPI; CD2 staining – OX34 primary antibody diluted 1/400, Abcam; 
goat anti-mouse FITC secondary antibody diluted 1/200, Southern Biotechnology; 
F-actin staining – phalloidin TRITC diluted 1/500, Sigma. The protein expression of 
truncated Mutant Plexin B1 conjugated with CD2 was detected using 
immunofluorescence with the anti-CD2 antibody. Membranous staining was seen 
indicating that the protein is transported to the cell surface. A low transfection 
efficiency was observed. Three photographs were taken using filters to look at 
nuclear staining (blue), actin staining (red) and staining for Plexin B1 (green). A 
merged image was then taken (larger image).  
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Figure 3.20 3T3 cells transiently transfected with Vector-CD2. Nuclear staining – 
DAPI; CD2 staining – OX34 primary antibody diluted 1/400, Abcam; goat anti-
mouse FITC secondary antibody diluted 1/200, Southern Biotechnology; F-actin 
staining – phalloidin TRITC diluted 1/500, Sigma. The protein expression of vector-
CD2 was detected using immunofluorescence with the anti-CD2 antibody. 
Membranous and nuclear staining was seen indicating that the protein is 
transported to the cell surface. Nuclear staining may be due to over expression of 
the protein. A low transfection efficiency was observed. Three photographs were 
taken using filters to look at nuclear staining (blue), actin staining (red) and 
staining for Plexin B1 (green). A merged image was then taken (larger image).  
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Figure 3.21 3T3 cells Mock transfected. Nuclear staining – DAPI; CD2 staining – 
OX34 primary antibody diluted 1/400, Abcam; goat anti-mouse FITC secondary 
antibody diluted 1/200, Southern Biotechnology; F-actin staining – phalloidin 
TRITC diluted 1/500, Sigma. Protein expression of CD2 Plexin B1 is not detected 
when 3T3 cells are mock transfected (no DNA). This indicates that 3T3 cells do not 
express endogenous CD2-Plexin B1. Three photographs were taken using filters to 
look at nuclear staining (blue), actin staining (red) and staining for Plexin B1 
(green). A merged image was then taken (larger image). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
              CD2 Plexin B1                                  Actin                                      Nuclear 
 
 
139 
 
The protein expression of truncated CD2 Plexin B1 was detected with the anti-CD2 
antibody using immunofluorescence. The wild type, mutant and vector constructs 
showed membranous and nuclear staining when transiently transfected in COS1 and 
3T3 cells. Plexin B1 expression was not detected in the samples when no primary 
antibody was added. From the immunofluorescence results the transfection 
efficiency in the transiently transfected cells was low (approximately 15%). The B-
Gal Kit (Invitrogen) was used to optimize the transfection efficiency by varying the 
concentrations of DNA and Lipofectamine and varying the confluence of the cells. 
 
The B- Gal staining kit provides reagents required to determine the percentage of 
cells transfected with a plasmid expressing lacZ. LacZ is a bacterial gene used as a 
reporter construct in eukaryotic transfection and the gene product B-galactosidase is 
easily assayed. B-galactosidase catalyses the hydrolysis of B-galactosides i.e X-gal. 
This produces a blue colour that can be visualised.  The steps for this involve 
transfecting cells with a plasmid expressing lacZ. The cells are fixed to the plates. 
They are then washed and incubated with an X-gal containing solution. The cells 
are then examined to determine the percentage of cells staining blue to estimate the 
transfection efficiency (Tables 3.2, 3.3, 3.4).  
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Table 3.2 Transfection Efficiency (%). Percentage of COS7 cells expressing B-
galactosidase. Cell density (95%-10%) and the DNA: Lipofectamine ratios (1:0.5 to 
1:5) were varied. The transfection efficiency was calculated using the formula:  
Total no. of blue cells/ Total no. of cells X 100. The conditions that gave the best 
tranfection efficiency were a DNA:Lipofectamine ratio of 1:2.5 with a high cell 
density.  
 
COS7 cells  
 
DNA(g): 
lipofectamine 
(l) ratio 
               
            Cell dilution with reducing cell density 
Highly confluent >>>>>>>>>>>>>>>>Low confluence 
(approx. 95%)                                            (approx. 10%) 
1:0.5 17 22 25 33 65 0 
1:1 34 37 37 38 55 0 
1:2.5 58 47 64 56 41 0 
1:5 53 59 36 0 0 0 
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Table 3.3 Transfection Efficiency (%). Percentage of COS1 cells expressing B-
galactosidase. Cell density (95%-10%) and the DNA: Lipofectamine ratios (1:0.5 to 
1:5) were varied. The transfection efficiency was calculated using the formula:  
Total no. of blue cells/ Total no. of cells X 100. The conditions that gave the best 
tranfection efficiency were a DNA:Lipofectamine ratio of 1:2.5 with a high cell 
density.  
  
 
COS1 cells 
 
DNA(g): 
lipofectamine 
(l) ratio 
          
          Cell dilution with reducing cell density 
Highly confluent >>>>>>>>>>>>>>>Low confluence 
(approx. 95%)                                         (approx. 10%) 
1:0.5 22 35 37 0 38 0 
1:1 30 37 0 25 26 0 
1:2.5 20 40 0 41 0 0 
1:5 15 0 22 27 0 0 
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Table 3.4 Transfection Efficiency (%). Percentage of NIH3T3 cells expressing B-
galactosidase. Cell density (95%-10%) and the DNA: Lipofectamine ratios (1:0.5 to 
1:5) were varied. The transfection efficiency was calculated using the formula:  
Total no. of blue cells/ Total no. of cells X 100. The conditions that gave the best 
tranfection efficiency were a DNA:Lipofectamine ratio of 1:2.5 with a high cell 
density.  
 
 
 
NIH3T3 cells  
 
 
 
DNA (g): 
lipofectamine 
(l) ratio 
 
         Cell dilution  with reducing cell density 
Highly confluent >>>>>>>>>>>>>>Low confluence 
(approx. 95%)                                       (approx. 10%) 
1:0.5 13 20 13 12 0 0 
1:1 19 13 20 16 12 0 
1:2.5 28 12 15 21 0 0 
1:5 17 0 5 2 0 0 
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The percentage of cells expressing B-galactosidase was calculated, using the 
formula: 
Total no. of blue cells   x   100 
Total no. of cells 
Using the B-Gal staining Kit, the DNA:Lipofectamine ratio that gave the best 
transfection rate was 1:2.5 for each cell line with the cells being highly confluent 
(approx. 90%). 
 
During the above optimisation, stable clones were grown up of truncated CD2-
Plexin B1 to examine the protein expression in 3T3 cells (Figure 3.22 – 3.25). As 
previously described, for each transfection three photographs were taken using 
filters to look at nuclear staining (blue), actin staining (red) and staining for Plexin 
B1 (green). A merged image was then taken (larger image).  
 
The results suggest that the stable transfections do not express CD2 Plexin B1 or 
that they express Plexin B1 at a very low level that could not be detected.   
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Figure 3.22 Stable transfection of 3T3 cells with WT-CD2 Plexin B1. Nuclear 
staining – DAPI; CD2 staining – OX34 primary antibody diluted 1/400, Abcam; 
goat anti-mouse FITC secondary antibody diluted 1/200, Southern Biotechnology; 
F-actin staining – phalloidin TRITC diluted 1/500, Sigma. Stable transfected 3T3 
cells with wild type CD2 Plexin B1 do not express Plexin B1. Three photographs 
were taken using filters to look at nuclear staining (blue), actin staining (red) and 
staining for Plexin B1 (green). A merged image was then taken (larger image).  
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Figure 3.23 Stable transfection of 3T3 cells with Mutant-CD2 Plexin B1. Nuclear 
staining – DAPI; CD2 staining – OX34 primary antibody diluted 1/400, Abcam; 
goat anti-mouse FITC secondary antibody diluted 1/200, Southern Biotechnology; 
F-actin staining – phalloidin TRITC diluted 1/500, Sigma. Stable transfected 3T3 
cells with Mutant CD2 Plexin B1 do not express the mutant Plexin B1. Three 
photographs were taken using filters to look at nuclear staining (blue), actin 
staining (red) and staining for Plexin B1 (green). A merged image was then taken 
(larger image).  
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Figure 3.24 Stable transfection of 3T3 cells with Vector-CD2. Nuclear staining – 
DAPI; CD2 staining – OX34 primary antibody diluted 1/400, Abcam; goat anti-
mouse FITC secondary antibody diluted 1/200, Southern Biotechnology; F-actin 
staining – phalloidin TRITC diluted 1/500, Sigma. Stable transfected 3T3 cells with 
Vector CD2 do not express Plexin B1. Three photographs were taken using filters 
to look at nuclear staining (blue), actin staining (red) and staining for Plexin B1 
(green). A merged image was then taken (larger image).  
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Figure 3.25 Mock transfected 3T3 cells. Nuclear staining – DAPI; CD2 staining – 
OX34 primary antibody diluted 1/400, Abcam; goat anti-mouse FITC secondary 
antibody diluted 1/200, Southern Biotechnology; F-actin staining – phalloidin 
TRITC diluted 1/500, Sigma. Protein expression of CD2 Plexin B1 is not detected 
when 3T3 cells are mock transfected (no DNA). This indicates that 3T3 cells do not 
express endogenous CD2-Plexin B1. Three photographs were taken using filters to 
look at nuclear staining (blue), actin staining (red) and staining for Plexin B1 
(green). A merged image was then taken (larger image). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                  CD2 plexin B1                               Actin                                      Nuclear 
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The stable transfections did not express CD2 Plexin B1. The experiments to 
optimise the transient transfection efficiency showed that COS7 cells gave the best 
transfection rate when highly confluent and therefore these were used for further 
assays.  
 
Using a confocal microscope (Zeiss LSM 510W), Wild type (WT) CD2-Plexin B1 
transiently transfected in COS7 cells showed membranous staining of CD2-Plexin 
B1 (Figure 3.26).  
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Figure 3.26 Confocal microscopy showing protein expression of CD2-Plexin B1 in 
COS7 cells (x40 Magnification). Nuclear staining – DAPI; CD2 staining – OX34 
primary antibody diluted 1/400, Abcam; goat anti-mouse FITC secondary antibody 
diluted 1/200, Southern Biotechnology; F-actin staining – phalloidin TRITC diluted 
1/500, Sigma. COS7 cells transiently transfected with CD2 Plexin B1 showing 
expression of CD2 Plexin B1. Membranous and nuclear staining was seen 
indicating that the protein is transported to the cell surface.  
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3.2.5 Expression of Semaphorin 4D and Plexin B1 in Prostate 
cancer cell lines 
 
Since mutations were found in Plexin B1 in prostate cancer cell specimens, the 
mRNA of Sema4D and Plexin B1 in prostate cell lines was determined.  RT-PCR 
was used to analyse the expression of Semaphorin 4D and Plexin B1 mRNA in 
normal and prostate cancer cell lines.  The PCR reaction was carried out using 3μl 
(30ng) of cDNA, 2.5μl of Reaction IV 10x buffer, 1.5μl of 25mM MgCl2, 0.5ul of 
10mM deoxynucleoside triphosphates, 25pmol of each primer and 1.25U of Taq 
DNA polymerase on a Eppendorf thermocycler. The cycling conditions were 94°C 
for 5 minutes to activate the Taq polymerase followed by 40 cycles of 94°C for 45s, 
the annealing temperature 58°C for 45s, 72°C for 60s, and a final extension at 72°C 
for 7min. PCR products were electrophoresed on 0.8% agarose gels. GAPDH was 
used as a control as it was known to express Plexin B1 and Sema 4D.  
 
Semaphorin 4D and Plexin B1 mRNA were expressed in all normal and prostate 
cancer cell lines (Figures 3.27 and 3.28). A PCR product was seen for PC3 cells 
using the 5‟ set of primers, and not the 3‟ set. This may be due to a splice variant in 
this cell line. Alternative splicing was first observed in 1977 (Berget et al. 1977). It 
was found that the primary RNA transcript produced by adenovirus type 2 was 
spliced in different ways, resulting in mRNAs encoding different viral proteins 
(Berget et al. 1977). Since then, alternative splicing has been found to be ubiquitous 
in eukaryotes (Black et al. 2003). To further investigate the splicing pattern in PC3, 
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more Sema4D primers would need to be designed to span the entire cDNA. Work 
would then need to be carried out to determine whether this affects the function of 
the protein. If the transmembrane domain is involved this could generate a protein 
that was secreted and not membrane bound and this would alter the function of the 
protein.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
152 
 
 
 
Figure 3.27 RT-PCR of Semaphorin 4D mRNA in cell lines. PCR products were 
electrophoresed on 0.8% agarose gels. GAPDH was used as a control. Semaphorin 
4D (30ng cDNA) was expressed in all cell lines used. No PCR product was seen 
with the 3’ primers in PC3 cells. This may be due to a splice variant in this cell line.  
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Figure 3.28 RT-PCR of Plexin B1 mRNA in cell lines. PCR products were 
electrophoresed on 0.8% agarose gels. GAPDH was used as a control. Plexin B1 
was expressed in all cell lines. This data was provided by M. Williamson.  
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3.3 Discussion 
 
The aim of this research was to determine whether the mutation, C5662T, in the 
Plexin B1 gene at position 1798 contributes to prostate cancer progression. This 
section concentrates on the generation of vectors that expresses the wild type and 
mutant Plexin B1. Initially the mutation C5662T needed to be introduced into an 
expression vector. Two expression vectors had been provided. One had the full 
length cDNA of Plexin B1 cloned into the vector pcDNA3 and the other had only 
the cytoplasmic domain of Plexin B1 fused with CD2 (a T lymphocyte antigen) 
cloned into the vector pcDNA3. .  
 
Primers were specifically designed so as to contain the mutation and site directed 
mutagenesis was used to generate a single base change in the constructs, so as to 
create the mutation. DNA was then extracted and the constructs were then checked 
using two methods. Digestion with the restriction enzyme Hae III, was able to 
confirm the mutation had been introduced. Cycle sequencing confirmed the 
presence of the mutation and also ensured that no other mutation had been 
introduced.   
 
The mutant, wild type (no mutation), vector (no plexin B1) and mock cells were 
transfected into NIH3T3 cells and stable clones were generated. The relative 
expression of Plexin B1 RNA was estimated. This confirmed expression of mutant 
and wild type RNA.  
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Protein expression was initially measured by western blotting, however despite 
various attempts to optimize the western blot, it was not possible to reliably show 
that the protein was expressed in the full length constructs.  
Possible reasons for this include:  
a) The stable clones do produce low levels of RNA and protein, but only the 
RNA is detected as reverse transcription is more sensitive than western blotting 
b) The antibody used in the western blot was non specific 
c) The stable clones expressed a low level of protein that was unable to be 
observed in the western blot 
d) The stable transfections switched off the expression of the  protein 
 
Stable transfections of 3T3 cells transfected with CD2-Plexin B1 were then 
examined by immunofluorescence. The results suggest that the stable transfections 
do not express Plexin B1. 
 
Transient transfections of the truncated CD2-Plexin B1 in 3T3 cells and COS1 cells 
did show expression of the protein using the anti CD2 antibody. Wild type Plexin 
B1, mutant Plexin B1 and vector only constructs (containing CD2) showed 
membranous and nuclear staining indicating that the wild type and mutant express 
CD2-Plexin B1.  
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The issue with the transient transfections was a low transfection efficiency when 
using Lipofectamine, COS1 cells and 3T3 cells. This was overcome by optimizing 
the tranfection efficiency using the B- gal staining kit and using COS7 cells which 
gave a better transfection efficiency. 
 
Since the CD2 truncated construct did not have an extracellular domain, it would 
not be able to interact with other proteins such as Met, which may make the 
functional analysis difficult. For that reason the full length Plexin B1 would be 
more useful in the functional assays. During the optimisation of the 
immunofluorescence a commercial antibody for Plexin B1 became available, anti-
Plexin B1 (#H300, Santa Cruz).  
 
In the following chapter the protein expression of full length Plexin B1 is shown in 
transiently transfected COS7 cells.  
 
In order to establish whether the semaphorin signalling pathway has any role in 
prostate cancer development or metastasis, an expression profile of components of 
this pathway in prostate cancer cells was performed. The endogenous mRNA 
expression of Plexin B1 and Sema4D in prostate cancer cell lines were studied 
using RT-PCR. Sema4D and Plexin B1 mRNA were expressed in these cell lines. 
The mRNA expression of Sema4D was altered in the PC3 cell line, this may be due 
to a splice variant of Sema4D in the metastatic cell line PC3. 
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Chapter 4 
 
 
 
The Collapse Assay 
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4.1 Introduction 
 
Semaphorins have a variety of functions from axon guidance where they were 
initially implicated to cardiac and skeletal development, immune function, 
morphogenesis and cancer progression.  
 
The molecular mechanisms mediating semaphorin function are poorly understood. 
Recent studies suggest that Rho family small GTPases are involved in the 
downstream signalling of plexins (Etienne-Manneville et al. 2002). Rho family 
small GTPases are well known key regulators of the actin cytoskeleton in different 
cell types (Etienne-Manneville et al. 2002). Many Rho proteins have been identified 
including Rho (A,B, and C), Rac, Cdc42 and Rnd. Rho causes growth cone collapse 
(Negishi et al. 2002). Constitutively activated forms of  Rho, Rac and Cdc42 induce 
the assembly of contractile actin and myosin filaments (stress fibres), actin-rich 
surface protrusions (lamellipodia), and finger-like membrane extensions (filopodia) 
respectively, when introduced into fibroblasts (Nobes and Hall, 1995).  
 
Plexin B1 activates RhoA and induces growth cone collapse through PDZ-RhoGEF 
(Oinuma et al. 2003). Coexpression of Rnd and Plexin B1 induces cell contraction 
in COS7 cells in response to Semaphorin 4D (Oinuma et al. 2003). In dorsal root 
ganglia, Sema3A induced collapse has been shown to require Rac activity and 
Sema3A induced collapse of COS7 cells expressing Plexin A1 also requires Rac 
and Cdc42 activity (Turner et al. 2004).   
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The collapse assay is used as the standard functional assay for semaphorins and 
plexins (Barberis et al. 2004; Turner et al. 2004; Oinuma et al. 2004). In this study, 
the assay was used to determine whether the mutant Plexin B1 transiently 
transfected into COS7 cells behaved differently to the wild type Plexin B1 when 
activated by its ligand Semaphorin 4D. Semaphorin 4D was required for the 
collapse assay and this was purified from medium of Sema4D-Fc expressing COS7 
cells. Oinuma et al. have shown that collapse in COS7 cells is dependent on Rnd1 
and that collapse occurs after the addition of Sema4D. The morphology of the 
collapsed cell, is a rounded COS7 cell that has been defined as having an area of 
less than 350µm² (Oinuma et al. 2003). Using the same definition, a collapsed 
COS7 cell was defined as a cell with a surface area of less than 350µm² (Oinuma et 
al. 2003).  
 
Protein expression of the truncated CD2 Plexin B1 has already been shown. There 
were initial difficulties showing the expression of full length Plexin B1 due to 
problems with antibodies. These problems were overcome once a suitable antibody 
became available. 
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4.2 Results 
 
4.2.1 Purification of recombinant Sema 4D-Fc 
 
For the collapse assay a soluble form of Sema4D expressed as a fusion protein with 
the Fc fragment of human IgG was harvested from the medium of transiently 
transfected COS7 cells (see materials and methods). Purified Sema4D-Fc was run 
on an 8% SDS-PAGE gel with Sema3A-Fc. On western blot analysis, Sema3A-Fc 
(R&S systems) was known to produce two protein bands representing the full 
length Sema3A-Fc (130KDa) and the Fc fragment (35KDa) (Kumanogoh et al. 
2001).  
The Sema4D-Fc product showed a double band at around 150KDa compared to the 
130KDa Sema3A-Fc product (Figure 4.1). The double band is likely to represent 
the precursor and a proteolytically cleaved form of Sema4D-Fc, as described by 
Turner et al. 2006. The full length Sema4D was 150KDa and a cleaved form of 
Sema4D which occurs at the transmembrane domain was 140KDa. The 35KDa 
band is the size of the Fc fragment alone (not shown for Sema4D). The 
concentration of purified Sema4D-Fc could be estimated from the known 
concentration of Sema3A-Fc (200µg/ml, R&D systems) by comparing the density 
of the western blot bands. The protein concentration of Sema4D-Fc was estimated 
to be 100µg/ml.  
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Figure 4.1 Western Blot showing protein expression of Sema4D-Fc and Sema3A-
Fc. Primary Antibody was goat anti-human IgG Fc Ab, 1:10000 (Jackson 
ImmunoResearch Laboratories): secondary antibody was mouse anti-goat,1:5000 
(Santa Cruz). Recombinant Sema4D-Fc was harvested from transiently transfected 
COS7 cells and purified using protein A as described previously. The purified 
Sema4D-Fc was run on an 8% SDS-PAGE gel. This showed a doublet band at 
150KDa which represents the precursor and cleaved forms of Sema4D-Fc (Turner 
at al. 2006). The concentration of Sema4D was estimated by comparing the band 
brightness with the known concentration of Sema3A-Fc (200µg/ml).  
 
         Mock                Sema4D-Fc             Sema 3A-Fc 
  0.05    0.1    0.25    0.05    0.1   0.25   0.05   0.1   0.25 (µl) 
 
 
 
250 KDa 
160 KDa 
 
105 KDa 
75 KDa 
 
 
50 KDa 
 
35 KDa 
30 KDa 
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4.2.2 Optimising the collapse assay 
 
Using the purified Sema4D-Fc the next step was to optimize the conditions for the 
collapse assay. COS7 cells were used, when compared with NIH3T3 and COS1 
cells they were found to give the highest transfection rates (Table 3.2). COS7 cells 
had been used for collapse assays by previous teams and they had successfully 
shown collapse on addition of Sema4D when transfected with Plexin B1 (Onuma et 
al. 2003, Turner et al. 2006).  
 
COS7 cells were transiently transfected with Plexin B1, Sema4D was added and the 
percentage of collapsed cells scored. In the protocol set out by Turner et al. 2006, 
cells that were transfected with Plexin B1 could be detected using an antibody 
against the ligand Sema4D-Fc. The antibody used was against the Fc fragment of 
Sema4D-Fc (Jackson Immunoresearch labs, PA). To optimize the 
immunocytochemistry conditions for detection of Sema4D, COS7 cells were 
transiently transfected with Sema4D-Fc and varying concentrations of the primary 
antibody (goat anti-human Fc) and the secondary antibody (mouse anti-goat) were 
used to detect the protein. The ideal concentration of the primary antibody was 
20µg/ml.  
 
Figure 4.2 shows Sema4D expression in COS7 cells transfected with Sema4D-Fc 
with the addition of triton X. The staining seen is cytoplasmic and not membranous 
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since the addition of triton X permeabilises the cell membrane. Figure 4.3 shows 
COS7 cells transfected with Sema4D-Fc without triton X and the Sema4D is not 
detected indicating Sema4D is cytoplasmic.  
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Figure 4.2 Sema4D expression in COS7 cells transfected with Sema4D-Fc (with 
Triton X). Primary antibody  Goat anti-human Fc Ab 1:100, Secondary antibody 
mouse anti-goat FITC 1:200. When COS7 cells are transfected with Sema4D-Fc, 
intracytoplasmic Sema4D protein expression is seen. The larger picture is a merged 
image of the two smaller images (Dapi stained cells and antiFc-FITC stained cells). 
The cells were viewed using a fluorescent microscope (Nikon, C-SHG1 with 
epifluorescent attachment).   
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Dapi                                                     Sema4D-Fc 
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Figure 4.3 COS7 cells transfected with Sema4D-Fc (no Triton X). Primary antibody  
Goat anti-human Fc Ab 1:100, Secondary antibody mouse anti-goat FITC 1:200. 
When COS7 cells are transfected with Sema4D-Fc and Triton X is not added, 
Sema4D protein expression is not detected. The larger picture is a merged image of 
the two smaller images (Dapi stained cells and antiFc-FITC stained cells). The 
cells were viewed using a fluorescent microscope (Nikon, C-SHG1 with 
epifluorescent attachment).  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dapi                                                       Sema4D-Fc 
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Despite showing intracellular protein expression of Sema4D in COS7 cells 
transfected with Sema4D-Fc, the addition of Sema4D-Fc protein to COS7 cells 
transfected with Plexin B1 did not highlight any cells (images not shown). Until this 
time, an antibody against Plexin B1 was not available and the method described 
above, of indirectly detecting Plexin B1 using Sema4D-Fc and the Fc antibody had 
to be abandoned. Therefore this method could not be used in the collapse assay. 
 
An alternative method to identify which cells had been successfully transfected with 
Plexin B1, was to stain the cells with an antibody to the Plexin B1. The 
immunofluorescence technique using a rabbit polyclonal antibody against human 
Plexin B1 extracellular amino acids 771-1070 and a goat anti-rabbit IgG antibody 
conjugated to TRITC as the secondary antibody (Southern Biotech) was optimised.  
Using the newly acquired antibody for Plexin B1 (Plexin B1 H300 rabbit 
polyclonal, Santa Cruz), protein expression of full length Plexin B1 transfected in 
COS7 cells could be shown.  
 
Figure 4.4 shows protein expression, in COS7 cells, of the wild type full length 
Plexin B1 (1º Ab Santa Cruz Plexin B1 rabbit polyclonal 1/200, 2º Ab Goat anti 
rabbit TRITC 1/100).  
 
Plexin B1 is a cell surface receptor. In order to determine whether the mutant Plexin 
B1 was transported to the cell membrane, confocal images were obtained. With the 
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addition of Triton X, which permeabilises the cell membrane, cell surface 
expression of Plexin B1 could be seen. These images were generated using a 
confocal microscope (Zeiss LSM 510W upright confocal microscope).  
 
Figure 4.5-4.6 show the expression of the wild type full length Plexin B1 and the 
mutant Plexin B1 in transfected COS7 cells. Cytoplasmic staining is seen with the 
addition of Triton X and membranous staining is seen without the Triton X.  
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Figure 4.4 Protein expression of Wild Type Full Length Plexin B1. Primary 
antibody Santa Cruz Plexin B1 rabbit polyclonal 1/200, secondary antibody Goat 
anti rabbit TRITC 1/100. Shows expression of wild type Plexin B1 in COS7 that 
have been transfected with wild type Plexin B1 (Dapi stained cells and anti-Plexin 
B1 stained cells). The cells were viewed using a fluorescent microscope (Nikon, C-
SHG1 with epifluorescence attachment).  
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Figure 4.5 Protein expression of wild type Plexin B1 (Confocal Image) a) with the 
addition of Triton X b) without Triton X. Primary antibody Santa Cruz Plexin B1 
rabbit polyclonal 1/200, secondary antibody Goat anti rabbit TRITC 1/100. COS7 
cells transfected with wild type Plexin B1, showing expression of wild type Plexin 
B1. Cytoplasmic staining is seen with the addition of Triton X. Membranous 
staining is seen without Triton X (Zeiss LSM 510W). 
a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
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Figure 4.6 Protein expression of mutant Plexin B1 (Confocal Image) a) with the 
addition of Triton X b) without Triton X. Primary antibody Santa Cruz Plexin B1 
rabbit polyclonal 1/200, secondary antibody Goat anti rabbit TRITC 1/100. COS7 
cells transfected with mutant Plexin B1, showing protein expression of mutant 
Plexin B1. Cytoplasmic staining is seen with the addition of Triton X. Membranous 
staining is seen without Triton X (Zeiss LSM 510W). 
 
 a)           
 
                                      
 
 
 
b)  
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In 2003, Oinuma et al showed that Rnd 1, a member of the Rho family small 
GTPases, directly interacted with the cytoplasmic domain of Plexin B1 and that 
coexpression of Rnd1 and Plexin B1 induced cell contraction in COS7 cells in 
response to Sema4D. Expression of Plexin B1 alone or Rnd1 alone did not result in 
cell collapse (Oinuma et al. 2003).  
 
To express Rnd1, Myc-Rnd1 was transfected into COS7 cells and using anti-myc 
antibodies and the appropriate secondary antibody, Rnd1 expression was shown 
using immunofluorescence. The optimal concentration for the anti-myc mouse 
monoclonal antibody (Santa Cruz) and for the secondary antibody, goat anti- mouse 
FITC antibody (Southern Biotech) was 5µg/ ml. Expression of Rnd1 was 
membranous and perinuclear (Figure 4.7).  
 
The protein expression of the wild type and mutant full length Plexin B1 has now 
been shown using the newly acquired anti-Plexin B1 antibody. The protein 
expression of Rnd1 has also been shown in COS7 cells transfected with Myc-Rnd1 
and stained using an anti-myc antibody. The next aim was to transfect COS7 cells 
with the full length Plexin B1 construct and add Sema4D-Fc and stain for Plexin B1 
using the Plexin B1 (Santa Cruz) antibody and determine whether the cells collapse. 
If collapsed cells are seen then a comparison can be made between the wild type 
and the mutant constructs. The question as to whether Rnd1 is required for cell 
collapse would also need to be addressed.  
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Figure 4.7 COS7 cells transfected with Rnd1 using Immunofluorescence. Anti-Myc 
9E10 mouse monoclonal antibody, Santa Cruz (primary antibody), Goat anti-mouse 
FITC antibody, Southern Biotech (secondary antibody). When Rnd1 was transfected 
into COS7 cells membranous and perinuclear staining were seen.  The cells were 
viewed using a fluorescent microscope (Nikon, C-SHG1 with epifluorescence 
attachment). 
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4.2.3 The Collapse Assay  
 
COS7 cells were transfected with either wild type Plexin B1 (WT) or mutant Plexin 
B1 (M) and cotransfected with Rnd1 or without Rnd1 and treated with and without 
Sema4D. The rabbit polyclonal antibody against Plexin B1, Santa Cruz (primary 
antibody) and goat anti-rabbit IgG antibody conjugated to TRITC (secondary 
antibody) were used for the immunofluorescence.  
 
On initial inspection it appeared that cells transfected with Plexin B1 and Rnd1 
(figs. 4.9, 4.11) appeared smaller and more rounded than cells transfected with 
Plexin B1 alone (figs. 4.8, 4.10). This suggested that when Plexin B1 and Rnd1 
were cotransfected into COS7 cells, collapse was seen.  It also appeared that Rnd1 
and Plexin B1 were needed for the cells to collapse regardless of whether Sema4D 
was present or not.  
Does this mean that Rnd1 alone is causing the collapse? According to Oinuma et al, 
2003 this should not be the case. 
This was tested by transfecting COS7 cells with Rnd1 alone with and without 
Sema4D. Few cells collapsed, implying that both Rnd1 and Plexin B1 are required 
for cell collapse (figure 4.12). This data was objectively analysed using image j 
software that allowed the area of each cell to be calculated (figure 4.13).  
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Figure 4.8 COS7 cells transfected with wild type Plexin B1 (without Rnd1) a) 
without Sema4D-Fc b) with Sema4D. Primary antibody Santa Cruz Plexin B1 
rabbit polyclonal 1/200, secondary antibody Goat anti rabbit TRITC 1/100. 
Collapsed cells were counted as a percentage of the total number of transfected 
cells and are the mean of three independent experiments, with 50 cells sized per 
experiment. When COS7 cells were transfected with wild type Plexin B1 (no Rnd1) 
15% of cells were collapsed (+/- SEM) when Sema4D was added and 10% (+/-
SEM) collapsed without Sema4D.  
 
a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
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Figure 4.9 COS7 cells cotransfected with wild type Plexin B1 and Rnd1 a) without 
Sema4D-Fc b) with Sema4D. Primary antibody santa cruz Plexin B1 rabbit 
polyclonal 1/200, secondary antibody Goat anti rabbit TRITC 1/100. Collapsed 
cells were counted as a percentage of the total number of transfected cells and are 
the mean of three independent experiments, with 50 cells sized per experiment. 
When COS7 cells were cotransfected with wild type Plexin B1 and Rnd1 82% of 
cells were collapsed (+/- SEM) when Sema4D was added and 79% (+/-SEM) 
collapsed without Sema4D.  
 
 
a) 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
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Figure 4.10 COS7 cells transfected with Mutant Plexin B1 without Rnd1 a) without 
Sema4D-Fc b) with Sema4D. Primary antibody santa cruz Plexin B1 rabbit 
polyclonal 1/200, secondary antibody Goat anti rabbit TRITC 1/100. Collapsed 
cells were counted as a percentage of the total number of transfected cells and are 
the mean of three independent experiments, with 50 cells sized per experiment. 
When COS7 cells were transfected with Mutant Plexin B1 (no Rnd1) 21% of cells 
were collapsed (+/- SEM) when Sema4D was added and 11% (+/-SEM) collapsed 
without Sema4D.  
 
a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
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Figure 4.11 COS7 cells cotransfected with Mutant Plexin B1 and Rnd1 a) without 
Sema4D-Fc b) with Sema4D. Primary antibody santa cruz Plexin B1 rabbit 
polyclonal 1/200, secondary antibody Goat anti rabbit TRITC 1/100. Collapsed 
cells were counted as a percentage of the total number of transfected cells and are 
the mean of three independent experiments, with 50 cells sized per experiment. 
When COS7 cells were cotransfected with Mutant Plexin B1 and Rnd1 72% of cells 
were collapsed (+/- SEM) when Sema4D was added and 91% (+/-SEM) collapsed 
without Sema4D.  
 
 
a) 
 
 
 
 
 
 
 
 
 
 
 
b) 
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Figure 4.12 COS7 cells transfected with Rnd1 a) with Sema4D-Fc b) without 
Sema4D-Fc. Anti-Myc 9E10 mouse monoclonal antibody, Santa Cruz (primary 
antibody), Goat anti-mouse FITC antibody, Southern Biotech (secondary antibody). 
Collapsed cells were counted as a percentage of the total number of transfected 
cells and are the mean of three independent experiments, with 50 cells sized per 
experiment. When COS7 cells were transfected with Rnd1 alone 18% of cells were 
collapsed (+/- SEM) when Sema4D was added and 6% (+/-SEM) collapsed without 
Sema4D.  
 
a) 
 
b) 
 
  
179 
 
 
Collapsed cells were defined as those with a surface area of less than 350µm² 
(Oinuma et al. 2003). The area of each cell was calculated by using Image J, 
version 1.38 (Image J\ plugins\Particle counting\Cell_Area.txt). Using the image 
tool, transfected cells were drawn around. The area of the cells could then be 
analysed using the analysis tool, ensuring that the calibration had been controlled 
(Fig 4.14).  Collapsed cells were counted as a percentage of the total number of 
transfected cells and the results are the mean of three independent experiments, with 
50 cells sized per experiment. Figure 4.13 shows the percentage of transfected 
COS7 cells that were less than 350µm². There is a clear increase in the proportion 
of collapsed cells in the wild type and mutant Plexin B1 constructs that had been 
cotransfected with Rnd1. The addition of the ligand Sema4D did not change the 
level of collapse. When COS7 cells were transfected with Rnd1 alone, the 
proportion of collapsed COS7 cells was small. This rate of collapse is similar to that 
described by Oinuma et al. 2003, with a background collapse rate of 10-20%.  
 
The Fishers exact test was used to analyse the statistical difference in collapse rate 
between the wild type Plexin B1 and the mutant Plexin B1 (both with Rnd1 and 
Sema4D).  The two tailed „p‟ value equals 0.0518, suggesting that the difference 
between the two is not statistically significant. There was not a significant 
difference in the collapse rate when comparing the wild type Plexin B1 to the 
mutant Plexin B1 (C5662T mutation) when the constructs were co-transfected with 
Rnd1 and treated with Sema4D. 
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Figure 4.13 Analysis of COS7 cell collapse (%). WT = wild type, M= Mutant. 
Quantative analysis of COS7 collapse. Collapsed cells (defined as <350µm²) were 
counted as a percentage of the total number of transfected cells and are the mean of 
three independent experiments (Error bars indicate standard error of mean, SEM), 
with 50 cells sized per experiment. There was not a significant difference in the 
collapse rate when comparing the wild type Plexin B1 to the mutant Plexin B1 
(C5662T mutation), P=0.0518 Fishers exact test. Collapse was not dependent on 
the addition of Semaphorin4D. Both Plexin B1 and Rnd1 are required for cell 
collapse.  
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Figure 4.14 COS 7 cells transfected with Plexin B1 and Rnd were sized using image 
J software. The white bordered area shows the area of interest. The red bordered 
area drawn around the cell is selected for in the free hand selection tool. This is the 
area that is calculated. Analyze>Set Scale was used to calibrate the image (using 
the tool bar below). The image is converted to grayscale (image>type>8-bit). The 
area of the outlined region is calculated (Analyse>Analyse particles). The Data 
window gives an area of 2460μm2. The area of each cell was calculated 
individually.  
 
  
 
182 
 
 
4.3 Discussion 
 
Semaphorins have mainly been studied for their ability to induce the retraction of 
axonal processes ie axonal collapse. This has been attributed to a turnover of actin 
filaments and microtubules (Kolodkin et al. 1993) and it has been postulated that 
semaphorins may similarly act to mediate retraction of pseudopodia of a migrating 
cell and affect its motility.  The cellular mechanism mediating this function is not 
known. However a role for Rho GTPase has been proposed.  
 
In 2003, Oinuma et al had shown that Rnd1, a member of the Rho family GTPases, 
interacted with the cytoplasmic domain of Plexin B1.  In COS7 cells, coexpression 
of Rnd1 and Plexin B1 induced cell contraction in response to Semaphorin 4D. The 
association of Plexin B1 and Rnd1 seems to require PDZ Rho-GEF for this 
morphological effect (Oinuma et al. 2003). In COS7 cells the association of Rnd1 
and Plexin B1 promotes the interaction between Plexin B1 and PDZ-RhoGEF. 
When Plexin B1 is activated, this results in cell contraction/collapse by activating 
RhoA which causes an increase in the contractile force at the cell surface (Oinuma 
et al. 2003).  
 
The same authors have also found that the Plexin B1-Rnd1 complex stimulates 
GTPase activity of R-Ras in hippocampal neurons (Oinuma et al, 2004). R-Ras 
promotes cell adhesion and neurite outgrowth by activating integrins (Zhang at al. 
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1996; Ivins et al. 2000). More recently Oinuma et al, 2004 show that Rnd1 opens 
the two R-Ras GAP domains of Plexin B1, and Sema4D-induced receptor 
clustering stimulates R-Ras GAP activity and neurite remodelling in hippocampal 
neurons. 
 
The results presented in these experiments confirm that Plexin B1 and Rnd 1 are 
required for COS7 cell collapse but this is independent of Sema4D suggesting that 
collapse in our experiment was ligand independent. This may be due to 
overexpression of Plexin B1 during transfection leading to clustering of Plexin B1 
and activation. Giordano et al, 2002 have shown that liver progenitor cells 
overexpressing Plexin B1 demonstrate a ligand independent phenotype. It is 
speculated that overexpression of Plexin B1 causes clustering of the Plexin B1 
receptor and this activates downstream regulators, mimicking Sema4D binding.  
 
In contrast to the above experimental work, it is possible that instead of regulating 
cell migration via cytoskeletal dynamics, that plexins may act by directly impinging 
on cell adhesion to the extracellular matrix (Barberis et al, 2004). Barberis et al 
show that semaphorin stimulation rapidly induces disassembly of focal adhesive 
structures and of F-actin cables in adherent cells. Plexin activation inhibits cell 
adhesion, lamellipodia extension and cell migration. 
 
It is likely that collapse is the net result of a combination of many pathways 
including Rho activation resulting in stress fibre formation and loss of adhesion, 
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resulting from disassembly of focal adhesive structures which include integrins. 
Loss of adhesion may be via the R-RasGAP activity of Plexin B1 (Ito et al. 2006). 
R-Ras activates integrins and promotes adhesion via PI3K (Kinbara et al. 2003). 
Plexin B1 acts as a GTPase-activating protein for R-Ras which inactivates R-Ras 
resulting in loss of integrin activation and loss of adhesion (Oinuma et al. 2006). 
Plexin B1 also binds and sequesters Rac thereby inactivating it, leading to loss of 
lamellipodia (Vikis et al. 2002). 
 
It seems to be clear that semaphorins do regulate many biological events, including 
guidance of migrating cells, however the mechanisms mediating these have yet to 
be defined.  
 
To determine whether a mutant form of Plexin B1 would behave differently from 
the wild type Plexin B1, the cell collapse assay was used. A collapsed COS7 cell in 
these experiments was defined as a cell with a surface area of less than 350µm². 
COS7 cells transfected with mutant Plexin B1 did not show any difference in the 
collapse rate when compared to the wild type Plexin B1. The C5662T mutation may 
not be functionally significant. The mutation C5662T is predicted to result in a 
substitution of a proline to a serine at position 1798. Amino acid 1798 is in the 
RhoGTPase binding domain (residues 1743–1862), this is required for Rac1, Rnd1 
and RhoD binding (Tong et al. 2007). Therefore, the mutation would be expected to 
result in a loss of Rnd1 binding. However, from the results presented, it is 
speculated that the mutant binds to Rnd as collapse still occurs. It is possible that 
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Amino Acid 1798, although in the binding region, is not essential for binding. 
Further functional studies would be required to further evaluate this.  
 
The COS7 cell collapse assay seems to be a useful method of investigating 
semaphorin function. However it does have its limitations. Semaphorin4D is a 
transmembrane protein and the recombinant protein used in this assay is a 
secretable form of the extracellular domain of this protein. Therefore the effects of 
this may cause a different response to that of the endogenous protein (Turner et al. 
2006). 
 
In conclusion, activation of wild-type Plexin B1 causes COS7 cell collapse but this 
is independent of Sema4D and requires Rnd1.  A mutant form of Plexin B1 does 
not change the rate of COS7 cell collapse.  
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Chapter 5 
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Initially when the cytoplasmic domain and part of the extracellular domain (exons 
1-5) of Plexins A1, A3 and B1 were sequenced using cDNA from the human 
prostate cancer cell lines PC3, DU145 and LNCaP a single nucleotide change 
(A5359G) was found in Plexin B1 in LNCaP. LNCaP was derived from a patient of 
Caucasian origin and the sequence change was absent from the DNA of 60 control 
individuals (Wong et al. 2007).  The rest of the Plexin B1 cDNA was sequenced in 
PC3, DU145 and LNCAP and no further mutations were found. Quantitative RT-
PCR showed high levels of Plexin B1 in LNCaP compared to other prostate cancer 
cell lines (Personal communication M. Williamson).  
 
The mRNA expression was determined in a number of prostate cell lines. It was 
shown that Semaphorin 4D and Plexin B1 mRNA were expressed in all normal and 
prostate cancer cell lines. The expression profile of Plexin B1 was initially shown in 
the nervous system (Winberg et al. 1998). Although best characterised in the 
nervous system, plexins are widely expressed in other tissues. Using in situ 
hybridization, Plexin B1 is expressed in the immature glomeruli and mesenchyme 
of the developing kidney. In the tooth bud, Plexin B1 is expressed in the oral 
epithelium, enamel knot and in both the inner and outer enamel epithelium. In the 
testis, Plexin B1 is expressed in the developing sex chords (Perala et al. 2005). On 
Northern blot analysis, Semaphorin 4D, is expressed in haematopoietic and 
nonhaematopoietic tissues. Sema4D transcript is detected in peripheral blood 
lymphocytes, spleen, thymus and skeletal muscle and is present in testes, brain, 
kidney, small intestine, prostate, heart, placenta, lung and pancreas, but not in colon 
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or liver (Delaire et al. 1998). Semaphorin 4D is highly expressed in cell lines 
derived from head and neck squamous cell carcinomas, a similar result is also seen 
in prostate, colon, breast and lung cancer tissues (Basile et al. 2006).  
 
To look for further mutations, the study was extended using SSCP analysis of exons 
22-29 of the cytoplasmic domain of the Plexin B1 gene in DNA microdissected 
from eighty nine primary prostate tumours treated by radical prostatectomy, 
seventeen lymph node metastases and nine prostate cancer bone metastases. Twelve 
further missense mutations were found. Mutations were present in 89% (8/9) of 
prostate cancer bone metastases, in 41% (7/17) of lymph node metastases and in 
46% (41/89) of primary cancers. Over 40% of prostate cancers contained the same 
mutation (Wong et al. 2007). The mutations found in Plexin B1 might contribute to 
the pathogenesis of prostate cancer or they could simply be passenger mutations 
which occur by chance and are not selected for. The data suggested that cells 
carrying mutated Plexin B1 are selected for during prostate cancer metastasis. It 
was therefore hypothesised that the semaphorin signalling pathway might be 
harnessed by the cancer cell during metastasis.  
 
To determine whether these mutations were functionally significant, one of the 
mutations was studied in more detail. The aim was to determine if the C5662T 
mutation altered the function of the protein. The C5662T mutation is predicted to 
result in a substitution of a proline to a serine at position 1798. This mutation was 
found in 1/9 prostate cancer metastases.  The amino acid, at position 1798 is highly 
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conserved in evolution. A proline is present in the protein in mouse, Drosophila and 
C elegans and other classes of the Plexin family- A1, A2, B2, B3. 
 
Three objectives were originally set. Using primers containing the point mutation, 
the altered sequence would be introduced into the wild type gene. The altered 
construct would be used to transform E.Coli. and colonies selected, grown up and 
the identity of the mutation  be confirmed by direct sequencing. 
 
The mutation would then be transfected into suitable cells. Transfected cells would 
be selected in G418 and individual colonies expanded and frozen stocks produced. 
The presence of the mutation would be confirmed and the level of protein 
expression measured by western blotting and immunofluorescence.  
 
In vitro assays would be used to assess the effect of the mutation on the behaviour 
of cells. It was not known which components of the semaphorin signalling pathway 
would be affected by the mutation.  
 
The work in this thesis has achieved a number of the objectives that were originally 
set out. An expression vector containing the mutation had been constructed using 
the full length Plexin B1 and the truncated CD2 Plexin B1. This was done using a 
process of in-vitro mutagenesis of the wild type Plexin B1.  
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Before using the vector, the presence of the mutation was confirmed using 
restriction enzyme analysis and direct sequencing. The mutant, wild type and vector 
constructs were then tranfected into suitable cells using lipofectamine. Transient 
transfections and stable transfections were used. Transfected cells were selected in 
G418 and individual colonies were expanded and frozen stocks produced. The 
presence of the mutation was confirmed again using restriction enzyme analysis and 
cycle sequencing. The whole of the cytoplasmic domain of Plexin B1 was also 
sequenced to confirm the presence of the mutation and that no new mutations had 
been introduced. 
 
The relative expression of Plexin B1 mRNA was measured using clones stored at -
80ºC. RNA was extracted and cDNA synthesis performed with and without 
superscript II. This showed that there was strong expression in all of the mutant and 
most of the wild type clones.  
 
With western blotting, protein expression was not shown and this was likely to be 
due to a non-specific antibody and therefore attention was turned towards 
immunofluorescence. This confirmed protein expression in the transiently 
tranfected cells but not in the stable tranfections.  
 
To determine the effect of the mutation the collapse assay was used, this has 
become the standard assay to assess Plexin B1 function.  Plexin B1 is the receptor 
for Semaphorin 4D, and for the functional assays it was necessary to produce 
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recombinant Semaphorin 4D. Recombinant Sema4D-Fc was produced and purified. 
It was not known which components of the semaphorin signalling pathway will be 
affected by the mutation. It was possible to show that Plexin B1 is involved in cell 
collapse and that Rnd1 is required for this process. Cell collapse was seen in cells 
expressing the wild type and mutant Plexin B1.  I have been unable to show a 
functional difference between the wild type Plexin B1 and the mutant (C5662T). 
This suggested that the mutant Plexin B1 does not affect the collapse response and 
more work in the future will be needed to define whether this is a significant 
mutation. This work has been continued by scientists in the same lab. Using the 
collapse assay, the other mutations that were originally found are being assessed 
and other functional assays are being optimized.  
 
So far, some of the mutations that have been tested have been shown to alter the 
function of the Plexin B1 protein and result in increased cell motility, adhesion and 
decrease cell collapse when compared with the wild type (Wong et al. 2007). These 
results suggest a role for Plexin B1 in prostate cancer progression. The mutations 
are unlikely to affect the pathways mediated by c-MET and ErbB2, as these 
proteins interact with the extracellular domain of Plexin B1 and the mutations are in 
the cytoplasmic domain. The mutations may inhibit Plexin B1 inhibitory pathways 
via R-Ras and Rac resulting in an increase in adhesion, motility and invasion 
(Wong et al. 2007).  
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The mutation, C5662T, may affect one or more of the many signalling pathways 
downstream of Plexin B1 via Rho, R-Ras or Rac and it may affect cell migration, 
cell adhesion or cell spread. This could be determined by Rho activity assays, R-
Ras GAP activity assays, Rac binding, lamellipodia formation and adhesion 
experiments using the vector constructed in this work.  
 
An understanding of the role of the Plexin B1 mutations in cancer may provide 
insight into the role of semaphorin signalling in cancer progression and these 
studies may facilitate the design of anti-cancer therapies to target this pathway with 
the aim of delaying or preventing the progression of prostate cancer. Currently, 
prostate specific antigen (PSA) is used to diagnose and manage prostate cancer. 
However, the PSA is unable to differentiate the prostate cancers that have a high 
metastatic potential and therefore are potentially incurable. Identifying a Plexin B1 
mutation in patients when they are diagnosed with prostate cancer, may allow us 
determine those patients that have slow progressing prostate cancer and those that 
have aggressive disease.  
 
In conclusion, a high frequency of somatic missense mutations in the Plexin B1 
gene in localized and metastatic prostate cancer have been found. The C5662T 
mutation in Plexin B1 does not alter cell collapse, but a number of the mutations 
have been found to alter the function of the Plexin B1 protein, suggesting that 
Plexin B1 mutations are functionally significant. The resources that were generated 
during this research, mutant (C5662T), wild type and vector constructs of truncated 
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and full-length Plexin B1, recombinant Semaphorin 4D, are being used for further 
investigations to see if Plexin B1 is a key player in the progression of prostate 
cancer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
194 
 
REFERENCES 
 
Alexander EE, Qian J, Wollan PC, Myers RP, Bostwick DG. Prostatic 
intraepithelial neoplasia does not appear to raise serum prostate-specific antigen 
concentration. Urology 1996;47(5):693-8. 
 
Antipenko A, Himanen JP, van Leyen K, Nardi-Dei V, Lesniak J, Barton WA et al. 
Structure of the semaphorin-3A receptor binding module. Neuron 2003;39(4):589-
598. 
 
Argast GM, Croy CH, Couts KL, Zhang Z et al. Plexin B1 is repressed by 
oncogenic B-Raf signaling and functions as a tumor suppressor in melanoma cells. 
Oncogene. 2009;28(30):2697-709.  
 
Artigiani S, Barberis D, Fazzari P, Longati P, Angelini P, van de Loo JW, Comoglio 
PM, Tamagnone L. Functional regulation of semaphorin receptors by proprotein 
convertases. J Biol Chem. 2003;278:10094-101. 
 
Artigiani S, Comoglio PM, Tamagnone L. Plexins, semaphorins, and scatter factor 
receptors: a common root for cell guidance signals? IUBMB Life 1999;48(5):477-
82.  
 
195 
 
Aurandt J, Vikis HG, Gutkind JS, Ahn N, Guan KL. The semaphorin receptor 
plexin-B1 signals through a direct interaction with the Rho-specific nucleotide 
exchange factor, LARG. Proc Natl Acad Sci U S A 2002;99(19):12085-90. 
 
Barberis D, Artigiani S, Casazza A, Corso S, Giordano S, Love CA, Jones EY, 
Comoglio PM, Tamagnone L. Plexin signaling hampers integrin-based adhesion, 
leading to Rho-kinase independent cell rounding, and inhibiting lamellipodia 
extension and cell motility. FASEB J. 2004;18(3):592-4. 
 
Basile JR, Castilho RM, Williams VP, Gutkind JS. Semaphorin 4D provides a link 
between axon guidance processes and tumor induced angiogenesis. Proc Natl Acad 
Sci USA 2006;103(24):9017-9022. 
 
Basile JR, Gavard J, Gutkind JS. Plexin-B1 utilizes RHOA and ROK to promote the 
integrin-dependent activation of AKT and ERK, and endothelial cell motility. J Biol 
Chem 2007;282(48):34888-95. 
 
Behar O, Golden JA, Mashimo H, Schoen FJ, Fishman MC. Semaphorin III is 
needed for normal patterning and growth of nerves, bones and heart. Nature 
1996;383(6600):525-8. 
 
Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev 
Cancer 2003;3(6):401-10.  
196 
 
 
Berget S, Moore C, Sharp P. Spliced segments at the 5' terminus of adenovirus 2 
late mRNA. Proc Natl Acad Sci U S A. 1977;74(8):3171–3175. 
 
Black D. Mechanisms of alternative pre-messenger RNA splicing. Annual Review 
of Biochemistry 2003;72:291-336.    
 
Bork P, Doerks T, Springer TA, Snel B. Domains in plexins: links to integrins and 
transcription factors. Trends Biochem Sci. 1999;24(7):261-3. 
 
Brambilla E, Constantin B, Drabkin H, Roche J.  Semaphorin SEMA3F localization 
in malignant human lung and cell lines: A suggested role in cell adhesion and cell 
migration. Am J Pathol. 2000;156(3):939-50. 
 
Bratt O. Hereditary prostate cancer: clinical aspects. J of Urology 2002;168(3):906-
913. 
 
Buckwalter JA, Brandser EA. Metastatic disease of the skeleton. Am Fam 
Physician1997;55(5):1761-8. 
 
Butler TP, Gullino P. Quantitation of cell shedding into efferent blood vessels of 
mammary adenocarcinoma. Cancer Res. 1975;35:512-6. 
 
197 
 
Cancer research UK. Prostate Cancer statistics, Internet communication. 
www.cancerresearchuk.org 
 
Carter HB, Coffey DS. The prostate: an increasing medical problem. Prostate 
1990;16(1):39-48. 
 
Chamberlain J, Melia J, Moss S, Brown J. The diagnosis, management, treatment 
and costs of prostate cancer in England and Wales. Health Technol Assess. 
1997;1(3):1-53. 
 
Christensen C, Ambartsumian N, Gilestro G, Thomsen B et al. Proteolytic 
processing converts the repelling signal Sema3E into an inducer of invasive growth 
and lung metastasis. Cancer Res. 2005;65(14):6167-77. 
 
 
Christensen CR, Klingelhofer J, Tarabykina S, Hulgaard EF, Kramerov D, 
Lukanidin E. Transcription of a novel mouse semaphorin gene, M-semaH, 
correlates with the metastatic ability of mouse tumor cell lines. Cancer Res. 
1998;58(6):1238-44. 
 
Comoglio PM, Trusolino L. Invasive growth: from development to metastasis. J 
Clin Invest. 2002;109(7):857-62. 
 
198 
 
Conrotto P, Valdembri D, Corso S, Serini G, Tamagnone L,Comoglio PM et al. 
Sema4D induces angiogenesis through Met recruitment by Plexin B1. Blood 
2005;105(11):4321-9. 
 
Delaire S, Elhabazi A, Bensussan A, Boumsell L. CD100 is a leukocyte 
semaphorin. CMLS, Cell. Mol. Life Sci. 1998;1265–1276.   
 
Deng S, Hirschberg A, Worzfeld T, Penachioni JY et al. Plexin-B2, but not Plexin-
B1, critically modulates neuronal migration and patterning of the developing 
nervous system in vivo. J Neurosci. 2007;27(23):6333-47. 
 
Dickson BJ. Rho GTPases in growth cone guidance. Curr Opin Neurobiol. 
2001;11(1):103-10. 
 
Driessens MH, Hu H, Nobes CD, Self A, Jordens I, Goodman CS, Hall A. Plexin-B 
semaphorin receptors interact directly with active Rac and regulate the actin 
cytoskeleton by activating Rho. Curr Biol. 2001;11(5):339-44. 
 
Driessens MH, Olivo C, Nagata K, Inagaki M, Collard JG. B plexins activate Rho 
through PDZ-RhoGEF. FEBS Lett. 2002;529:168-72. 
 
199 
 
Elhabazi A, Marie-Cardine A, Chabbert-de Ponnat I, Bensussan A, Boumsell L. 
Structure and function of the immune semaphorin CD100/SEMA4D. Crit Rev 
Immunol. 2003;23:65-81. 
 
Epstein JI, Partin AW, Sauvageot J, Walsh PC. Prediction of progression following 
radical prostatectomy. A multivariate analysis of 721 men with long-term follow-
up. Am J Surg Pathol. 1996;20(3):286-92. 
 
Esper P, Redman BG. Supportive care, pain management, and quality of life in 
advanced prostate cancer. Urol Clin North Am. 1999;26(2):375-89. 
 
Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 
2002;420(6916):629-35. 
 
Ewing, J. Neoplastic diseases; a treatise on tumors. 4
th
 ed., rev. and enl. 
Philadelphia, W.B. Saunders, 1940. 
 
Feiner L, Koppel AM, Kobayashi H, Raper JA. Secreted chick semaphorins bind 
recombinant neuropilin with similar affinities but bind different subsets of neurons 
in situ. Neuron 1997;19(3):539-45. 
 
Fidler IJ, Nicolson GL. Organ selectivity for implantation survival and growth of 
B16 melanoma variant tumor lines. J Natl Cancer Inst. 1976;57:1199-1202. 
200 
 
 
Fidler IJ. Modulation of the organ microenvironment for treatment of cancer 
metastasis. J Natl Cancer Inst. 1995;87(21):1588-92. 
 
Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. 
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. 
Cancer Cell 2004;5(4):317-28. 
 
Giger RJ, Urquhart ER, Gillespie SK, Levengood DV, Ginty DD, Kolodkin AL. 
Neuropilin-2 is a receptor for semaphorin IV: insight into the structural basis of 
receptor function and specificity. Neuron. 1998;21(5):1079-92. 
 
Gillenwater JY. Adult and Pediatric Urology. 4
th
 Edition . Vol. 2; Chapter 33:1477-
1479. 
 
Giordano S, Corso S, Conrotto P, Artigiani S, Gilestro G, Barberis D, Tamagnone 
L, Comoglio PM. The semaphorin 4D receptor controls invasive growth by 
coupling with Met. Nat Cell Biol. 2002;4(9):720-4. 
 
Giordano S, Ponzetto C, Di Renzo MF, Cooper CS, Comoglio PM. Tyrosine kinase 
receptor indistinguishable from the c-met protein. Nature 1989;339(6220):155-6. 
 
Gittes RF. Carcinoma of the prostate. N Engl J Med. 1991;324(4):236-45. 
201 
 
Gleason DF, Mellinger GT. Prediction of prognosis for prostate adenocarcinoma by 
combined histological grading and clinical staging. J Urol. 1974;111:58-64. 
 
Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol. 
1992;23:273-9. 
 
Green GA, Hanlon AL, Al-Saleem T, Hanks GE. A Gleason score of 7 predicts a 
worse outcome for prostate carcinoma patients treated with radiotherapy. Cancer. 
1998;83(5):971-6. 
 
Gronberg H. Prostate cancer epidemiology. Lancet 2003;361(9360):859-864. 
Hage WD, Aboulafia AJ, Aboulafia DM. Incidence, location, and diagnostic 
evaluation of metastatic bone disease. Orthop Clin North Am. 2000;31(4):515-28. 
 
Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998;279(5350):509- 14. 
 
Hall KT, Boumsell L, Schultze JL, Boussiotis VA, Dorfman DM, Cardoso AA, 
Bensussan A, Nadler LM, Freeman GJ. Human CD100, a novel leukocyte 
semaphorin that promotes B-cell aggregation and differentiation. Proc Natl Acad 
Sci U S A 1996;93(21):11780-5. 
 
202 
 
Hill PB, Wynder EL.Effect of a vegetarian diet and dexamethasone on plasma 
prolactin, testosterone and dehydroepiandrosterone in men and women. Cancer Lett. 
1979;7(5):273-82. 
 
Holleb AI, Folkman J. Tumor angiogenesis. CA Cancer J Clin. 1972;22(4):226-9. 
 
Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM et al. 
LNCaP model of human prostatic carcinoma. Cancer Res 1983;43(4):1809-1818. 
 
 
Housseau F, Bright RK, Simonis T, Nishimura MI, Topalian SL.Recognition of a 
shared human prostate cancer-associated antigenby nonclassical MHC-restricted 
CD8+ T cells. J Immunol 1999;163(11):6330-6337. 
 
Hsing A, Tsao L, Devesa S. International trends and patterns of prostate cancer 
incidence and mortality. International Journal of cancer 2000;85:60-67.  
Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 
2002;110(6):673-87. 
 
Ito Y, Oinuma I, Katoh H, Kaibuchi K, Negishi M. Sema4D/plexin-B1activates 
GSK-3beta through R-Ras GAP activity, inducing growth cone collapse. EMBO 
Rep 2006; 7(7):704-709. 
 
203 
 
Ivins JK, Yurchenco PD, Lander AD. Regulation of neurite outgrowth by integrin 
activation. J Neurosci. 2000;20(17):6551-60. 
 
Jainchill JL, Aaronson SA, Todaro GJ. Murine sarcoma and leukemia viruses: assay 
using clonal lines of contact-inhibited mouse cells. J Virol 1969;4(5):549-553. 
 
Jensen FC, Giardi AJ, Gilden RV, Koprowski H. Infection of human and simian 
tissue cultures with rous sarcoma virus. PNAS 1964;52:53-59. 
 
Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and 
characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 
1979;17(1):16-23. 
 
Kamoi K, Troncoso P, Babaian RJ. Strategy for repeat biopsy in patients with high 
grade prostatic intraepithelial neoplasia. J Urol. 2000;163(3):819-23. 
 
Keetch DW, Humphrey P, Stahl D, Smith DS, Catalona WJ. Morphometric analysis 
and clinical followup of isolated prostatic intraepithelial neoplasia in needle biopsy 
of the prostate. J Urol. 1995;154:347-51. 
 
Kigel B, Varshavsky A, Kessler O, Neufeld G. Successful inhibition of tumor 
development by specific class-3 semaphorins is associated with expression of 
appropriate semaphorin receptors by tumor cells. PLoS One. 2003;(9):3287. 
204 
 
 
Kinbara K, Goldfinger LE, Hansen M et al. Ras GTPases: integrins' friends or foes? 
Nat Rev Mol Cell Biol. 2003;4(10):767-76. 
 
 
Kim KJ, Li B, Winer J, Armanini M, Gillet N, Phillips HS, Ferrara N. Inhibition of 
vascular endothelial growth factor-induced angiogenesis suppresses tumour growth 
in vivo. Nature 1993;362:841-844. 
 
Kolodkin AL, Levengood DV, Rowe EG, Tai YT, Giger RJ, Ginty DD. Neuropilin 
is a semaphorin III receptor. Cell 1997;90(4):753-62. 
 
Kolodkin AL, Ginty DD. Steering clear of semaphorins: neuropilins sound the 
retreat. Neuron 1997;19(6):1159-62. 
 
Kolodkin AL, Matthes DJ, Goodman CS. The semaphorin genes encode a family of 
transmembrane and secreted growth cone guidance molecules. Cell 
1993;75(7):1389-1399. 
 
Kolodkin AL, Matthes DJ, O'Connor TP, Patel NH, Admon A, Bentley D, 
Goodman CS. Fasciclin IV: sequence, expression, and function during growth cone 
guidance in the grasshopper embryo. Neuron 1992;9(5):831-45. 
 
205 
 
Kong-Beltran M, Stamos J, Wickramasinghe D. The Sema domain of Met is 
necessary for receptor dimerization and activation. Cancer Cell 2004;6(1):75-84. 
 
Korostylev A, Worzfeld T, Deng S, Friedel RH, Swiercz JM, Vodrazka P et al. A 
functional role for semaphoring 4D/plexin B1 interactions in epithelial branching 
morphogenesis during organogenesis. Development 2008;135(20):3333-3343.  
 
Kourlas PJ, Strout MP, Becknell B, Veronese ML, Croce CM, Theil KS, Krahe R, 
Ruutu T, Knuutila S, Bloomfield CD, Caligiuri MA. Identification of a gene at 
11q23 encoding a guanine nucleotide exchange factor: evidence for its fusion with 
MLL in acute myeloid leukemia. Proc Natl Acad Sci U S A 2000;97(5):2145-50. 
 
Kruger RP, Aurandt J, Guan KL. Semaphorins command cells to move. Nat Rev 
Mol Cell Biol. 2005;6(10):689-800. 
 
Kumanogoh A, Kikutani H. The CD100-CD72 interaction: a novel mechanism of 
immune regulation. Trends Immunol. 2001;22(12):670-6. 
 
Langer JE, Rovner ES, Coleman BG, Yin D, Arger PH, Malkowicz SB, Nisenbaum 
HL, Rowling SE, Tomaszewski JE, Wein AJ, Jacobs JE. Strategy for repeat biopsy 
of patients with prostatic intraepithelial neoplasia detected by prostate needle 
biopsy. J Urol. 1996;155(1):228-31. 
 
206 
 
Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes 
HL, Minasian LM et al. Effect of selenium and vitamin E on risk of prostate cancer 
and other cancers: the Selenium and Vitamin E Prevention Trial. JAMA 
2009;301(1):39-51.  
 
Liotta LA. An attractive force in metastasis. Nature 2001;410(6824):24-5. 
 
Love CA, Harlos K, Mavaddat N, Davis SJ, Stuart DI, Jones EY, Esnouf RM. The 
ligand-binding face of the semaphorins revealed by the high-resolution crystal 
structure of SEMA4D. Nat Struct Biol. 2003;10(10):843-8. 
 
Luo Y, Raible D, Raper JA. Collapsin: a protein in brain that induces the collapse 
and paralysis of neuronal growth cones. Cell 1993;75(2):217-27. 
 
Mackay DJ, Hall A. Rho GTPases. J Biol Chem. 1998;273(33):20685-8. 
 
Maestrini E, Tamagnone L, Longati P, Cremona O, Gulisano M, Bione S, Tamanini 
F, Neel BG, Toniolo D, Comoglio PM. A family of transmembrane proteins with 
homology to the MET-hepatocyte growth factor receptor. Proc Natl Acad Sci U S A 
1996;93(2):674-8. 
 
Majeed A, Babb P, Jones J, Quinn M. Trends in prostate cancer incidence, mortality 
and survival in England and Wales 1971-1998. BJU Int. 2000;85(9):1058-62. 
207 
 
 
Martin-Satue M, Blanco J. Identification of semaphorin E gene expression in 
metastatic human lung adenocarcinoma cells by mRNA differential display. J Surg 
Oncol. 1999;72(1):18-23. 
 
Matthes DJ, Sink H, Kolodkin AL, Goodman CS. Semaphorin II can function as a 
selective inhibitor of specific synaptic arborizations. Cell 1995;81(4):631-9. 
 
McNeal JE, Bostwick DG. Intraductal dysplasia: a premalignant lesion of the 
prostate. Hum Pathol. 1986;17(1):64-71. 
 
McNeal JE. Origin and development of carcinoma in the prostate. Cancer 
1969;23(1):24-34. 
 
McNeal JE, Villers AA, Redwine EA, Freiha FS, Stamey TA. Histologic 
differentiation, cancer volume, and pelvic lymph node metastasis in 
adenocarcinoma of the prostate. Cancer 1990;66(6):1225-33. 
 
Miao HQ, Lee P, Lin H, Soker S, Klagsbrun M. Neuropilin-1 expression by tumor 
cells promotes tumor angiogenesis and progression. FASEB J. 2000;14(15):2532-9. 
 
Miao HQ, Soker S, Feiner L, Alonso JL, Raper JA, Klagsbrun M. Neuropilin-1 
mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: 
208 
 
functional competition of collapsin-1 and vascular endothelial growth factor-165. J 
Cell Biol. 1999;146(1):233-42. 
 
Mostofi FK, Davis CJ, Sesterhenn IA. Pathology of carcinoma of the prostate. 
Cancer 1992;70:235-53. 
 
Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, 
Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A. 
Involvement of chemokine receptors in breast cancer metastasis. Nature 
2001;410(6824):50-6. 
 
Jin H, Varner J. Integrins: roles in cancer development and as treatment targets. Br J 
Cancer 2004;90(3):561-565. 
 
Nakamura F, Kalb RG, Strittmatter SM. Molecular basis of semaphorin-mediated 
axon guidance. J Neurobiol. 2000;44(2):219-29. 
 
Nakamura F, Tanaka M, Takahashi T, Kalb RG, Strittmatter SM. Neuropilin-1 
extracellular domains mediate semaphorin D/III-induced growth cone collapse. 
Neuron 1998;21(5):1093-100. 
 
Narayan P. Neoplasms of the prostate gland. Smiths general urology. 14
th
 ed. 
Norwalk, CT: Appleton & Lange, 1995:238 
209 
 
 
Negishi M, Katoh H. Rho family GTPases as key regulators for neuronal network 
formation J. Biochem. 2002;132:157-166. 
 
Nobes CD, Lauritzen I, Mattei MG, Paris S, Hall A, Chardin P. A new member of 
the Rho family, Rnd1, promotes disassembly of actin filament structures and loss of 
cell adhesion. J Cell Biol 1998;141(1):187-197. 
 
Nobes CD, Hall A. Rho, rac, and cdc42 GTPases regulate the assembly of 
multimolecular focal complexes associated with actin stress fibers, lamellipodia, 
and filopodia. Cell 1995;81(1):53-62.  
 
Office for National Statistics, 2009 Mortality Statistics: Deaths registered in 
England and Wales.2007. 
http://www.statistics.gov.uk/downloads/theme_health/DR2007/DR_07_2007.pdf 
 
Office for National Statistics CSR. Registrations of cancer diagnosed in 2004, 
England.London:NationalStatistics.1-1-2006.  
http://www.statistics.gov.uk/articles/hsq/HSQ38_Cancer_trends_in_UK.pdf 
 
Okamoto T, Ogiu K, Sato M. Primary squamous cell carcinoma of the prostate: a 
case report. Hinyokika Kiyo 1996;42:67-70. 
 
210 
 
Oinuma I, Katoh H, Harada A, Negishi M. Direct interaction of Rnd1 with Plexin-
B1 regulates PDZ-RhoGEF-mediated Rho activation by Plexin-B1 and induces cell 
contraction in COS-7 cells. J Biol Chem. 2003;278(28):25671-7. 
 
Oinuma I, Katoh H, Negishi M. Semaphorin 4D/Plexin-B1-mediated R-Ras 
GAPactivity inhibits cell migration by regulating beta(1) integrin activity. J Cell 
Biol. 2006;173(4):601-13. 
 
Oinuma I, Ishikawa Y, Katoh H, Negishi M. The Semaphorin 4D receptor Plexin-
B1 is a GTPase activating protein for R-Ras. Science 2004;305(5685):862-5. 
 
Parkin DM, Whelan SL, Perlay J, Teppo L, Thomas DB. Cancer incidence in five 
continents. Lyon: IACR Sci Publ, 1997. 
 
Paget S. The distribution of secondary growths in cancer of the breast. Lancet 
1889;1:99-101. 
 
Pasterkamp RJ, Kolodkin AL. Semaphorin junction: making tracks toward neural 
connectivity. Curr Opin Neurobiol. 2003;13(1):79-89. 
 
Perala NM, Immonen T, Sariola H. The expression of plexins during mouse 
embryogenesis. Gene Expression Patterns 2005;5(3):355-362. 
 
211 
 
Poste G, Paruch L, Stephen Paget, M.D., F.R.C.S., (1855-1926). A retrospective. 
Cancer Metastasis Rev. 1989;8(2):93-7. 
 
Ramos CG, Carvahal GF, Mager DE, Haberer B, Catalona WJ. The effect of high 
grade prostatic intraepithelial neoplasia on serum total and percentage of free 
prostate specific antigen levels. J Urol. 1999;162(5):1587-90. 
 
Reese J H, Freiha FS, Gelb AB, Lum BL, Torti FM. Transitional cell carcinoma of 
the prostate in patients undergoing cystoprostatectomy. J Urol. 1992;147:92-5.  
 
Ridley AJ, Hall A. The small GTP-binding protein rho regulates the assembly of 
focal adhesions and actin stress fibers in response to growth factors. Cell 
1992;70(3):389-99. 
 
Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G et al. Cell 
migration: integrating signals from front to back. Science 2003;302(5651):1704-
1709. 
 
Ronnett BM, Carmichael MJ, Carter HB, Epstein JI. Does high grade prostatic 
intraepithelial neoplasia result in elevated serum prostate specific antigen levels? J 
Urol. 1993;150:386-9. 
 
212 
 
Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B. Serum testosterone 
levels in healthy young black and white men. J Natl Cancer Inst. 1986;76(1):45-8. 
 
Saiti Y, Oinuma I, Fujimoto S, Negishi M. Plexin B1 is a GTPase activating protein 
for M-Ras, remodelling dendrite morphology. EMBO Rep. 2009;10(6):614-621. 
 
Semaphorin Nomenclature Committee. Cell 1999;97(5):551-2.  
 
Serini G, Valdembri D, Zanivan S, Morterra G, Burkhardt C, Caccavari F, 
Zammataro L, Primo L, Tamagnone L, Logan M, Tessier-Lavigne M, Taniguchi M, 
Puschel AW, Bussolino F. Class 3 semaphorins control vascular morphogenesis by 
inhibiting integrin function. Nature 2003;424(6947):391-7. 
 
Shepherd D, Keetch DW, Humphrey PA, Smith DS, Stahl D. Repeat biopsy strategy 
in men with isolated prostatic intraepithelial neoplasia on prostate needle biopsy. J 
Urol. 1996;156:460-2. 
 
Sierra J, Corso S, Caione L, Cepero V, Conrotto P, Cignetti A, Piacibello W et al. 
Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-
associated macrophages. J Exp Med. 2008;205(7):1673-1685. 
 
Souhami RL, Tannock I, Hohenberger P, Horiot JC. Oxford Textbook of Oncology. 
2
nd
 Ed. Vol.1 2002:103-113. 
213 
 
 
Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human 
prostate carcinoma cell line (DU 145). Int J Cancer 1978; 21(3):274-281. 
 
Swiercz JM, Kuner R, Offermanns S. Plexin-B1/RhoGEF-mediated RhoA 
activation involves the receptor tyrosine kinase ErbB-2. J Cell Biol. 
2004;165(6):869-80. 
 
Swiercz JM, Worzfeld T, Offermanns S. ERBB-2 and met reciprocally regulate 
cellular signaling via plexin-B1. J Biol Chem 2008;283(4):1893-1901. 
 
Tamagnone L, Artigiani S, Chen H, He Z, Ming GI, Song H, Chedotal A, Winberg 
ML, Goodman CS, Poo M, Tessier-Lavigne M, Comoglio PM. Plexins are a large 
family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in 
vertebrates. Cell 1999;99(1):71-80. 
 
Tamagnone L, Comoglio PM. Signalling by semaphorin receptors: cell guidance 
and beyond. Trends Cell Biol. 2000;10(9):377-83. 
 
Takahashi T, Fournier A, Nakamura F, Wang LH, Murakami Y, Kalb RG, Fujisawa 
H, Strittmatter SM. Plexin-neuropilin-1 complexes form functional semaphorin-3A 
receptors. Cell 1999;99(1):59-69. 
 
214 
 
Tessier-Lavigne M, Goodman CS. The molecular biology of axon guidance. 
Science 1996;274(5290):1123-33.  
 
Tomizawa Y, Sekido Y, Kondo M, Gao B et al. Inhibition of lung cancer cell 
growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor 
suppressor gene SEMA3B. Proc Natl Acad Sci U S A. 2001;98(24):13954-9. 
 
Tong Y, Chugha P, Hota PK, Alviani RS, Li M, Tempel W et al. Binding of Rac1, 
Rnd1 and RhoD to a novel Rho GTPase interaction motif destabilizes dimerization 
of the plexin-B1 Effector domain. J Biol Chem 2007;282(51):37215-24. 
 
Touijer K, Rabbani F, Otero JR, Secin FP et al. Standard versus limited pelvic 
lymph node dissection for prostate cancer in patients with a predicted probability of 
nodal metastasis greater than 1%. J Urol. 2007;178(1):120-4. 
 
Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signalling 
for invasive growth. Nat Rev Cancer 2002;2(4):289-300. 
 
Tse C, Xiang RH, Bracht T, Naylor SL. Human Semaphorin 3B (SEMA3B) located 
at chromosome 3p21.3 suppresses tumor formation in an adenocarcinoma cell line. 
Cancer Res. 2002;62(2):542-6. 
 
215 
 
Turner LJ, Hall A. Plexin-induced collapse assay in COS cells. Methods Enzymol. 
2006;406:665-676.  
 
Turner LJ, Nicholls S, Hall A. The activity of the plexin-A1 receptor is regulated by 
Rac. J Biol Chem. 2004;279(32):33199-205. 
 
Usui H, Taniguchi M, Yokomizo T, Shimizu T. Plexin-A1 and plexin-B1 
specifically interact at their cytoplasmic domains. Biochem Biophys Res Commun 
2003;300(4):927-31. 
 
Vikis HG, Li W, Guan KL. The plexin-B1/Rac interaction inhibits PAK activation 
and enhances Sema4D ligand binding. Genes Dev. 2002;16(7):836-45. 
 
Vikis HG, Li W, He Z, Guan KL. The semaphorin receptor plexin-B1 specifically 
interacts with active Rac in a ligand-dependent manner. Proc Natl Acad Sci U S A 
2000;97(23):12457-62. 
 
Webcutter. 2004. http://www.firstmarket.com/cutter/cut2.html Ref Type: Internet 
Communication. 
 
Welch DR, Rinker-Schaeffer CW. What defines a useful marker of metastasis in 
human cancer? J Natl Cancer Inst 1999;91:1351-1353. 
 
216 
 
Weiss L, Grundmann E, Torhorst J, Hartveit F, Moberg I, Eder M, Fenoglio-Preiser 
CM, Napier J, Horne CH, Lopez MJ, et al. Haematogenous metastatic patterns in 
colonic carcinoma: an analysis of 1541 necropsies. J Pathol. 1986;150(3):195-203. 
 
Weiss L, Harlos JP. The validity of negative necropsy reports for metastases in solid 
organs. J Pathol. 1986;148(3):203-6. 
 
Weiss L, Harlos JP, Torhorst J, Gunthard B, Hartveit F, Svendsen E, Huang WL, 
Grundmann E, Eder M, Zwicknagl M, et al. Metastatic patterns of renal carcinoma: 
an analysis of 687 necropsies. J Cancer Res Clin Oncol. 1988;114(6):605-12. 
 
Winberg ML, Noordermeer JN, Tamagnone L, Comoglio PM, Spriggs MK, Tessier-
Lavigne M, Goodman CS. Plexin A is a neuronal semaphorin receptor that controls 
axon guidance. Cell 1998;95(7):903-16. 
 
Winter H, Cheng KK, Cummins C, Maric R, Silcocks P, Varghese C. Cancer 
incidence in the south Asian population of England (1990-92). Br J Cancer 
1999;79(3-4):645-54.  
 
Wong OGW, Nitkunan T, Oinuma I, Zhou C, Blanc V, Brown R, Bott SRJ, 
Nariculum J, Box G, Munson P, Constantinou J et al. Plexin B1 Mutations in 
Prostate Cancer. PNAS 2007;104(48):19040-19045. 
 
217 
 
Woodhouse EC, Fisher A, Bandle RW, Bryant-Greenwood B, Charboneau L, 
Petricoin EF 3rd, Liotta LA. Drosophila screening model for metastasis: 
Semaphorin 5c is required for l(2)gl cancer phenotype. Proc Natl Acad Sci U S A 
2003;100(20):11463-8. 
 
Worzfeld T, Püschel AW, Offermanns S, Kuner R. Plexin-B family members 
demonstrate non-redundant expression patterns in the developing mouse nervous 
system: an anatomical basis for morphogenetic effects of Sema4D during 
development. Eur J Neurosci. 2004;19(10):2622-32. 
 
Xiang R, Davalos AR, Hensel CH, Zhou XJ, Tse C, Naylor SL. Semaphorin 3F 
gene from human 3p21.3 suppresses tumor formation in nude mice. Cancer Res. 
2002;62(9):2637-43. 
 
Yamada T, Endo R, Gotoh M, Hirohashi S. Identification of semaphorin E as a non-
MDR drug resistance gene of human cancers. Proc Natl Acad Sci U S A 
1997;94(26):14713-8. 
 
Zhang Z, Vuori K, Wang H, Reed JC, Ruoslahti E. Integrin activation by R-ras. Cell 
1996;85(1):61-9. 
 
 
 
218 
 
Appendix 
 
 
Plexin B1 sequence 
 
NM_002673  [gi:6631105] 
 
Protein sequence:  
 
MPALGPALLQALWAGWVLTLQPLPPTAFTPNGTYLQHLARDPTSGTLYLG
ATNFLFQLSPGLQLEATVSTGPVLDSRDCLPPVMPDECPQAQPTNNPNQLLL
VSPGALVVCGSVHQGVCEQRRLGQLEQLLLRPERPGDTQYVAANDPAVST
VGLVAQGLAGEPLLFVGRGYTSRGVGGGIPPITTRALWPPDPQAAFSYEET
AKLAVGRLSEYSHHFVSAFARGASAYFLFLRRDLQAQSRAFRAYVSRVCLR
DQHYYSYVELPLACEGGRYGLIQAAAVATSREVAHGEVLFAAFSSAAPPTV
GRPPSAAAGASGASALCAFPLDEVDRLANRTRDACYTREGRAEDGTEVAYI
EYDVNSDCAQLPVDTLDAYPCGSDHTPSPMASRVPLEATPILEWPGIQLTA
VAVTMEDGHTIAFLGDSQGQLHRVYLGPGSDGHPYSTQSIQQGSAVSRDLT
FDGTFEHLYVMTQSTLLKVPVASCAQHLDCASCLAHRDPYCGWCVLLGRC
SRRSECSRGQGPEQWLWSFQPELGCLQVAAMSPANISREETREVFLSVPDLP
PLWPGESYSCHFGEHQSPALLTGSGVMCPSPDPSEAPVLPRGADYVSVSVE
LRFGAVVIAKTSLSFYDCVAVTELRPSAQCQACVSSRWGCNWCVWQHLCT
HKASCDAGPMVASHQSPLVSPDPPARGGPSPSPPTAPKALATPAPDTLPVEP
GAPSTATASDISPGASPSLLSPWGPWAGSGSISSPGSTGSPLHEEPSPPSPQNG
PGTAVPAPTDFRPSATPEDLLASPLSPSEVAAVPPADPGPEALHPTVPLDLPP
ATVPATTFPGAMGSVKPALDWLTREGGELPEADEWTGGDAPAFSTSTLLS
GDGDSAELEGPPAPLILPSSLDYQYDTPGLWELEEATLGASSCPCVESVQGS
TLMPVHVEREIRLLGRNLHLFQDGPGDNECVMELEGLEVVVEARVECEPPP
219 
 
DTQCHVTCQQHQLSYEALQPELRVGLFLRRAGRLRVDSAEGLHVVLYDCS
VGHGDCSRCQTAMPQYGCVWCEGERPRCVTREACGEAEAVATQCPAPLIH
SVEPLTGPVDGGTRVTIRGSNLGQHVQDVLGMVTVAGVPCAVDAQEYEVS
SSLVCITGASGEEVAGATAVEVPGRGRGVSEHDFAYQDPKVHSIFPARGPR
AGGTRLTLNGSKLLTGRLEDIRVVVGDQPCHLLPEQQSEQLRCETSPRPTPA
TLPVAVWFGATERRLQRGQFKYTLDPNITSAGPTKSFLSGGREICVRGQNL
DVVQTPRIRVTVVSRMLQPNQGLGRRRRVVPETACSLGPSCSSQQFEEPCH
VNSSQLITCRTPALPGLPEDPWVRVEFILDNLVFDFATLNPTPFSYEADPTLQ
PLNPEDPTMPFRHKPGSVFSVEGENLDLAMSKEEVVAMIGDGPCVVKTLTR
HHLYCEPPVEQPLPRHHALREAPDSLPEFTVQMGNLRFSLGHVQYDGESPG
AFPVAAQVGLGVGTSLLALGVIIIVLMYRRKSKQALRDYKKVQIQLENLES
SVRDRCKKEFTDLMTEMTDLTSDLLGSGIPFLDYKVYAERIFFPGHRESPLH
RDLGVPESRRPTVEQGLGQLSNLLNSKLFLTKFIHTLETQRTFSARDRAYVA
SLLTVALHGKLEYFTDILRTLLSDLVAQYVAKNPKLMLRRTETVVEKLLTN
WMSICLYTFVRDSVGEPLYMLFRGIKHQVDKGPVDSVTGKAKYTLNDNRL
LREDVEYRPLTLNALLAVGPGAGEAQGVPVKVLDCDTISQAKEKMLDQLY
KGVPLTQRPDPRTLDVEWRSGVAGHLILSDEDVTSEVQGLWRRLNTLQHY
KVPDGATVALVPCLTKHVLRENQDYVPGERTPMLEDVDEGGIRPWHLVKP
SDEPEPPRPRRGSLRGGERERAKAIPEIYLTRLLSMKGTLQKFVDDLFQVILS
TSRPVPLAVKYFFDLLDEQAQQHGISDQDTIHIWKTNSLPLRFWINIIKNPQF
VFDVQTSDNMDAVLLVIAQTFMDACTLADHKLGRDSPINKLLYARDIPRY
KRMVERYYADIRQTVPASDQEMNSVLAELSWNYSGDLGARVALHELYKYI
NKYYDQIITALEEDGTAQKMQLGYRLQQIAAAVENKVTD 
220 
 
 
Nucleic acid sequence: 
 
 
 
         1 atgcctgctc tgggcccagc tcttctccag gctctctggg ccgggtgggt cctcaccctc 
       61 cagccccttc caccaactgc attcactccc aatggcacgt atctgcagca cctggcaagg 
      121 gaccccacct caggcaccct ctacctgggg gctaccaact tcctgttcca gctgagccct 
      181 gggctgcagc tggaggccac agtgtccacc ggccctgtgc tagacagcag ggactgcctg 
      241 ccacctgtga tgcctgatga gtgcccccag gcccagccta ccaacaaccc gaatcagctg 
      301 ctcctggtga gcccaggggc cctggtggta tgcgggagcg tgcaccaggg ggtctgtgaa 
      361 cagcggcgcc tggggcagct cgagcagctg ctgctgcggc cagagcggcc tggggacaca 
      421 caatatgtgg ctgccaatga tcctgcggtc agcacggtgg ggctggtagc ccagggcttg 
      481 gcaggggagc ccctcctgtt tgtggggcga ggatacacca gcaggggtgt ggggggtggc 
      541 attccaccca tcacaacccg ggccctgtgg ccgcccgacc cccaagctgc cttctcctat 
      601 gaggagacag ccaagctggc agtgggccgc ctctccgagt acagccacca cttcgtgagt 
      661 gcctttgcac gtggggccag cgcctacttc ctgttcctgc ggcgggacct gcaggctcag 
      721 tctagagctt ttcgtgccta tgtatctcga gtgtgtctcc gggaccagca ctactactcc 
      781 tatgtggagt tgcctctggc ctgcgaaggt ggccgctacg ggctgatcca ggctgcagct 
      841 gtggccacgt ccagggaggt ggcgcatggg gaggtgctct ttgcagcttt ctcctcggct 
      901 gcacccccca ctgtgggccg gcccccatcg gcggctgctg gggcatctgg agcctctgcc 
      961 ctctgtgcct tccccctgga tgaggtggac cggcttgcta atcgcacgcg agatgcctgc 
     1021 tacacccggg agggtcgtgc tgaggatggg accgaggtgg cctacatcga gtatgatgtc 
     1081 aattctgact gtgcacagct gccagtggac accctggatg cttatccctg tggctcagac 
     1141 cacacgccca gccccatggc cagccgggtc ccgctggaag ccacaccaat tctggagtgg 
     1201 ccagggattc agctaacagc tgtggcagtc accatggaag atggacacac catcgctttc 
     1261 ctgggtgata gtcaagggca gctgcacagg gtctacttgg gcccagggag cgatggccac 
     1321 ccatactcca cacagagcat ccagcagggg tctgcagtga gcagagacct cacctttgat 
     1381 gggacctttg agcacctgta tgtcatgacc cagagcacac ttctgaaggt tcctgtggct 
     1441 tcctgtgctc agcacctgga ctgtgcatct tgccttgctc acagggaccc atactgtggg 
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     1501 tggtgcgtgc tccttggcag gtgcagtcgc cgttctgagt gctcgagggg ccagggccca 
     1561 gagcagtggc tatggagctt ccagcctgag ctgggctgtc tgcaagtggc agccatgagt 
     1621 cctgccaaca tcagccgaga ggagacgagg gaggttttcc tatcagtgcc agacctgcca 
     1681 cccctgtggc caggggagtc atattcctgc cactttgggg aacatcagag tcctgccctg 
     1741 ctgactggtt ctggtgtgat gtgcccctcc ccagacccta gtgaggcccc agtgctgccg 
     1801 agaggagccg actacgtatc cgtgagcgtg gagctcagat ttggcgctgt tgtgatcgcc 
     1861 aaaacttccc tctctttcta tgactgtgtg gcggtcactg aactccgccc atctgcgcag 
     1921 tgccaggcct gtgtgagcag ccgctggggg tgtaactggt gtgtctggca gcacctgtgc 
     1981 acccacaagg cctcgtgtga tgctgggccc atggttgcaa gccatcagag cccgcttgtc 
     2041 tccccagacc ctcctgcaag aggtggaccc agcccctccc cacccacagc ccccaaagcc 
     2101 ctggccaccc ctgctcctga cacccttccc gtggagcctg gggctccctc cacagccaca 
     2161 gcttcggaca tctcacctgg ggctagtcct tccctgctca gcccctgggg gccatgggca 
     2221 ggttctggct ccatatcttc ccctggctcc acagggtcgc ctctccatga ggagccctcc 
     2281 cctcccagcc cccaaaatgg acctggaacc gctgtccctg cccccactga cttcagaccc 
     2341 tcagccacac ctgaggacct cttggcctcc ccgctgtcac cctcagaggt agcagcagtg 
     2401 ccccctgcag accctggccc cgaggctctt catcccacag tgcccctgga cctgccccct 
     2461 gccactgttc ctgccaccac tttcccaggg gccatgggct ccgtgaagcc cgccctggac 
     2521 tggctcacga gagaaggcgg cgagctgccc gaggcggacg agtggacggg gggtgacgca 
     2581 cccgccttct ccacttccac cctcctctca ggtgatggag actcagcaga gcttgagggc 
     2641 cctcccgccc ccctcatcct cccgtccagc ctcgactacc agtatgacac ccccgggctc 
     2701 tgggagctgg aagaggcgac cttgggggca agctcctgcc cctgtgtgga gagcgttcag 
     2761 ggctccacgt tgatgccggt ccatgtggag cgggaaatcc ggctgctagg caggaacctg 
     2821 caccttttcc aggatggccc aggagacaat gagtgtgtga tggagctgga gggcctcgag 
     2881 gtggtggttg aggcccgggt cgagtgtgag ccacctccag atacccagtg ccatgtcacc 
     2941 tgccagcagc accagctcag ctatgaggct ctgcagccgg agctccgtgt ggggctgttt 
     3001 ctgcgtcggg ccggccgtct gcgtgtggac agtgctgagg ggctgcatgt ggtactgtat 
     3061 gactgttccg tgggacatgg agactgcagc cgctgccaaa ctgccatgcc ccagtatggc 
     3121 tgtgtgtggt gtgaggggga gcgtccacgt tgtgtgaccc gggaggcctg tggtgaggct 
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     3181 gaggctgtgg ccacccagtg cccagcgccc ctcatccact cggtggagcc actgactggg 
     3241 cctgtagacg gaggcacccg tgtcaccatc aggggctcca acctgggcca gcatgtgcag 
     3301 gatgtgctgg gcatggtcac ggtggctgga gtgccctgtg ctgtggatgc ccaggagtac 
     3361 gaggtctcca gcagcctcgt gtgcatcacc ggggccagtg gggaggaggt ggccggcgcc 
     3421 acagcggtgg aggtgccggg aagaggacgt ggtgtctcag aacacgactt tgcctaccag 
     3481 gatccgaagg tccattccat cttcccggcc cgcggcccca gagctggggg cacccgtctc 
     3541 accctgaatg gctccaagct cctgactggg cggctggagg acatccgagt ggtggttgga 
     3601 gaccagcctt gtcacttgct gccggagcag cagtcagaac aactgcggtg tgagaccagc 
     3661 ccacgcccca cgcctgccac gctccctgtg gctgtgtggt ttggggccac ggagcggagg 
     3721 cttcaacgcg gacagttcaa gtataccttg gaccccaaca tcacctctgc tggccccacc 
     3781 aagagcttcc tcagtggagg acgtgagata tgcgtccgtg gccagaatct ggacgtggta 
     3841 cagacgccaa gaatccgggt gaccgtggtc tcgagaatgc tgcagcccaa ccaggggctt 
     3901 ggacggaggc gtcgcgtggt cccggagacg gcatgttccc ttggaccctc ctgcagtagc 
     3961 cagcaatttg aggagccgtg ccatgtcaac tcctcccagc tcatcacgtg ccgcacacct 
     4021 gccctcccag gcctgcctga ggacccctgg gtccgggtgg aatttatcct tgacaacctg 
     4081 gtctttgact ttgcaacact gaaccccaca cctttctcct atgaggccga ccccaccctg 
     4141 cagccactca accctgagga ccccaccatg ccattccggc acaagcctgg gagtgtgttc 
     4201 tccgtggagg gggagaacct ggaccttgca atgtccaagg aggaggtggt ggctatgata 
     4261 ggggatggcc cctgtgtggt gaagacgctg acgcggcacc acctgtactg cgagcccccc 
     4321 gtggagcagc ccctgccacg gcaccatgcc ctccgagagg cacctgactc tttgcctgag 
     4381 ttcacggtgc agatggggaa cttgcgcttc tccctgggtc acgtgcagta tgacggcgag 
     4441 agccctgggg cttttcctgt ggcagcccag gtgggcttgg gggtgggcac ctctcttctg 
     4501 gctctgggtg tcatcatcat tgtcctcatg tacaggagga agagcaagca ggccctgagg 
     4561 gactataaga aggttcagat ccagctggag aatctggaga gcagtgtgcg ggaccgctgc 
     4621 aagaaggaat tcacagacct catgactgag atgaccgatc tcaccagtga cctcctgggc 
     4681 agcggcatcc ccttcctcga ctacaaggtg tatgcggaga ggatcttctt ccctgggcac 
     4741 cgcgagtcgc ccttgcaccg ggacctgggt gtgcctgaga gcagacggcc cactgtagag 
     4801 caagggctgg ggcagctctc taacctgctc aacagcaagc tcttcctcac caagttcatc 
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     4861 cacacgctgg agacccagcg caccttttca gctcgggacc gtgcctacgt ggcatctctg 
     4921 ctcaccgtgg cactgcatgg gaagcttgag tatttcactg acatcctccg cactctgctc 
     4981 agtgacctgg ttgcccagta tgtggccaag aaccccaagc tgatgctgcg caggacagag 
     5041 actgtggtgg agaagctgct caccaactgg atgtccatct gtctgtatac cttcgtgagg 
     5101 gactccgtag gggagcctct gtacatgctc tttcgaggga ttaagcacca agtggataag 
     5161 gggccagtgg acagtgtgac aggcaaggcc aaatacacct tgaacgacaa ccgcctgctc 
     5221 agagaggatg tggagtaccg tcccctgacc ttgaatgcac tattggctgt ggggcctggg 
     5281 gcaggagagg cccagggcgt gcccgtgaag gtcctagact gtgacaccat ctcccaggca 
     5341 aaggagaaga tgctggacca gctttataaa ggagtgcctc tcacccagcg gccagaccct 
     5401 cgcacccttg atgttgagtg gcggtctggg gtggccgggc acctcattct ttctgacgag 
     5461 gatgtcactt ctgaggtcca gggtctgtgg aggcgcctga acacactgca gcattacaag 
     5521 gtcccagatg gagcaactgt ggccctcgtc ccctgcctca ccaagcatgt gctccgggaa 
     5581 aaccaggatt atgtccctgg agagcggacc ccaatgctgg aggatgtaga tgaggggggc 
     5641 atccggccct ggcacctggt gaagccaagt gatgagccgg agccgcccag gcctcggagg 
     5701 ggcagccttc ggggcgggga gcgtgagcgc gccaaggcca tccctgagat ctacctgacc 
     5761 cgcctgctgt ccatgaaggg caccctgcag aagttcgtgg atgacctgtt ccaggtgatt 
     5821 ctcagcacca gccgccccgt gccgctcgct gtgaagtact tctttgacct gctggatgag 
     5881 caggcccagc agcatggcat ctccgaccag gacaccatcc acatctggaa gaccaacagc 
     5941 ttgcctctga ggttctggat caatataata aaaaacccgc agtttgtgtt cgacgtgcaa 
     6001 acatctgata acatggatgc ggtgctcctt gtcattgcac agaccttcat ggacgcctgc 
     6061 accctggccg accacaagct gggccgggac tccccgatca acaaacttct gtatgcacgg 
     6121 gacattcccc ggtacaagcg gatggtggaa aggtactatg cagacatcag acagactgtc 
     6181 ccagccagcg accaagagat gaactctgtc ctggctgaac tgtcctggaa ctactccgga 
     6241 gacctcgggg cgcgagtggc cctgcatgaa ctctacaagt acatcaacaa gtactatgac 
     6301 cagatcatca ctgccctgga ggaggatggc acggcccaga agatgcagct gggctatcgg 
     6361 ctccagcaga ttgcagctgc tgtggaaaac aaggtcacag atctatagga acccaggagc 
     6421 cacggcctgc tgttgcttca gcctggcctg ggcagccctg gaagctcgga ggagaggcca 
     6481 ccttcttagg tgcctgtagt gactgacaag cagagttagt ggaaggtgac tcccagtctc 
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     6541 ctggtggctc tggcctcggc cctgctggat ccacctccta gacccggggc ctcaaggctc 
     6601 atggggtagt acccagcctg ctccccgagt ccagcgaccc tgt 
 
Key – Primers 
Plexin B1-52   
Plexin B1-2   
Plexin B1-3   
Plexin B1-4   
Sp6    
 
 
 
Ref: http://www.ncbi.nlm.nih.gov/nuccore/6631105?report=genbank  
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